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SMQCARX
The complement system, which comprises a group of at least 20 
plasma proteins, plays a major role in host defence against bacterial 
infections and in immunologically-mediated inflammation. The pro- 
inflammatory biological activities generated as a result of complement 
activation include increased vascular permeability, chemotaxis of 
neutrophils and mononuclear phagocytes, enzyme secretion by phagocytic 
cells and cytolysis. Complement activation occurs within inflamed synovial 
joints of patients with rheumatoid arthritis and is thought to play a role 
in the pathogenesis of the condition.
Although plasma levels of most complement components are 
maintained by hepatic synthesis, the cell responsible being the hepatocyte, 
it is now well established that other cells including monocytes, 
macrophages, fibroblasts and epithelial cells of the gastrointestinal and 
genitourinary tracts synthesise complement components when cultured in 
vitro. Such cells are potential sources of extrahepatic synthesis of 
complement components in vivo. Synovial fluid macrophages and adherent 
synovial membrane cells have been shown to synthesise complement components 
when cultured in vitro, as have isolated fragments of synovial membrane 
from patients with either rheumatoid arthritis or osteoarthritis. However, 
the only evidence for extrahepatic synthesis occurring in vivo comes from 
metabolic studies with radiolabelled (12SI) C3, which indicated that up to 
50% of C3 present in the rheumatoid joint was synthesised locally.
The princip.&f aim of this study was to provide conclusive _
evidence that a large number of complement components including C4, C2, C3, 
C5, factor B and Cl-inhibitor, were synthesised in synovial tissue in vivo.
The availability of cDNA probes for these complement components allowed the
- xvii -
use of molecular biological technology, in addition to immunochemical 
techniques, to study complement biosynthesis by synovial tissue from 
patients with rheumatoid arthritis or osteoarthritis and by normal synovial 
tissue from a patient undergoing patellectomy.
Using Northern and dot-blot analyses, mRNAs coding for Cl- 
inhibitor (2.1 kb), factor B (2.6 kb), Clq B-chain (1.4 kb), C2 (2.9 kb),
C3 (5.2 kb) and C4 (5.5 kb) were detected in RNA isolated from both 
rheumatoid synovium and synovial membrane from osteoarthritis patients. 
Although the presence of C5 mRNA was also investigated, it was not detected 
in any sample. Dot-blot analysis showed the presence of mRNA coding for Cl- 
inhibitor in RNA isolated from normal synovial membrane.
Quantitative analyses of the data using the students t-test did 
not show any statistically significant difference between the steady state 
levels of C3, Cl-inhibitor or factor B mRNA in synovium from rheumatoid 
arthritis and osteoarthritis patients. Although ' the levels of C2 mRNA were 
significantly higher in rheumatoid synovium, and C4 mRNA levels were higher 
in osteoarthritis synovium, the P value was only marginally significant in 
both cases (<0.05).
Vhen fragments of normal synovium or synovial membrane fragments 
from patients with rheumatoid arthritis or osteoarthritis, were cultured in 
vitrot synthesis of Cl-inhibitor, C2, C3, C4 and factor B was detected by 
ELISA and C2, C3 and factor B were shown to be functionally active.
Following the demonstration of complement biosynthesis in 
synovial tissue in vivo, the next step would be to identify the cells 
within the synovium reponsible for complement biosynthesis. A number of ~~~ 
cell-types that are present in synovial membrane have previously been shown 
to be capable of synthesising complement components in vitro. These include
- xviii -
mononuclear phagocytes and possibly the B-cells of the synovial membrane 
lining, fibroblasts and endothelial cells. However, the cells responsible 
for complement biosynthesis in vivo remain unidentified. This question may 
only be answered with the use of in situ hybridisation on frozen sections 
of synovial tissue.
As an initial step in this study, cells were isolated from 
synovial tissue of patients with rheumatoid arthritis and osteoarthritis 
and cultured in vitro, ELISA analyses of the culture supernatants showed 
synthesis of C4, C3, factor B and Cl-inhibitor by both the adherent and 
non-adherent synovial cells. Immunohistochemistry showed that in both cell 
populations, fibroblasts were present in by far the greatest abundance 
095%), although a small proportion (<5%) of macrophages w a s  identified.
This study thus provides conclusive evidence that synthesis of 
complement components occurs locally within normal and inflamed synovial 
tissue in vivo. The local synthesis of complement within normal synovial 
joints may be of importance in their defence against infection, whereas in 
inflamed joints it may contribute to the inflammatory response.
Further work is required to define the regulation of complement 
synthesis within the synovial joint as well as to identify the cells 
responsible for complement biosynthesis in vivo.
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THE COMPLEMENT SYSTEM
The principal role of the complement system is as an effector 
mechanism in host defence against infection by microorganisms. The 
activation products of the complement system cause lysis of cells, 
attract phagocytic cells to the site of activation and opsonise 
microorganisms which promotes their phagocytosis and killing by 
phagocytes.
The activation of complement is initiated by two pathways - the 
classical and alternative pathways - and is dependent on the sequential 
activation of zymogens to proteases, ie. the complement components 
circulate in an inactive form and as a result of their limited 
proteolysis, they acquire proteolytic activity, the substrate being the 
next protein in the activation sequence.
The classical pathway is activated mainly by the formation of 
antigen-antibody complexes, whereas activation of the alternative 
pathway is generally antibody independent ie. the alternative pathway 
can be activated by polysaccharides such as are present on bacterial 
cell walls.
A simplified view therefore is that the alternative pathway 
forms a first line of defence against infection prior to an immune 
response and the classical pathway becomes more important after antibody 
production has been stimulated. However, antibody-independent activation 
of the classical pathway has been described for bacterial lipid A 
(Cooper & Morrison, 1978), heart mitochondrial membranes (Giclas, 
Pinckhard & Olsen, 1979) and retrovirus membranes (Bartholomew & Esser, 
1980). In addition, antibody-dependent activation of the alternative 
pathway has also been described and hence the true mechanism of how the
- 1 -
COMPONENT MOLECULAR
VE1GHT
SERUM CORC. 
(pg/ml)
POLYPEPTIDE CHAIR 
STRUCTURE
Classical pathway
Clq 400,000 250 18 (6 x 3)
Clr 90,000 100 1
Cls 90,000 80 1
C4 204,000 430 3
C2 100,000 20 1
Alternative pathway 
Factor B 93,000 150 1
Factor D 25,000 2 1
Properdin 220,000 30 4
C3 190,000 1300 2
Terminal sequence
C5 185,000 75 2
C6 128,000 60 1
C7 121,000 60 1
C8 153,000 80 3
C9 79,000 50 1
TABLE 1 - Complement proteins of the classical and alternative pathways 
and terminal sequence.
two pathways interact is likely to be more complex.
The human complement system is composed of at least 20 plasma 
proteins, 13 proteins of the classical and alternative pathways and at 
least 7 control proteins. From Fig.1, it can be seen that the end result 
of activation of either pathway is the generation of C3 convertases 
which activate C3. This is the key step in complement activation and 
initiates activation of the terminal sequence which is responsible for 
the cytolytic effects and other biological activities which are 
generated during activation.
The Classical. Pathway.
The classical pathway (Fig.2) consists of five proteins, Clq, 
Clr, Cls, C4 and C2, responsible for the assembly of the C3-cleaving 
enzyme (C4b2a) and three control proteins, Cl-inhibitor (Cl-INH), C4 
binding protein (C4BP) and factor I (Whaley & Ferguson, 1981; Reid & 
Porter, 1981; Kuller-Eberhard, 1988).
(a) Cl activation and its regulation
Cl is a macromolecule consisting of one molecule of Clq, two 
molecules of Clr and two molecules of Cls, held together by calcium 
ions (Ziccardi & Cooper, 1977). Cl is activated by interaction with 
antibody molecules of the IgK class or IgGl, IgG2 or IgG3 subclasses. 
Activation of Cl proceeds by three distinct steps: binding of Clq to 
antibody, activation of Clr to Clr and finally activation of Cls to Cls.
Clq is the recognition unit of the Cl macromolecule and 
possesses a hexameric structure, with six globular heads being joined 
by collagen-like fibrillar stalks (Reid & Porter, 1975). Each of the 
heads is capable of binding to the CH2 domain of the IgG heavy chain or 
the CH3 domain of the IgM heavy chain. The affinity of Clq for monomeric
- 2 -
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terminal sequence
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Figure 1 - Activation of C3: the end result of the classical and 
alternative pathways.
Clq
Ag/Ab ■ .... —>
Clq Cls
Clr
C2
Cls
Cl-IITH
C4
C4b2a
C3a
C4BP
>■ C3bC3
—  activated state 
~  conformational change
Figure 2 - Classical pathway activation.
IgG is weak but is enhanced when IgG has been aggregated in an immune 
complex (Ziccardi, 1984).
The Clr^:Clss: tetramer binds to the collagen-like region of Clq 
(Strang et al., 1982). Both Clr and Cls have structural and functional 
similarities. They are single polypeptide chain zymogens which when 
activated by proteolytic cleavage, are converted to active enzymes 
consisting of disulphide-linked heavy and light chains. The enzymatic 
site of both is located on the light chains (Villiers, Arlaud & Colomb, 
1985).
Upon binding with immunoglobulin, the heads of Clq undergo a 
conformational change (Hanson, Siegel & Schumaker, 1985) which is 
transmitted along the rigid collagen-like stalks to Clr. The shearing 
force presumably results in a realignment of the Clr molecule exposing a 
susceptible peptide bond to an enzymatic site at another part of the Clr 
molecule. Autocatalysis results in the generation of Clr (Ziccardi & 
Cooper, 1976) which has only one known natural substrate, Cls. It should 
be noted that activation of Clr can only occur in the presence of Cls. 
Clr produces a single proteolytic cleavage of Cls to convert it to Cls 
which carries the enzymatic site of Cl and thus cleaves C4 and C2 
(Campbell, Dodds 8? Porter, 1980; Ziccardi, 1981).
Activated Cl has a half-life of only 13 seconds in the presence 
of Cl-inhibitor (Cl-INH) (Ziccardi, 1981). It has also been shown that 
in the absence of Cl-INH, there is spontaneous activation of Cl even 
without any activator, (Ziccardi, 1982a,b). Two conformationally 
distinct forms of unactivated Cl have been hypothesised (Schumaker, 
Zavodsky & Poon, 1987): the "closed" complex which is incapable of 
autoactivation and the "open" complex in which catalytic sites of
- 3 -
unactivated Clr are exposed. Being in sevenfold molar excess over Cl, 
Cl-INH reversibly binds to Cl presumably when it is in the open complex 
state in which the Clr procatalytic sites are exposed. Two molecules of 
Cl-INH bind to the two Clr sites, thus preventing autocatalytic 
activation (Muller-Eberhard, 1988). The active state of activated Cl has 
a half life of only 13 sec because Cl-INH rapidly enters into covalent 
interaction with Cls, abrogating its enzyme activity. Cl-INH also gains 
access to activated Clr which results in the release of two molecules of 
the fluid phase complex ClrCls(Cl-INH) 2  (Laurell et al,, 1978; Ziccardi 
& Cooper, 1979).
(b) Formation of the classical pathway .,£3. CQnyextasg, C4b2&.
C4 consists of three polypeptide chains - a, j3 and - held 
together by disulphide bonds. Cl or Cls produce a limited proteolytic 
cleavage in the cx-chain, separating a 6 kDa peptide, C4a from the N- 
terminus (Schreiber & Muller-Eberhard, 1974). The remainder of the C4 
molecule, C4b possesses the ability to bind to antigen-antibody 
complexes. Failure to bind within 50msec results in loss of the labile 
binding site (by hydrolysis) and the molecule becomes fluid phase C4b. 
The ability of C4b to bind to surfaces is due to the presence of an 
internal thiolester group in C4 which upon cleavage by Cls is able to 
form amide or ester bonds with respective groups on the target surface. 
C4 occurs in two structurally and functionally distinct isotypes, C4A 
and C4B, each of which is encoded by a distinct gene (Carroll et al. , 
1984), C4A reacts preferentially with amino groups and C4B with hydroxyl 
groups,
C4b possesses a magnesium ion-dependent site for C2. C2 is 
cleaved by Cl or Cls to yield two fragments C2a (73 kDa) and C2b (34
- 4 -
kDa). Primarily because the molar concentration of C2 is about one 
twentieth of that of C4, only ^4 C2 molecules are activated by one 
activated Cl molecule as opposed to ==35 C4 molecules (Ziccardi, 1981). 
Although Cls can activate C2 in the absence of C4b, the reaction occurs 
more efficiently in the presence of the latter molecule (Gigli & Austen,
1969). C2 binds to C4b via the C2b fragment which remains bound to C2a
by non-covalent bonds. C2a contains the enzymatic site of the C4b2a
molecule (Nagasawa & Stroud, 1977).
C4b2a is an unstable enzyme, having a very short half-life at 
37°C. C2 decays from the complex, which can be regenerated by fresh C2
in the presence of Cl or Cls.
(c) Regulation of the classical pathway C3 convertase formation
The control of C4b activity is performed by the action of factor 
I and its cofactor C4BP (Fujita, Gigli & Nussenzweig, 1978; Gigli,
Fujita & Hussenzweig, 1979). C4BP binds to C4b and renders it
susceptible to cleavage by factor I. Two cleavages occur in the a-chain
while the j3 and y subunits remain intact. l\Acilei\ I S> KOc, v'T'-A PvJ -Vg-.-'w oj- (-)tc_
a ’-chain of C4b is (47 kDa), the remainder of the chain and the 
intact £ and y chains comprise C4c (Fujita et al., 1978). C4c is 
released into the fluid phase, the C4d fragment remains bound to the 
immune complexes which can no longer bind to C3b/C4b receptors (CRD on 
erythrocytes or leukocytes.
C4BP will also displace C2a from C4b by binding to the latter 
protein. The rate of decay of this already labile enzyme is therefore 
accelerated (Gigli et al., 1979).
C4BP is found with two different molecular weights. The smaller
is only found in free form, while the larger is found in two forms,
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either free or bound in a complex with protein S (Dahlback & Stenflo, 
1981; Dahlback, 1985) (the most important function of protein S is in 
the coagulation system (Comp et al., 1984).) C4BP retains its C4 binding 
property in complex with protein S, but the importance of protein S 
together with C4BP is unknown.
The Alternative Pathway
Vhen polysaccharides e.g endotoxin, are added to C4 or C2 
deficient serum, C3 consumption is still observed. Furthermore, when 
these polysaccharides are added to normal serum, C3 consumption occurs 
without significant utilisation of Cl, C4 or C2. Therefore an 
alternative pathway for C3 cleavage and activation must exist (Reid & 
Porter, 1981; Vhaley & Ferguson, 1981; Pangburn, 1983; Muller-Eberhard, 
1988).
(a) Activation and amplification of the alternative pathway
The alternative pathway exists in its activated state at all 
times due to the spontaneous reaction of C3 with water. Mative C3 
possesses an internal thiolester that undergoes low-grade hydrolysis 
giving rise to a continuous supply of C3(Hs.O) which possesses all the 
functional properties of C3b (Iseni'^ c.n et al. , 1981; Pangburn, Schreiber 
& Muller-Eberhard, 1981; von Zabern, Nolte & Vogt, 1981; Muller- 
Eberhard, 1988). Vhen as a result of formation of the initial enzyme, 
native C3 is cleaved, and the fragment C3b deposited on the surface of 
particles, the alternative pathway is able to distinguish between self 
and non-self. Only on particles recognised as foreign will amplification 
of C3b deposition occur and membrane attack be initiated (Muller- 
Eberhard, 1988).
In the presence of magnesium ions, C3b will complex with factor
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Factor H
C3
C4b2a
C3bBC3bBb <C3bBbP
C3bActivating
surface
C3a
C3b
Factor I
Figure 3 - Alternative pathway activation.
CLASSICAL PATHWAY ALTERNATIVE PATHWAY
C4b 1. Binds C2, Mg2"* dependent C3b 1. Binds B f Hg2^ dependent
2. Degraded by I + C4BP 2. Degraded by I + H.
C2 1. Single polypeptide chain B 1. Single polypeptide chain
2. Cleaved by Cls C2a + C2b 2. Cleaved by D -» Ba + Bb
3. Enzymatic site for C3 on 3. Enzymatic site for C3 on
larger fragment (C2a) larger fragment (Bb)
4. Decays from C42 4. Decays from C3bBb
5. Structural gene on 5. Sructural gene on
chromosome 6 chromosome 6
Cls 1. Serine protease cleaves D 1. Serine protease cleaves
C4 and C2 factor B
I 1. Enzymatically inactivates I 1. Enzymatically inactivates
C4b in the presence of C4BP C3b in the presence of H
C4BP 1. Binds to C4b H 1. Binds to C3b
2. Cofactor for I in C4b 2. Cofactor for I in C3b
cleavage cleavage
3. Accelerates decay of 3. Accelerates decay of C3bBb
TABLE 2 - Similarities between, the classical and alternative pathways.
B which is itself cleaved by factor D resulting in an unstable C3bBb 
complex and a fluid phase Ba fragment. The complex is stabilised by the 
binding of properdin (P) to C3b forming the stable C3 convertase, C3bBbP 
(Fearon, Austen & Ruddy, 1973; Fearon & Austen, 1975),
(b) Regulation of the alternative pathway.
Activation of the alternative pathway is controlled by factor I 
but in this pathway the cofactor is factor H (Whaley & Ruddy, 1976a,b). 
Factor H can bind to C3b alone or in convertases and competes for the 
binding site for factor B (Pangburn & Muller-Eberhard, 1978). It is a 
cofactor for factor I in the enzymatic inactivation of C3b (Pangburn, 
Schreiber & Muller-Eberhard, 1977) and accelerates the decay of the 
alternative pathway C3 convertase, C3bBb (Weiler et al., 1976).
Meabrane-phase regulation of the classical and alternative pathways.
Cofactors for factor I in the membrane-phase are CR1, which is 
found on many erythrocytes and leukocytes and binds C3b and C4b alone or 
in the convertases (Fearon, 1979; Iida & Nussenzweig, 1981; Medof et 
al., 1982; Medof & Nussenzweig, 1984) and membrane cofactor protein 
(MCP) which binds C3b and C4b alone or in the convertases (Cole et al., 
1985; Holers et al., 1985; Yu et al., 1986). CR1 also increases the 
dissociation of both C3 convertases (Seya, Halers & Atkinson, 1985) 
while no decay accelerating activity has been found for MCP. It has been 
shown there is reciprocity between the amount of CR1 and MCP on 
particular cells (Holers et al., 1985) suggesting that these two 
proteins have similar functions. However, CR1 also serves as a receptor"* 
which in response to certain stimuli can increase its expression on 
neutrophil membranes (Lee, Hakim & Fearon, 1984; Yancey et al., 1985) 
while MCP has no such receptor function.
MOLECULAR
WEIGHT
SERUM CONC. 
(pg/ml)
Cl-inhibitar 105,000 180
Anaphlatoxin inactivator 300,000 35
C4 binding protein 540,000 250
Factor I 90,000 50
Factor H 150,000 300
Properdin 220,000 30
S-protein 88,000 100-500
CR1 200,000 V
Decay accelerating factor 70,000 •-?
Membrane cofactor protein 60,000 y
Homologous restriction factor 80,000
TABLE 3 - The major regulatory proteins of the complement system.
Decay accelerating factor (DAF) is found on erythrocytes, 
platelets and all types of leukocytes (Kinoshita et al., 1985) and 
accelerates the decay of the C3 convertases by binding to the catalytic 
subunits Bb and C2b (Pangburn, 1986). DAF also binds to C3b and C4b 
alone and may therefore prevent the formation of convertases (Medof, 
Kinoshita & Nussenzweig, 1984). Hence CR1 and DAF work together to 
protect autologous cells against attack by complement.
C3 activation
Both C4b2a and C3bBbP cleave the a-chain of C3 to release a 
small peptide C3a (9 kDa) from the N-terminus. The remainder of the 
molecule, C3b comprises the rest of the a-chain and the j3-chain.
Cleavage of the a-chain of C3 by either of the C3 convertases exposes a 
labile binding site by which C3b binds to immune complexes or 
polysaccharides. The thiolester in the a-chain of C3 is exposed on 
activation and a covalent bond is formed between the thiolester and 
hydroxyl groups (ester bond) or amino groups (amide bond) (Tack et al. , 
1980; Law, Lichtenberg & Levine 1980). Failure to bind quickly to a 
suitable acceptor molecule results in the loss of binding activity 
because the thiolester reacts with water to form inactive fluid-phase 
C3b.
C3b, which is a product of both pathways, is a constituent of 
the alternative pathway C3 convertase and hence a positive feedback loop 
mechanism is in operation.
The Terminal Sequence
The terminal sequence is activated when C3 is cleaved by either 
of the two C3 convertases, C4b2a and C3bBbP. As described above, C3b
binds covalently to immune complexes and cell membranes. Some of the C3b 
will bind close to the C3 convertase enzyme thus changing the 
specificity of the enzyme to a C5 convertase (Cooper & Muller-Eberhard, 
1970; Medicus, Gotze 8t Muller-Eberhard, 1976).
Following classical pathway activation, the change in substrate 
specificity of C4b2a is accomplished by activation of C5
(Vogt, Schmidt & von Buttlar, 1978). High- 
C S -Vending sites were demonstrated on C3b-C4b dimers in which 
C3b was linked covalently to the a-chain of C4b through an ester bond 
(Takata et al., 1987). The high-affinity binding may allow selective 
binding of C5 to the convertase in spite of surrounding monomeric C3b 
molecules generated by the C3 convertase.
The role of the second C3b molecule following alternative 
pathway activation is to bind C5 and modify it for cleavage by Bb 
(Isenman, Podack & Cooper, 1980; Vogt et al., 1978),
C5 has several structural and functional similarities to C3. It 
consists of a double polypeptide chain (185 kDa), the a-chain of which 
is cleaved by the C5 convertases releasing a small peptide, C5a (10 kDa) 
from the N-terminus, and a larger fragment, C5b which comprises the 
remainder of the a-chain and the J3-chain.
The C5a peptide is a patent anaphylatoxin which is inactivated, 
along with C3a and C4a by anaphylatoxin inactivator (Bokisch & Muller- 
Eberhard, 1970). By splitting off the terminal arginine residue, C4a and 
C3a are completely inactivated, while C5a is partly inactivated (Huey et 
al., 1983; Marder et al., 1985).
The labile binding site of C5b has specificity for C6 and 
bimolecular C5b6 remains loosely bound to C3b on the target cell surface
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until it reacts with. C7. The trimolecular complex undergoes hydrophilic- 
amphiphilic transition (Preissner, Podack & Muller-Eberhard, 1985a), and 
anchors itself firmly in the lipid bilayer. It would appear that C5b6 
converts C7 to an activated state in which it expresses hydrophobic 
binding sites that are concealed in the native molecule (Preissner et 
al., 1985a,b). This leads to C5b-7 membrane insertion which commits 
membrane attack complex (MAC) assembly to a discrete site. This step is 
controlled by S-protein which competes with membranes for binding to 
C5b-7 (Podack et al., 1978; Bhakdi & Tranum-Jensen, 1982), thus 
preventing its attachment to the cell surface.
Inserted C5b-7 constitutes an integral membrane protein that 
functions as a receptor for C8, C8 binds to C5b-7 with its jJ-chain which 
possesses a recognition site for C5b (Stewart & Sodetz, 1985). While 
C5b-7 interacted strongly with the ionic part of the bilayer and 
penetrated only slightly into the hydrophobic region, C5b-8 penetrated 
into the hydrophobic phase more deeply (Esser, Kolb & Podack, 1979).
Binding of C9 to the C5b-8 complex accelerates the cytolytic 
process. The C5b-9 complex consists of one molecule each of C5b, C6, C7, 
C8 and up to 18 molecules of C9. C5b-8 forms a small functional channel 
of *30A diameter (Mayer, 1982; Martin et al., 1987). As increasing 
numbers of C9 molecules are incorporated into the channel structure, its 
functional size increases to =100A (Martin et al., 1987). Hence, the 
hydrophobic exterior of the complex binds to the membrane lipid and the 
hydrophilic interior facilitates the passage of water and electrolytes. 
Once the loss of ion flux occurs the cell is doomed to osmotic lysis 
(Mayer, 1972).
Homologous restriction factor (HRF), which is found on the
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membranes of erythrocytes, and peripheral blood leukocytes, acts to 
control the final assembly of the terminal complement complex to protect 
autologous cells against complement mediated lysis (Schonermark et al., 
1986; Shin et al., 1986; Zalman, Wood & Muller-Eberhard, 1986). HRF 
binds to C8 and C9, inhibiting the trans-membrane channel formation.
Biological Activities of.Complement
At major effect of the complement system is the cytolytic 
effect of the C5b-9 complex but there are many other biological 
activities generated during complement activation;
(a) Increased vascular permeability
C4a, C3a and C5a are anaphylatoxins, C5a being the most potent 
and C4a the least. C3a and C5a act on mast cells and basophils to 
release histamine while C3a also causes platelets to release serotonin 
(Johnson, Hugli & Muller-Eberhard, 1975). C3a and C5a also induce smooth 
muscle contraction which presumably has a direct effect on the 
endothelial cells of the post-capillary venules, opening up inter­
cellular gaps and increasing exudation of fluid.
As described above, the effects of C3a and C5a are inhibited by 
the action of anaphylatoxin inactivator which cleaves the C-terminal 
arginine residues from these patent peptides (Bokisch & Muller-Eberhard,
1970).
lb) Chemotaxis
C5a and C5a which has been degraded by anaphylatoxin inactivator 
(C5a.=i®«.«,r.a) are powerful chemotactic agents, attracting neutrophils, 
eosinophils and monocytes (Fernandez et al., 1978). C3bBb is also 
chemotactic for neutrophils (Ruddy, Austen & Goetzl, 1975).
- 11 -
ACTIVITY PRODUCT
Pro-inf 1 animat ory
1. Increased vascular permeability C4a, C3a, C5a, C2-kinin
2. Chemotaxis C5a, C5adesarg, C5b67, C3bBb
3. Lysosomal enzyme secretion C3b
Cytolitic C5b-9
Bystander lysis C5b-7
Opsonic
1. Adherence to receptors C4b, C3b, C3bi, C3d
2. Enhancement of phagocytosis
3. Increased intracellular
C3b
killing of bacteria 
4. Increased intracellular
C3b
degradation of immune complexes C3b
Solubilisation of complexes C3b C4b
Antibody production
1. T-dependent responses C3
2. Generation of B memory cells C3
TABLE 4 - Biological activities of complement.
(c) Leukocytosis
C3e, a peptide from the a-chain of C3, causes initial 
leukopenia, followed by leukocytosis. This is probably achieved by 
mobilising neutrophils from the bone marrow (McCall et al., 1974;
Rother, 1972).
(d) Phagocytosis
Cells such as polymorphonuclear leukocytes, mononuclear 
phagocytes and B lymphocytes possess C3b receptors on their membranes, 
which can bind C3b-coated immune complexes or particulate material, C3b 
by itself promotes adherence to monocytes but not ingestion, whereas 
when IgG antibody also coats organisms ingestion is enhanced. It has 
been shown that activated macrophages are capable of binding and 
'ingesting particles coated only with C3b while resting macrophages 
require IgG for ingestion to occur (Griffin, Bianco & Silverstein,
1975). C3b acting on macrophage C3b receptors enhances the rate of 
intracellular killing of bacteria (Leigh et al., 1979).
It should be noted there is more than one type of C3b receptor. 
Receptors for C3b/C4b (CR1) and C3bi (CR3) are found on the surface of 
neutrophils and monocytes. Receptors for C3bi and C3d (CR2) as well as 
CR1 are present on B-lymphocytes (Abrahamson & Fearon, 1983). CR1 alone 
is found on erythrocytes and CR1, CR2 and CR3 are all found on dendritic 
cells,
(e> Solubility of immune complexes
Complement-mediated prevention of immune precipitation (PIP) 
occurs when immune complexes are farmed in the presence of complement 
(Schifferli, Bartolotti & Peters, 1981). The phenomenon depends upon an 
intact classical pathway (Schifferli, Woo & Peters, 1982; Maama et al. ,
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1984) with C3 convertase formation leading to C3 activation and the 
binding of C3b to immune complexes (Naama et al., 1984,1985). The 
alternative pathway plays a secondary role in PIP, helping to retain in 
solution, immune complexes which have already been rendered soluble by 
complement (Naama et al., 1985), In contrast, another complement- 
dependent function, the solubilisation of immune precipitates, displays 
an absolute dependency upon the alternative pathway (Czop & Hussenzweig,
1976) although optimal solubilisation also requires classical pathway 
activation (Takahashi et al., 1978). 
il) .Lymphocyte function
C3b is required for the generation of B-memory cells (Klaus & 
Humphrey, 1977) and T-dependent antibody responses (Pepys, 1974). C3a 
and possibly other C3 derived peptides suppress antibody production 
(Ochs et al., 1983).
The numerous biological activities generated during complement 
activation emphasise the importance of the complement system as a 
defence mechanism against infection of the host by microorganisms and 
helps explain why deficiency of complement componenents can lead, in 
some cases, to serious disease states.
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THE MOL E CU L AR  B I O L O G Y  Q F  C QM P L E M E H T
The isolation of cDNA and genomic clones for nearly all the 
complement components has helped scientists gain a clearer understanding 
of the complement system at the molecular level. These powerful tools of 
molecular biology have been used in a wide range of applications:
(a) deriving the primary structure of complement proteins
(b) establishing the precise molecular defect in deficiency states
(c) detailed examination of polymorphic variants of a particular 
component and their possible relationship to disease states
(d> examination of tissue specific expression and hormonal control 
of expression
(e) in vitro expression studies by transfection of mammalian cells 
with cloned complement genes
(f) control of expression levels and biosynthesis
(g) establishing chromosomal localisation
(h) examination of the processing of precursor molecules
(i) provision of insight into the evolution of protein families
Studies with these clones have divided the complement proteins
into six separate structurally and functionally related groups, many of 
which are coded on the same chromosomes and are closely linked: (1) the 
Cl complex and Cl-IB'H, (2) the class III region of the major histo­
compatibility complex (MHC) ie. C2, factor B and C4, (3) C3, C4 and C5, 
(4) the regulators of complement activation ie. factor I, C4BP, factor 
H, CR1, CR2, DAF and MCP, (5) CR3 as a member of the cell adhesion
glycoprotein family, and (6) the membrane attack complex, C5b-9.
eJr <^l7 ic]<8s> ^
- 14 -
1. THE Cl - C Q M P L E X  A F P  C1-1JTHIB1TQR
(a) Clq
Macrophages may be a major source of Clq (Tenner & Volkin, 1986; 
Rabs et al., 1986). Both the Clq B-chain and the A-chain have been 
assigned to chromosome lp (Reid, 1985; Sellar et al., 1987) and the B- 
chain gene, which has been studied more extensively, is approximately 
2.6 kb long (Reid, 1985). The B-chain gene contains a single intron of 
1.1 kb located within the codon where the triple helical chains of Clq 
appear to bend. It is not yet known whether the A- and C-chain genes 
have an intron at the equivalent position.
(b) Clr.,.and Cls
Amino acid sequences show 40% homology between these two 
proteins. In the activated form of both enzymes, the A- or heavy chain 
which does not possess the active site, contains two different pairs of 
internal repeating units. The first set has not been found on any other 
proteins and hence may account for the control of specificity of Clr and 
Cls. The second set of repeating units, found toward the C-terminal end 
of the A-chain, are units of approximately 60 amino acids and are 
homologous to the 60 amino acid repeats (short consensus repeat, SCR) 
found in the C3b/C4b binding proteins such as C4BP and factor H. The Clr 
and Cls genes are both found in the region pl3 on human chromosome 12 
and studies with pulse field gel electrophoresis (PFGE) have indicated 
the genes are tightly linked within a 50 kb stretch of DMA (Tosi et al., 
1987).
IsX. Cl-inhibitor
The isolation and characterisation of cDNA clones encoding Cl- 
INH together with sequence analysis of the protein (Bock et al., 1986)
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show that Cl-INH is a member of the serpin "superfamily" of serine 
protease inhibitors (Carrell, 1984; Davis et al., 1986). This 
"superfamily" includes a-l-antitrypsin, antithrombin III, a-l-anti- 
chymotrypsin, a-2-antiplasmin and heparin cofactor II.
The entire Cl-INH gene is 17 kb long (which is larger than those 
encoding the other serpins) and gives rise to a 2,1 kb transcript. The 
gene contains eight exons and seven introns and has been mapped to 
subregion pll.2-ql3 of human chromosome 11 (Bock et al,, 1986; Carter & 
Fothergill, 1987).
2. THE HLA CLASS III COMPLEMENT GENES
Using the powerful technique of PFGE, the orientation and 
position of the complement genes in both the human and mouse MHC class 
III region have been determined (Spies et al., 1986; Hardy et al. , 1986) 
(see figure 4). These studies indicated that the MHC could span up to 
3800 kb and that the class III region spans approximately 1100 kb on the 
short arm of human chromosome 6, and contains two C4 loci as well as 
single C2 and factor B loci. In the mouse these genes have been mapped 
to the S region of the H-2 complex on chromosome 17 (Chaplin, 1985) and 
also to the MHC of a number of other species (Alper, 1981).
In common with the MHC class I and class II genes, the class III 
region genes, particularly C4, are highly polymorphic, with more than 35 
alleles described for the two C4 isotypes (Mauff et al., 1983).
The C2 and factor B genes are 421 bp apart (Wu, Morley & 
Campbell, 1987) and lie about 30 kb from the C4A locus, which is 
separated from the C4B locus by about 10 kb. Further mapping iden|jfied a 
gene encoding the cytochrome P450 21-hydroxylase (21-OHase), 
approximately 3 kb from the 3 1 end of each C4 gene (Carroll, Campbell &
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MOUSE (Balb/c) H-2 COMPLEX
L J 500 kb
Clsiss CldSS Cisss CldSS
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C4B 210HA C2
Figure 4 - Molecular map of the HLA-region on human chromosome 6 and the 
H-2 complex on mouse chromosome 17.(&°r* a\- cl.^ )
Porter, 1985; White et al., 1985). The DRa and C4 genes were found to be 
separated by at least 300 kb. A similar organisation was established for 
the mouse where single C2 and factor B genes were found to be closely 
linked and lie about 50 kb from two C4-like genes separated by 80 kb 
(Chaplin, 1985). It was later established that the gene closest to 
factor B encoded Sip.
(a) C2
Characterisation of the gene encoding C2 has shown that it spans 
18 kb of DMA (Campbell, 1987), but no exon-intron organisation has yet 
been reported. The C2 gene gives rise to a 2.9 kb transcript which 
directs the synthesis of C2 protein, C2, like several other complement 
and non-complement proteins, possesses three 60 amino acid internal 
repeats (SCRs), which are found at the IT-terminal end of the protein.
(b) Factor B
The factor B gene is 6 kb long and is split into 18 exons 
(Campbell et al., 1985). Three of the exons at the 5' end encode the 
three SCRs within the Ba fragment that show significant homology to 
similar repeating units in a number of other proteins. The eight exons 
in the 3* one third of the gene encode the serine protease domain.
The homology in structure and function between factor B and C2 
proteins and the close linkage of the genes suggests they arose from an 
ancestral gene by duplication. However, although the mRlfA molecules 
encoding C2 and factor B are similar in size (2.9 kb and 2.6 kb), the C2 
gene is three times longer than the factor B gene.
DITA sequencing, SI mapping and primer extension experiments have 
established the transcription initiation site of the factor B gene lies 
only 421 bp from the poly A site of the C2 gene (Wu, Morley & Campbell,
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Figure 5 - Close linkage of the human C2 and factor B  genes on 
chromosome 6.
M A  SEQUENCE
TATA Box consensus G-GTATAt A^-G— g
M M M M I i
Factor B
I) i l   I i
TTGTATAAAAGGCTG 
-31 -17
a-Interferon consensus - TTC-£-ACCTC-GCAGTTTCTCt TCTCT 
I 1 1 11 11111 I 11 1 1! II 
GGTGGGACTTCTGCAGTTTCTGTTTCCT 
-154 -127
Factor B
Enhancer core consensus g t g g ^ W g
1111111 i 
GTGGTTTG 
-234 -227
Factor B
. MCHV enhancer 18bp consensus TCAATAGGGACTTTCCAt
f ! 1 M i  M M 1 1
Factor B
1 i 1 I I I  I I \ M i
TTCACATGGAATTTCCCA 
-472 -455
HCMV enhancer 19bp consensus CACCATTGACGTCAAT GGG
Mi  M i  1 M l  Ml
Factor B
i M i  i i l l  l
GACCTTTGGCAGCAAAGGG 
-171 -153
TABLE 5 - Homologies found in the factor B 5'-flanking region with known 
regulatory sequence, (from Vu et al., 1987a).
1987).
The presence of cis-acting DNA elements, essential for the cell 
specific expression of the factor B gene has been suggested by deletion 
analysis of the factor B 5 ‘-flanking region (Wu, Morley & Campbell,
1987). A transcriptional enhancer was defined between nucleotides -496 
to -201, and a promoter was found to extend up to 260 bp from the factor 
B CAP site.
The factor B enhancer is found at the 5' end of the gene, but is
also at the 3 1 end of the C2 gene. It was thought it may also act as a
C2 enhancer although it may not be able to work over a distance of 18 kb 
ie, the distance to the C2 promoter. However recent studies have 
demonstrated the presence of a transcriptional enhancer in the 5'- 
flanking region of the C2 gene (Vu & Campbell, unpublished). 
fc>. -Cl
In humans there are two C4 genes, C4A and C4B, which lie about 
10 kb apart, C4 genes can differ in size (Yu et al., 1986; Schneider et 
al., 1986; Palsdottir et al., 1987) so that C4B genes can be either 22 
kb or 16 kb depending on the presence of a 6-7 kb intron situated about
2.5 kb from the 5 ’ end of the gene (Yu et al., 1986). An unusual
phenomenon is the high frequency of null alleles at either locus 
(Schendel et al., 1984; Partanen & Koskimies, 1986). These null alleles 
may be clinically important as they occur at high frequency in patients 
suffering from some HLA-related diseases such as SLE (Fielder et al., 
1983).
Both human C4 genes give rise to 5.5 kb transcripts and 
comparison of cDNA sequences has revealed less than 1% nucleotide 
variation between C4A and C4B (Belt, Carroll & Porter, 1984).
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Several cis^acting DNA elements have been defined within 1 kb of 
the transcriptional start point of C4 (Vu et al. , 1987). The C4 gene 
contains a non-TATA box promoter within nucleotides -147 to +13 as well 
as a transcriptional enhancer. In the 5'-flanking region there appears 
to be quite a complex arrangement of regulatory elements with a positive 
regulator within less than 200 bp which includes also the promoter and 
the CAP site, and a distal positive regulator separated by a negative 
regulator.
In mouse the two C4-like genes, C4 and Sip, are both 16 kb in 
size (Chaplin, 1985) but they are not as conserved as the two human C4 
genes and share only 94% homology (Ogata & Sepich, 1985; Jfonaka et al.,
1986). However, Sip is not activated by Cls and extensive studies have 
led to the suggestion that Sip has no functional role (Sepich, Rosa & 
Ogata, 1987).
2 -C2»—GA.. -flnd__C5
Complete cDITA and derived amino acid sequences are available for 
human C3 (de Bruijn & Fey, 1985) and C4 (Belt et al., 1984,1985) and 
mouse C3 (Lundwall et al., 1984; Vetsel et al. , 1984), C4 (JTonaka et 
al., 1985; Sepich, Noonan & Ogata, 1985) and C5 (Vetsel, Ogata & Tack,
1987). Partial cDNA sequences are also available for human C5 (Lundwall 
et al., 1985; Vetsel et al., 1988) and rabbit C3 (Kusano et al., 1986). 
Striking homology has been shown between these proteins. C3, C4 and C5 
within each species show 25% identity while the same protein from 
different species shows 75-80% identity. -~~
The human C3 gene was mapped to chromosome 19 (Vhitehead et al., 
1982) while although the mouse C3 gene was mapped to chromosome 17, it 
is about 12cM from the H-2 region (da Silva et al. , 1978; Natsuume-
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Sakai, Hayakawa & Takahashi, 1978) and was estimated to be 24 kb long 
(Viebauer et al., 1982). The human C5 gene was located on chromosome 9 
(Vetsel et al., 1988) while the mouse C5 gene was mapped to chromosome 2 
(D'Eustachio et al., 1986).
4. FACTOR I AMD THE C3b/C4b BIITDING PRQTEIHS
Ca) Factor I
The factor I gene has been mapped to human chromosome 4 
(Goldberger et al., 1987) and gives rise to a 2.4 kb transcript in liver 
(Catterall et al., 1987). The heavy chain of factor I contains several 
recognisable homology units but agreement with the consensus sequence of 
SCRs is poor. So far, factor I polymorphisms have only been detected in 
the Japanese papulation but in no other racial group (Mishimukai & 
Tamaki, 1986).
Primary structure studies of the C3b/C4b binding proteins, 
factor H, C4BP, CR1 and MCP, all of which act as cofactors for factor I 
mediated degradation of C3b or C4b, have shown that factor H, C4BP and 
CR1 are highly homologous. They all contain the 60 amino acid repeat 
units referred to as SCRs (Klickstein et al., 1987a). Two other C3b/C4b 
binding proteins, DAF and CR2 contain these SCRs but lack cofactor 
activity. The genes for CR1, DAF, factor H, C4BP and MCP have been shown 
to be closely linked while studies with cDMA probes have mapped the CR1, 
MCP, C4BP, DAF, CR2 and factor H genes to chromosome 1 (Holers et al., 
1985; Reid et al., 1986; Kristensen et al., 1987a; Rey-Campos,
Rubinstein & Rodriguez de Cordoba, 1987; Rodriguez de Cordoba & ■
Rubinstein, 1986,1987). Using PFGE, a single 950 kb human genomic DNA 
fragment has been identified which hybridises to cDNA probes for MCP,
CR1, CR2, C4BP and DAF but not factor H (Rey-Campos, Rubinstein &
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Rodriguez de Cordoba, 1988; Carroll et al., 1988; Bora et al., 1989). 
This fragment can be split into two pieces, one of 500 kb, containing 
DAF and C4BP genes and the other 450 kb which contains CR1, CR2 and MCP. 
These studies have resulted in the identification of a major gene 
cluster known as the regulation of complement activation (RCA) cluster. 
The order of the genes in this RCA cluster is MCP-CR1-CR2-DAF-C4BP (Rey- 
Campos et al., 1988; Carroll et al., 1988; Bora et al., 1989).
{hi... Factor H
Factor H is the most abundant cofactor protein and the human and 
mouse factor H show 61% sequence identity. This identity is made up 
entirely of SCRs of which there are 20 in each protein (Ripoche et al., 
1988a; Kristensen & Tack, 1986) with individual SCRs showing 25-45% 
identity with each other. The C3b-binding site is likely to be found 
within SCR 4 or 5 (Alsenz et al., 1985).
Initial studies have suggested the factor H gene may be as large 
as 90 kb, with another gene or pseudogene also present (McAleer et al. ,
1987). Murine studies have revealed a 90 kb factor H gene with at least 
two H-related genes or pseudogenes of 60 and 120 kb (Vik et al., 1987).
Three factor H related mRJTA transcripts have been identified 
with Northern analysis of human liver poly A* mRNA (Ripoche et al. ,
1988a; Schwaeble et al., 1987). The longest transcript of 4,4 kb codes 
for the whole 155 kDa protein, while the 1.8 kb transcript codes for the
43 kDa shorter form of factor H seen in plasma. This short-form factor H
corresponds to the IT-terminal region of the whole protein, and only
hybridises to probes from the 5' end of the factor H cDNA probe. The
function of this truncated form of factor H is as yet unknown, although 
it does possess the C3b-binding site. The 43 kDa protein translated from
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the 1,8 kb transcript is distinct in size from the normal proteolytic 
cleavage products of factor H. This has led to the suggestion that the 
two factor H transcripts arise from separate genes rather than splicing 
of the 4.4 kb transcript (Schwaeble et al., 1987).
A third factor H transcript of 1.0 kb has also been detected and 
corresponds to the C-terminal portion of the cofactor (Schwaeble et al., 
1987; Ripoche et al., 1988a).
(C) C4BP,
The human C4BP gene is about 30 kb long, while the mouse gene is 
20-25 kb long (Barnum et al., 1987; Lintin & Reid, 1986). Unlike factor 
H, there is no evidence of C4BP-related genes or pseudogenes.
There is only one mRNA species of 2.5 kb detectable in human 
liver (Chung, Bentley & Reid, 1985) while the mouse C4BP liver 
transcript is 1.8 kb long (Kristensen et al., 1987b).
The E-terminal 491 residues of the seven human C4BP chains are 
in the form of eight SCRs while the C-terminal 57 residues do not follow 
this pattern (Chung et al., 1985). Structure-function studies suggest 
that the C4b-binding site is likely to be in the fourth SCR (Kristensen 
et al., 1987a,b). Comparison of the human and mouse C4BP amino acid 
sequence suggest SCRs 5 and 6 of the human C4BP are missing from the 
mouse protein (Kristensen et al., 1987b), although the human and mouse 
sequences show 52% identity when the appropriate regions are aligned.
Id) CR1 and CR2
CR1 exists as four allotypes, the most common being CR1-A 
(Klickstein et al., 1987a). The sequence of CR1 is much more repetitive 
than factor H and C4BP and contains at least 33 SCRs, most arranged into 
four groups of seven (Klickstein et al., 1987a). These 450 amino acid
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segments are termed long homologous repeats (LHR) which have a very high 
degree of homology ie. as high as 99% identity (Klickstein et al.,
1987a). This high level of homology shows good evidence for duplication 
and conversion events in the evolution of CR1.
cDNA sequencing has revealed a sequence of 5.5 kb, containing an 
open reading frame of 4.7 kb (Klickstein et al., 1987a). Northern 
blotting has suggested that each allele has two transcripts of un€^ual 
amount. In the case of CR1-A, the major transcript is 8.6 kb whileAfor 
Bt>11.6 kb, for Cp.7.3 kb and for Dj.^12.8 kb (Hourcade et al., 1987). As 
for factor H smaller transcripts corresponding to different regions of 
the protein have also been detected (Halers et al., 1987; Klickstein et 
al., 1987b).
CR1 cDNA probes hybridise to CR2 cDNA at low stringency thus
revealing a close sequence similarity. The CR2 mRNA has been shown to be
5 kb long (Weis et al., 1986) while cDNA sequencing has indicated 
L  U.
. CR2Amade up of 15 SCRs. Human CR1 cDNA probes also cross- 
hybridise to some mouse DNA sequences which most likely correspond to 
mouse CR1 and CR2 (Weis et al, , 1987). 
ie) DAF and MCP
The human DAF gene is 35 kb long (Stafford et al., 1987) and 
several mRNA transcripts have been reported (Caras et al., 1987; Medof 
et al., 1987). The shorter transcript, which is the major form found in 
HeLa cells, lacks the 118 bp intron seen in the longer, minor tran­
script. The shorter mRNA is thought to be responsible for producing the 
mature membrane bound DAF while the longer transcript is translated into 
the soluble form of DAF.
MCP, the C3b/C4b binding protein most recently mapped to the RCA
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gene cluster on chromosome 1 (Bora et al., 1989), produces a transcript
1.5 kb long (Lublin et al., 1988).
5, QE3.
CR3 is composed of two non-covalently linked subunits, a and £, 
with this same ^-subunit also present on two other cell surface adhesion 
antigens, pl50,95 and LFA-1 (Sanchez-Madrid et al., 1983). "The gene 
encoding this J3-subunit has been mapped to chromosome 21 (Marlin et al., 
1986) and is estimated to be about 32 kb long (Kishimoto et al., 1987).
A species of mRNA has been detected and is about 3.2 kb long.
An interesting finding was that patients deficient in CR3 are 
also deficient in pl50,95 and LFA-1, thus suggesting that it is their J3- 
subunit that is defective (Springer et al., 1987).
6, THE TERMINAL PATHWAY COMPONENTS
Components of the membrane attack complex, C6, C7, C8 and C9 are 
structurally, antigenically and functionally related. For example, C6 
and C7 are both single chain glycoproteins of about 115 kDa and have 
been shown to be closely linked.
C7, C8oc, C8jl and C9 have been cloned and show 21-26%
identity, while studies on the human C9 gene indicate a coding region of 
12 exons covering at least 80 kb of DNA (Muller-Eberhard, 1986; DiScipio 
et al., 1987; Howard, Rao & Sodetz, 1987; Marazziti et al., 1987). 
Studies with cDNA probes for the three C8 chains have localised them all 
to chromosome 1 (Rogde et al., 1986).
Homology with a number of other membrane-disrupting proteins 
such as perforin (Young, Cohn & Podack, 1986), has led to the suggestion 
that the terminal complement components are members of a large family of 
membrane attack proteins.
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CQMPLEMEim. BIOSYNTHESIS.
Although the complement system was first recognised more than 
one hundred years ago, the sites of complement biosynthesis remained 
unknown for a further eighty years. Various cell types have been shown 
to be capable of synthesising functionally active complement components 
in vitro but indications are that the full list of sites of complement 
biosynthesis is yet to be completed.
The study of complement biosynthesis by tissues in vivo has been 
revolutionised by the use of molecular hybridisation techniques to 
detect mRNAs coding for complement components. However, evidence using 
these powerful techniques is thus far extremely limited and nearly all 
complement biosynthesis work has been performed using in vitro culture 
systems.
The study of complement biosynthesis was greatly enhanced with 
the development of a number of well defined sensitive assays (Rapp & 
Borsos, 1970). However, failure to detect components using these assays 
does not necessarily mean that the cells are not producing them. Instead 
the level of the component in the culture medium may be less than the 
lower limit of sensitivity of the assay. Secondly, the component may not 
have been converted from its precursor state to its active form and 
hence not detected by the assay system. Finally, the component may U a 
degraded in the culture medium thus avoiding detection.
Detection of complement component biosynthesis may be first 
approached using an enzyme linked immunosorbent assay (ELISA) or radio--—  
immunoassay. Although these two assays are very sensitive neither give 
any indication of functional activity of the component.
To detect functionally active complement components, the use of
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the haemolytic assay system is essential, where the ability of the 
complement component to lyse antibody coated sheep erythrocyte cells is 
measured. The haemolytic plaque assay may also be used, which allows 
single cell synthesis to be studied.
The incorporation of radioactively labelled amino acids into 
immunoprecipitable protein is another important technique used for 
confirming synthesis of complement components with 3SS-methionine being 
the most commonly used label. Analysis of the immunoprecipitable protein 
by SDS-PAGE and fluorography confirms the subunit structure of the 
protein and enables the precursor form to be identified. Inhibition of 
synthesis by cycloheximide is a further requirement to prove complement 
biosynthesis by cultured tissue or cells.
As stated above, the isolation of cDNA clones for nearly all the 
complement components and the use of molecular hybridisation techniques 
have revolutionised the study of sites of complement biosynthesis in 
vivo. Northern and dot-blot analyses of RNA isolated from tissue that 
had been snap-frozen immediately after removal from the patient, have 
been used to detect mRNAs coding for complement components. These 
techniques have emerged as the most powerful tools for determining the 
sites of complement biosynthesis in vivo.
However, thus far much of the evidence for locating the sites of 
complement biosynthesis has been derived from in vitro culture 
techniques and the other methods outlined above. Combinations of these 
techniques have demonstrated the following tissues and cell types to be 
capable of synthesising complement components.
la) LIVER
The major site of synthesis of complement proteins found within
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blood is the liver or more specifically the hepatocyte. This conclusion 
is based on the observation made in patients undergoing orthotopic liver 
transplantation where their C 3, onA O g  allotypes quickly
changed to that of the donor following the operation (Alper et al.,
1969; Alper & Nathan, 1981). Other work has also shown that human fetal 
livers are capable of synthesising in vitro, biologically active C2, C4, 
C3 and Cl-IffH (Colten, 1972).
(b) Hep G2 CELLS
Further work with the human hepatoma cell line Hep G2 emphasised 
the liver as being the major site of complement synthesis. The Hep G2 
cell line was shown to synthesise and secrete functional Clr, Cls, C2,
C3, C4, C5, factor B, Cl-INH, factor H, C6 and C8 but failed to produce 
Clq, C7 or C9 (Morris et al. , 1982a,b). Work with this cell line, which 
was derived from a human hepatocellular carcinoma, also showed that 
human C5, like C3 and C4, is synthesised as a single chain precursor 
that is converted by limited proteolysis to the native two chain 
molecule and established the precursor-product relationship for human 
pro-C4 and native C4 and pro-C5 and native C5 (Morris et al., 1982b),
(c> XQHQSUCLEAR PHAGOCYTES
Biosynthesis of complement components by mononuclear phagocytes 
was first reported by Stecher and coworkers (1967). Human studies have 
revealed that human mononuclear phagocytes synthesise the following 
complement components: Cl and its subcomponents (Stecher, Morse & 
Thorbecke, 1967; Muller, Hanauske-Abel & Loos, 1978), C2 (Einstein, 
Schneeberger & Colten, 1976; Littraan & Ruddy, 1977; Ackerman et al.,
1978; Whaley, 1980; De Ceulaer, Papazoglou & Whaley, 1980; Cole et al. ,
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1982; Lappin et al., 1986), C3 (Stecher et al., 1967; Cole et al., 
1982,1983; Strunk, Kunke 8c Ciclas, 1983), factor B (De Ceulaer et al., 
1980; Whaley, 1980; Cole et al., 1982,1983), factor D, properdin, factor 
I, factor H (De Ceulaer et al,, 1980; Whaley, 1980) and Cl-IIfH (Yeung- 
Laiwah et al., 1985).
Although it has been suggested that synthesis of C4 (De Ceulaer 
et al., 1980; Whaley, 1980; Hetland et al., 1987) and the terminal 
complement components (C5-C9) occurs (Hetland, Johnson 8c Aaseb, 1986; 
Petterson, Johnson & Hetland, 1987), these reports have not been 
substantiated using the more conventional techniques listed above.
A number of complement components exist intracellularly as 
precursor molecules, namely, C4 and C3 in guinea pig peritoneal 
macrophages (Brade 8* Kreuzpainter, 1982; Colten, 1982) and C4 and C5 in 
mouse peritoneal and splenic macrophages (Colten, 1982), while pro-C3 
has been identified in human monocytes.
Processing of complement precursor molecules occurs intra­
cellularly (Fey & Colten, 1981) and several studies have examined the 
mechanism involved in the processing of these molecules. Pulse-chase 
experiments have shown that the precursor molecule appears intra­
cellularly before the native form appears in the supernatant.
Furthermore, the disappearance of the intracellular precursor coincides 
with the appearance of the secreted form (Parker, Roos & Schreffler, 
1979). Finally, the conversion of pro-C4 to C4 by plasmin (Goldberger 8? 
Colten, 1980) confirms the precursor-product relationship. The process 
would appear to involve limited proteolysis since the precursor proteins 
are all single chain molecules whereas the native forms are composed of 
three chains in the case of C4 and two chains each for C3 and C5.
- 28 -
Most of the complement components are glycoproteins but the 
importance of the carbohydrate moieties is not fully understood. 
Secretion of C4, C2 and factor B by guinea pig macrophages is greatly 
inhibited by the addition of tunicamycin, an inhibitor of dolichyl- 
phosphate-dependent glycosylation (Matthews et al., 1982) and there is 
an increased intracellular catabolism of under-glycosylated pro-C4. 
However the C4 secreted by these tunicamycin treated guinea pig 
macrophages has virtually the same functional activity as normal C4. 
Hence the carbohydrate moieties may be important in restricting 
intracellular proteolytic cleavage of the precursors and also in 
ensuring that the appropriate tertiary structure formation is achieved 
to facilitate secretion.
It has been shown that changes in the profile of complement 
component biosynthesis by mononuclear phagocytes occurs as they undergo 
maturation from monocytes to macrophages. Freshly isolated peripheral 
blood monocytes only start to produce C2 and factor B after 3 days in
culture after which synthesis increases with time (Einstein et al.,
1976; Whaley, 1980). In contrast, macrophages do not show this lag phase 
but produce complement proteins immediately (De Ceulaer et al., 1980; 
Cole et al., 1982). Furthermore, the ratio of C2 to factor B secretion 
in breast milk, bronchoalveolar and synovial fluid macrophages differs 
from the relative secretion rates of these components in monocytes (De 
Ceulaer et al., 1980; Cole et al., 1982) thus demonstrating that
mononuclear phagocytes are able to alter the synthesis rate of
individual components selectively as well as acting as a marker of 
monocyte-macrophage maturation. It has also been shown that the 
proportion of macrophages synthesising complement depends on the tissue
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of origin. Using a haemolytic plaque assay, only 2% of guinea pig 
bronchoaLveolar macrophages synthesised C2 compared with 45% of 
peritoneal and splenic macrophages from the same animals (Alpert et a l ., 
1983). Similar variations in human macrophage populations have also been 
reported (Cole et al., 1983).
Many studies have shown that complement protein secretion 
increases as the macrophage becomes more activated (Cole et al., 1980; 
Zimmer et al., 1982) but studies using murine peritoneal macrophages 
have produced conflicting results, in that C4 production by the 
activated cells fell despite an increase in total protein production and 
increased factor B secretion (Mewell & Atkinson, 1983). However this may 
be due to inhibition of C4 synthesis by secreted C4 (Matthews et al., 
1979).
It is now well established that functions of mononuclear 
phagocytes are modulated by various factors in their environment. For 
example there is enhanced complement production in vitro by macrophages 
from sites of inflamination such as active rheumatoid arthritis joints 
(De Ceulaer et al., 1980). Phagocytosis of bacteria or bacterial 
products such as lipopolysaccharide, stimulates complement production by 
mouse peritoneal macrophages although the ingestion of zymosan by human 
monocytes has the apposite effect (Morrison & Vhaley, 1983). T- 
lymphocyte derived lymphokines stimulate C2 production by monocytes 
(Littman & Ruddy, 1977) and the binding of immune complexes and 
polymerised IgGi and IgGs to monocytes has been shown to increase 
complement production (McPhaden, Lappin & Vhaley, 1981). This effect was 
shown to be Fc-receptor mediated as F(ab)s: fragments had no effect.
While the liver is responsible for the maintenance of plasma
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levels of most complement components, it is possible that mononuclear 
phagocytes play a role in the local production of complement in 
peripheral tissues. In other words, as a result of synthesis of 
complement components mononuclear phagocytes may play a key role in 
mounting the initial response to many infectious agents and hence act as 
an important mobile source of complement.
(d) SY10VIAL MEHBKAHE AID SY3TOVIAL JLfflD
Human synovial tissue from rheumatoid arthritis patients has 
been shown to be able to synthesise C2, C3, C4 and C5 when cultured in 
vitro (Ruddy & Colten, 1974). This study also provided the only evidence 
thus far for in vivo synthesis of complement by synovial tissue. 
Radiolabelled (1:2e-I) C3 was injected intravenously into a man suffering 
from rheumatoid arthritis. The specific activity (cpm/pg C3) of the 
radiolabelled C3 was then followed in both the plasma and synovial 
fluid. The results showed the specific activity of C3 in the synovial 
fluid never reached that of the plasma, and suggested that 50% of the C3 
found within the inflamed joint was synthesised locally. In vitro 
studies showed cultured fragments of synovial tissue synthesised 
functionally active C2, C3, C4 and C5 and also showed incorporation of 
14C-labelled amino acids into C3, C4 and factor B but not C5. These 
studies also demonstrated that synthesis of C2, C3, C4 and C5 was 
frequently observed in rheumatoid synovium but only rarely in 
degenerative or traumatic joint disease.
De Ceulaer et al (1980) demonstrated increased biosynthesis of 
complement components by cultured monocytes, synovial fluid macrophages 
and synovial membrane macrophages from patients with rheumatoid 
arthritis and degenerative joint disease. Synthesis of functionally
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active C2, factor B, factor D, properdin, factor I and factor H was 
observed in all three cell types while 14C-labelled amino acids were 
incorporated into immunoprecipitable, but functionally inactive C3, C4 
and C5. This final observation is particularly interesting because Ruddy 
and Colten (1974) showed synovial tissue fragments synthesised 
functionally active C3, C4 and C5, thus suggesting that other cells in 
the synovial membrane synthesise these components or that other cells in 
the cultured tissue are synthesising an enzyme (or enzymes) capable of 
activating precursor complement proteins.
Recently, fibroblast-like cells were isolated from normal 
synovial membrane and cultured in vitro. After several passages, these 
cells synthesised Clr, Cls, Cl-INH, C2, C3, factor B and factor H (Katz 
& Strunk, 1988b). These data suggest that cells in normal synovial 
tissue may also synthesise complement components.
Thus, in vitro work has led to the suggestion that synovial 
tissue in arthritic, and possibly normal individuals may be capable of 
synthesising a number of complement components. However the in vivo 
evidence is very limited but could be substantially expanded by using 
the powerful techniques of molecular biology. The isolation of RNA from 
synovial tissue that has been snap-frozen in liquid nitrogen immediately 
after removal from the joint would allow the detection of mRNAs coding 
for various complement components by Northern and dot-blot analyses. 
Detection of these mRNAs would be strong evidence for in vivo synthesis 
of complement components by the synovial tissue. Such evidence could be 
reinforced by the in vitro synthesis of these components by cultured 
fragments of synovial membrane from the same patient.
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SITE COMPLEMENT COMPONENTS
LIVER Maintains serum levels of the vast 
majority of complement components.
MONONUCLEAR PHAGOCYTES
/
Mobile source of most of the 
complement components.
EPITHELIAL CELLS OF THE GASTRO­
INTESTINAL AND GENITOURINARY TRACTS Main site Of Cl synthesis.
Table 6 - ltaj or sites of complement biosynthesis.
(e) EPITHELIAL AND ENDOTHELIAL CELLS
The evidence now is that the main site of human Cl synthesis in
vivo is the gastrointestinal and genitourinary epithelial cell (Colten,
1976). In vitro studies with human umbilical vein endothelial cells have 
shown these cells to be capable of synthesising and secreting C3 protein 
as well as expressing a C3 transcript of the correct size, 5.3Kb 
(Varren, Pantazis & Davies, 1987). These data suggest that C3 may be 
synthesised locally within the vascular bed. Recent studies have shown 
that^-interferon induces synthesis of alternative pathway components by 
cultured human endothelial cells (Ripoche et al., 1988b).
(f) FIBROBLASTS
Al-Adnani & McGee first showed in vitro synthesis of Clq by 
human and rat fibroblasts in 1976, Since then, fibroblasts have been
shown to be capable of synthesising C3, factor B, C2 (Katz, Cole &
Strunk, 1988) and factor H (Katz & Strunk, 1988a). As described above, 
fibroblast-like cells isolated from normal synovial membrane have been 
shown to be capable of synthesising seven complement components in vitro 
(Katz & Strunk, 1988b).
CONCLUSION
The above evidence shows that many different cell types are 
capable of complement component synthesis and secretion. It is likely 
the list of tissues and cell types responsible for complement 
biosynthesis will continue to grow.
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INFLAMMATION
Inflammation can be defined as the response of living tissue to 
any injury. It functions as a protective mechanism against injurious 
agents and acts to remove these agents and repair damaged tissue. 
Inflammation is characterised by dilatation of blood vessels, invasion 
of the tissue by leukocytes from the blood and the passage of blood 
proteins and fluid through capillary walls into the tissue space.
The effects of inflamination are usually beneficial by helping to 
eliminate microorganisms, limiting the injurious effects of irritating 
chemicals and bacterial toxins and participating in the removal of 
necrotic cells and tissue debris. However some effects of inflammation 
may be harmful such as the impairment of movement, constriction of 
airways, interference with blood flow (causing ischaemia and cell death) 
and allergic reactions (Anderson, 1985; Ryan & Majno, 1977; Hurley,
1972; Bessis, 1964).
There are two main types of inflammation: acute and chronic 
inflammation. A relatively intense injury over a short period of time 
stimulates an acute inflammatory reaction which frequently subsides 
without leaving residual effects, although the formation of granulation 
tissue with consequent fibrosis or scarring is possible (Gabbiani et 
al., 1972). Other agents which may not produce severe initial tissue 
injury may persist for long periods and result in chronic inflamination.
1*_ ACUTE INFLAMMATION
la) Active hyperaemia
Following injury, arteriolar contraction causes a transient 
blanching of the tissue which within a few minutes is followed by
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arteriolar dilatation in and around the injury site. Capillaries and 
post-capillary venules become engorged with rapidly flowing blood which 
accounts for the redness and heat seen in inflamed tissues.
The autonomic nervous system and in particular the sympathetic 
adrenergic nerves regulate changes in tone of the smooth muscle of 
arterioles which in turn controls the flow of blood through a tissue. 
Depending upon the metabolic state of the tissue there will also be a 
variety of local factors exerting their effects on the blood vessels. 
Hence active hyperaemia in acute inflammation is probably due to a 
predominance of local factors over the general arteriolar control 
mechanisms (Anderson, 1985).
(b) Exudation
As described above, the onset of an inflammatory reaction is 
marked by swelling caused by an exudation of fluid from the blood 
vessels into the surrounding tissues.
Landis (1927) first showed that the balance between the internal 
hydrostatic pressure and osmotic pressure of the plasma is disrupted by 
arteriolar dilatation at inflammatory sites, resulting in a net loss of 
fluid from the terminal vascular bed, Loss of fluid from the blood 
vessels causes an increase in the concentration of proteins and cells 
which results in a slowing of the blood flow due to an increase in blood 
viscosity (Anderson, 1985).
(g) Exudation of plasma proteins
Exudation of plasma proteins has been shown to occur in two 
phases: one immediate and transient and the other delayed and prolonged,
(i) the immediate phase: due to the release of mediators and in 
particular histamine, which cause opening of gaps between endothelial
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cells by causing their contraction resulting in escape of fluid and 
proteins (Sevitt, 1958).
(ii) the delayed phase: mainly due to the direct effect of the injury 
but may be amplified by inflammatory mediators exerting their effects on 
surrounding tissues (Lewis, 1927).
(d) Endogenous mediators
Endogenous mediators may be derived from plasma or released by
cells.
(i) Plasma: there are four related groups of proteins capable of 
producing mediators; the kinin system, the clotting system, the 
fibrinolytic system and the complement system. Contact to basement 
membrane and several other substances activates Hageman factor which 
results in activation of the kinin system (Miles, 1969; Anderson, 1985). 
Once activated the kinin system leads to activation of the clotting 
cascade and the fibrinolytic system, following the release of kinins 
such as bradykinin (Anderson, 1985). Activation of Hageman factor 
releases plasmin (from plasminogen), an enzyme capable of digesting 
fibrin, activating Hageman factor (thus feeding back to trigger the 
kinin system) and which may also activate Cl and cleave C3 of the 
complement system (Margolis, 1959; Willoughby, Cooke & Turk, 1969).
(ii) cells: a number of mediators are known to be released by cells but 
only a few have been characterised chemically. Mast cell granules, 
basophil leukocytes and platelets store an inactive form of histamine 
which is released on activation by many stimuli, e.g. heat irradiation, 
toxins, anaphylatoxins and IgE antibody complexed with an allergen 
binding to mast cells, as in the case of hay fever (Ryan, 1974). Factors 
promoting platelet aggregation also release histamine from platelets
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(Majno, Palade & Schoefl, 1961). 5-hydroxytryptamine (seretonin) is 
present in some tissues and may cause a brief increase in vascular 
permeability when it is released (Majno et al., 1961). Oxidation of 
polyunsaturated fatty acids such as arachidonic acid leads to release of 
prostaglandins (Majno et al., 1961). Prostaglandins are potent 
stimulators of smooth muscle contraction thus resulting in active 
hyperaemia. Although prostaglandins do not cause pain directly, they 
lower the pain threshold of nerve endings to histamine, seretonin and 
bradykinin.
(e) Emigration of leukocytes
Initially, leukocytes stick to the endothelium and then pass 
through the vessel wall. Emigration of leukocytes appears to be 
independent of gaps between endothelial cells which are responsible for 
increased vascular permeability (Marchesi, 1961).
In acute inflammatory lesions neutrophil polymorphs migrate 
earlier and in much greater numbers than monocytes (Anderson, 1985).
The polymorphonuclear (PMN) leukocytes take only a few minutes to pass 
through venule walls and then assume their scavenger role as they wander 
through tissues. Emigration of PMN leukocytes is thought to be mediated 
by chemotaxis and many substances have been shown to be chemotactic for 
polymorphs In vitro e.g. products of the activated complement, clotting, 
fibrinolytic and kinin systems, substances released by injured tissues 
and microorganisms (Wilkinson, 1974; Wilkinson, Russel & Allen, 1977).
In acute inflammation the peak of polymorph emigration has 
passed before monocytes migrate in sufficient numbers. Hence it would 
appear as though different factors control the infiltration of 
polymorphs and monocytes (Ryan, 1967). Although mononuclear phagocytes
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are attracted by some of the agents which are chemotactic for 
polymorphs such as C5a and CSades.arg, a number of substances are known 
to be predominantly chemotactic for monocytes,
2. CHRQIIC ISFLAXMATIOfl
Chronic inflammation, which may not have an acute onset, is 
elicited when the injurious stimulus persists resulting in a 
continuation of the inflammatory process.
Some bacteria are remarkably non-toxic and can survive and 
multiply within macrophages without being destroyed. The infected 
tissues become heavily infiltrated with macrophages containing huge 
numbers of the organisms and although little fibrosis occurs with such 
lesions the infiltrating cells are typical of a chronic inflammatory 
reaction (Ryan & Spector, 1970; Varren, 1972; Anderson, 1985). Other 
bacteria are equally nan-toxic but features of the lesion are altered by 
the development of delayed hypersensitivity by the host which not only 
promotes killing of the bacteria by macrophages but also causes tissue 
injury, necrosis granuloma formation and scarring. Hypersensitivity 
reactions develop as a result of the host's immune response (Varren,
1972; Unanue & Benaceraff, 1973) and is characterised by infiltration of 
the inflammatory site with lymphocytes and macrophages. In some chronic 
inflammatory diseases with features of hypersensitivity reactions, the 
causal agent remains obscure, e.g. Crohn's disease, sarcoidosis, 
rheumatoid arthritis (see later) and systemic lupus erythematosus.
There are considerable variations seen at chronic inflammatory..—  
sites and these variations are determined by the causal agent. The 
features include foci of acute exudative inflammation with P M  
leukocytes, macrophages, lymphocytes and plasma cells, necrosis,
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formation of granulation tissue and dense fibrous tissue. The variations 
result from the relative prominence of each of these features (Anderson, 
1985; Ryan & Majno, 1977).
Effects of chronic inflammation
Chronic inflammation either results from a hypersensitivity 
reaction to an otherwise harmless substance or occurs in autoimmune 
diseases and seems to serve no useful function (IJnanue & Benaceraff,
1973; Anderson, 1985). When tissue has been lost in an inflammatory 
process, healing occurs by fibrosis but this fibrous tissue may induce 
serious effects by blocking or constricting, e.g. the mitral valve in 
chronic rheumatic fever or the small intestine in Crohn's disease, and 
destruction of tissues by scarring and shrinkage.
-TYPES QF. CELLS. II IKFLAJMATQRY LESIQJTS 
la) Polymorphonuclear leukocytes; the neutrophil polymorph is the 
predominant phagocytic cell at sites of acute inflammation. They are 
highly specialised cells, actively motile, rich in lysosomal enzymes and 
respond readily to chemotaxins. Eosinophil polymorphs are also seen to 
accumulate at sites of inflammation when hypersensitivity reactions are 
involved and may play a regulatory role (Ryan, 1967; Hurley, 1972).
<b) Monocytes; are less actively motile and phagocytic than neutrophil 
polymorphs but provide a reserve of cells, which on infiltration of an 
inflammatory site mature into macrophages (Ryan, 1967; Van Furth, 1979; 
Ebert & Florey, 1939; Cronkite et al., 1960; Spector, Valter &
Villoughby, 1965; Van Furth, 1970). Monocytes develop an increase in 
lysosomal enzymes, metabolic activity, motility and phagocytic and 
microbicidal capacity.
(c) Macrophages: ingest and destroy inflammatory debris and indigestable
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material may also be taken up by macrophages and sequestered for long 
periods. Macrophages may be capable of limited division and long 
survival after phagocytic activity. They are able to synthesise plasma 
membrane, lysosomal enzymes and lysosomes. Such properties make 
macrophages particularly suited to sustained function in prolonged 
inflammatory reactions where they gradually replace neutrophils as the 
predominant phagocytic cell (Hurley, 1972; Ryan & Spector, 1970;
Spector, 1974).
(d) Lymphocytes: when present in large numbers are suggestive of either 
a delayed hypersensitivity reaction or of antibody-dependent lymphocyte 
cytotoxicity. The presence of plasma cells are indicative of antibody 
production (Hurley, 1972; Unanue & Benaceraff, 1973; Anderson, 1985).
(e) Fibroblasts: are seen in mast inflammatory lesions but their 
presence in large numbers is indicative of chronic inflammation and 
repair (Hurley, 1972; Ryan et al., 1974; Anderson, 1985).
(f) Serosal cells: which include endothelial lining cells and 
macrophages often pass into the exudate at an early stage of an 
inflammatory reaction (Hurley, 1972; Ryan, 1967; Anderson, 1985).
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is a classical example of chronic 
inflammation which due to its high incidence worldwide, its frequent 
onset in early adult life and its chronic and disabling effects, is 
one of the most important diseases of mankind.
(a) Course of the disease
Rheumatoid arthritis (RA) is one of the connective tissue 
diseases and is characterised by a subacute or chronic non-suppurative
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arthritis usually affecting several joints. The course of the disease is 
punctuated with periods of relapse and remission with the joint 
suffering further damage each time.
RA affects approximately 3% of the female and 1% of the male 
population. Those between the ages of 25 years and 55 years are most 
susceptible, although the disease is not restricted to this age group. 
Any synovial joint may be affected but those of the hands and feet are 
most often involved, the disease often being bilateral and symmetrical.
The onset of RA is often insidious but can be acute and during 
this early stage and during relapse, the joints become inflamed, hot, 
swollen (partly due to synovial effusion) and tender and the patient 
often suffers from fatigue, weight loss and fever. The inflammatory 
process occurs within the synovial membrane resulting in cartilage 
damage and subsequent bone erosion. The surrounding muscles become 
subject to wasting and weakness, and the tendons may be ruptured causing 
even further deformity ( Ccd-Vc ., 1985; Harris, 1984).
Synovitis in RA begins with a non-specific increase in the 
number of small capillaries and synovial blood flow associated with an 
accumulation of mononuclear cells around these blood vessels. The 
stimulus to new blood vessel formation in RA is probably related to the 
inflammatory response. Synovial cells then proliferate and the synovium 
thickens. After a while there is an infiltration of lymphocytes (mostly 
T-cells) (Van Boxel & Paget, 1975), around the blood vessels. Three main 
types of infiltration areas have been described: lymphocyte-rich, plasma 
cell rich and transitional areas (Ishikawa & Ziff, 1976). Transitional 
areas contain what are likely to be dendritic cells which may act as 
antigen presenting cells for the T-lymphocytes.
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Changes in other tissues can also be seen including sub­
cutaneous lesions known as rheumatoid nodules which develop over 
pressure sites in about 20% of patients. The nodules persist throughout 
life and are a helpful clinical and histological diagnostic aid. They 
tend to occur in more severely affected patients and are associated with 
a worse prognosis.
In severe RA, vasculitis may occur which results in skin 
ulceration and occasionally gangrene, bowel perforation and myocardial 
infarction (Anderson, 1985).
(b) Pathogenesis and aetiology of RA
The cause of RA is unknown but the disease presents features 
which suggest the lesions in the joints and elsewhere are secondary 
hypersensitivity reactions.
(i) Complement activation
Complement activation is now accepted as playing a major role in 
the pathogenesis of RA. Complement was first suspected of being involved 
when levels in serum were observed to be normal while complement levels 
in synovial fluid were depressed, leading to the suggestion that there 
was a high turnover of complement within the joint space (Pekin & 
Zvaifler, 1964; Ruddy 8i Austen, 1970). More recent work has identified 
complement breakdown products within the synovial joint (Berkowicz et 
al., 1983; Mollnes et al., 1986) confirming that complement activation 
does occur. Ruddy and Colten, (1974) have also shown that rheumatoid 
synovial tissues are capable of synthesising the complement components 
C2, C3, C4 and C5 in vitro as well as demonstrating local C3 synthesis 
in vi vo.
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(ii) Rheumatoid factors
Rheumatoid factors (RFs), are autoantibodies mainly of the IgH 
and IgG classes, which are present in the serum of most cases and react 
with antigenic components of the Fc region of IgG molecules, forming 
immune complexes. Patients with RF in their sera are said to be 
seropositive distinguishing their disease from a group of seronegative 
arthritides (RF is absent) which includes ankylosing spondylitis 
(Fong, Carson & Vaughan, 1986; Carson et al., 1987).
Rheumatoid factor activity was first recognised by the ability 
of the sera of RA patients to agglutinate erythrocytes coated with small 
amounts of IgG antibody (Waaler, 1940; Rose et al., 1948).
RFs will bind more avidly with IgG that has already bound to an 
antigen than free monomeric IgG and hence may act to further aggregate 
immune complexes (Fong et al., 1986; Carson et al,, 1987; Anderson,
1985).
However, rheumatoid factors (RFs) have only been found in 
approximately 80% of RA patients and have also been found in patients 
suffering from various other diseases and in a small proportion of 
healthy individuals, very few of whom subsequently develop RA (Anderson, 
1985; Harris, 1984; Carson et al., 1987).
RF in serum has a lower avidity than RF found in affected 
synovium, and serum RF in RA patients has been shown to be capable of 
activating complement whereas the RF present in the serum of some 
individuals without RA does not activate complement (Zvaifler & Schur, 
1968; Anderson, 1985). These findings could help to explain why serum RF 
is not always associated with disease but a high titre in patients with 
RA and particularly in the presence of IgG RF, is associated with severe
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disease .
Even if RFs^are suspected of being involved in the development 
of RA, it is still not known what initiates the production of RF.
Various infective agents have been considered e.g. exogenous antigens 
such as bacteria and viruses and endogenous antigens such as collagen, 
have all elicited RF but the results are inconsistent and no one antigen 
or group of antigens have been identified as being involved in all 
cases (Harris, 1984; Anderson, 1985).
The features of RA are consistent with the view that rheumatoid 
factor-IgG immune complexes within the joint, activate complement thus 
inducing inflammation by the emigration and activation of cells such as 
PMN leukocytes and monocytes which phagocytose the immune complexes, 
releasing agents such as lysosomal enzymes which can injure the 
cartilage and synovium.
1111.) Involvement of T-cells
Hence while immune complex disease could explain some of the 
major features of RA, there is some evidence that T-cells are also 
involved. The majority of lymphocytes found in the joint fluid of RA 
patients are T-helper cells which have been shown to be activated and 
secrete , lymphokines which play a role in the emigration and activation 
of several inflammatory mediators (Van Boxel & Paget, 1975). 
lly) Genetic predisposition
The major immunogenetic association with RA is the histo­
compatibility locus, HLA-Dw4 (Stastny, 1978; Panayi, Vooley & Batchelor, 
1979). The association however is by no means as strong as the HLA-B27 
locus for ankylosing spondylitis. The incidence of HLA-Dw4 in sero­
positive patients has been shown to be 52%, while seronegative patients
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had a frequency of 24% and control subjects had a frequency of 25% 
(Stastny, 1982). However it has also been shown that the HLA-Dw4 locus 
does not appear to be associated with rheumatoid factor because patients 
who have rheumatoid factor but do not have RA, do not have a higher 
demonstrated frequency of HLA-Dw4 (Harris, 1984).
2, OSTEOARTHRITIS
Osteoarthritis (OA) is the most common rheumatic disease 
(Lawrence, Bremener & Beir, 1966; Peyron, 1986) with the greatest 
increase in occurence between 40 and 50 years of age. Radiologic surveys 
have shown that more than 80% of the papulation over 55 years of age 
have OA, with the hands and feet most often affected, although the 
overall frequency of OA is equal in men and women (Hamerman, 1989).
(a) Pathogenesis and aetiology
While RA may be regarded as a chronic inflammatory disease, OA 
is looked upon more as a wear and tear disease, although features of 
inflammation may be seen. OA may be defined as a clinical syndrome 
resulting from defects in articular cartilage and related changes in 
subchondral bone, joint margins, synovium and para-articular structures 
(Howell, 1985).
There are no commonly accepted criteria for diagnosis of OA and 
diagnosis is often based on the presence of symptoms when other 
arthritic diseases have been excluded.
The synovial fluid from an OA patient is usually clear, may be 
yellow-tinged but is often colourless and highly viscous. It usually _
contains Wrwea.o 200 and 2000 white blood cells, mostly mononuclear, but 
if significant inflammation is present the synovial fluid white cell 
count may be 20000 (Altman, 1987).
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Several causative mechanisms have been postulated for OA but any 
single patient may have a different pathogenic mechanism or set of 
mechanisms all of which may be affected by aging.
Although joint damage may lead to OA (Lawrence et al., 1966), it 
is now considered that the disease has a biochemical basis. Histological 
examination of the synovium reveals proliferation of the synovial 
membrane lining cells, with occassionally perivascular foci of chronic 
inflammatory cells in the deeper layers.
A relationship between obesity and OA has been suggested but the 
evidence is rather controversial (Leach, Baumgrad & Broom, 1973).
However it is generally accepted that decreasing the body weight will 
relieve the symptoms and pain of OA.
Although complement activation has been demonstrated in 
rheumatoid joints and is thought to play a role in the pathogenesis of 
rheumatoid arthritis, it remains unclear as to whether complement 
components are synthesised locally in the rheumatoid synovial joint in 
vivo, Metabolic studies using radiolabelled (1:2S-I) C3 (Ruddy & Colten, 
1974) have thus far provided the only evidence for in vivo biosynthesis 
of complement in rheumatoid synovium.
Northern and dot-blot analyses of RHA isolated from rheumatoid 
synovial tissue have been used in these studies to detect mRMAs coding 
for complement components as a powerful means of determining in vivo 
biosynthesis of C4, C2, C3, C5, factor B and Cl-inhibitor in the 
rheumatoid synovial joint. In addition to the molecular hybridisation 
studies, in vitro cultures of synovial membrane fragments were also used 
to measure the synthesis of these complement components. The results of
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these studies were compared with those obtained from synovial tissue 
from osteoarthritis patients and normal synovium to investigate whether 
local synthesis of complement by synovium was specific to rheumatoid 
arthritis patients or a constitutive property of all synovial tissues.
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MATER I ATS 
A W T
METHOTS
BUFFERS AID REAGBHTS
The buffers and reagents listed below are arranged under the 
headings in which they first appear in the text. The 'water' used in 
each solution refers to sterile deionised water. Unless otherwise 
stated, all chemicals, acids and alcohols were supplied by BDH 
Chemicals, Poole, Dorset, UK..
1. Preparation of plasmid DMA
(a) ya medium - 5g yeast extract (Difco), 20g Bactotryptone (Difco) and 
5g magnesium sulphate were dissolved in water and the pH was adjusted to 
7.6 with concentrated KOH. The volume was adjusted to 1 litre with water 
and 14g Bactoragar (Difco) was added before autoclaving.
(b) Tfbl buffer - This buffer contained 30mM potassium acetate, lOOmM 
rubidium chloride, lOmM calcium chloride, 50mM manganese chloride and 
15% (v/v/) glycerol. The pH was adjusted to 5.8 with 0.2M acetic acid 
and the volume was made up to 500ml with water. Tfbl was filtered 
through 0.45pm filter units (Millipore) and stored at room temperature.
(c) Tfbll buffer - This buffer contained lOmM MOPS (sodium morpholino 
propanesulphonic acid; Sigma), 75mM calcium chloride, lOmM rubidium 
chloride and 15% (v/v) glycerol. The pH was adjusted to 6.5 with 
concentrated KOH and the volume was made up to 100ml with water. TfblI 
was filtered through 0.45pm filter units (Millipore) and stored at room 
temperature.
(d) L-broth medium - lOg Bactotryptone (Difco), lOg sodium chloride and 
5g yeast extract (Difco) were dissolved in 800ml water and the volume 
made up to 1 litre. The medium was then autoclaved and stored at room 
temperature. When the L-brath had cooled, ampicillin (50pg/ml; Sigma)
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[or tetracycline (12.5pg/ral; Sigma) for the j^r-microglobulin plasmid] 
was added.
(e) Bactoagar - lOg Bactotryptone (Difco), lOg sodium chloride and 5g 
yeast extract (Difco) were dissolved in water and the volume made up to 
1 litre. Bactoagar (Difco; 20g) was added prior to autoclaving during 
which time the agar dissolved. When cool, the appropriate antibiotic was 
added to the same final concentration as above. The medium was then 
poured into 9cm Petri dishes (Sterilin) and allowed to set. The plates 
were stored at 4°C for up to two weeks.
(f) Lvsosyme mix - Lysosyme (Sigma) was dissolved to a final 
concentratiom of 2mg/ml in 25mM Tris.HCl pH8.0 containing 50mM glucose 
and lOmM EDTA. The lysosyme mix was stored at 4°C.
(g) TE buffer - 0.5M TrisHCl pH8.0 (2ml) and 0.5M EDTA pH8.0 (20pl) were 
mixed and the volume was made up to 100ml with water. The solution was 
autoclaved and stored at room temperature.
2. Characterisation of the plasmid DWA
(a) 1 x Tris Borate (TBE) - Tris (10.8g) and baric acid (5.5g) were 
dissolved in 500ml water after which 0.5M EDTA (4ml) was added. The pH 
was adjusted to 8.0 before making the volume up to 1 litre with water.
(b) 10 x ligation buffer - This buffer was composed of lOOmM Tris.HCl 
pH7,6 containing lOOmM ItgCl^, lOmM dithiothreitol (Sigma) and lmg/ml 
bovine serum albumin (Sigma),
3. Isolation of REA
(a) 5M guanidinium isothiocvanate - A 6M stock solution was prepared by 
dissolving 141.8g guanidinium isothiocyanate (Bethesda Research 
Laboratories) in heated water and the volume made up to 200ml with
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water. 24ml 0.5M Tris.HCl pH7.0 containing 0.5M EDTA and 4ml of water 
were added and the pH of the resultant solution was adjusted to 7.0 if 
necessary. Several drops of diethylpyrocarbonate* (Sigma) were added and 
the solution was autoclaved. Once cooled, 12ml mercaptoethanol (Sigma) 
was added and the final solution was filtered through 0.45pM filter 
units (Millipore) to ensure freedom from bacterial contamination. The 
sterile solution was stored in 20ml aliq. ts at 4°C for up to two weeks.
* Diethylpyrocarbonate (DEPC or 'Baycovin') is commonly used as 
an inhibitor of exogenous ribonucleases, inactivates all proteins
as a result of an esterification reaction. It is particularly useful for 
solutions and glassware and any excess can be quickly 
hydrolysed to CCb and ethanol by heating. This last step is important 
because DEPC reacts with RITA and DMA and hence excess must be removed 
from any extraction buffer (Birnie & Graham, 1984).
_(b) 5.7M cesium chloride in 50mM EDTA (pH7,0) - 95.97g CsCl (Bethesda 
Research Laboratories) were dissolved in 60ml water and 12.5ml 0.4M EDTA 
were added. The pH of the solution was adjusted to 7.0 before the volume 
was made up to 100ml with water and the refractive index adjusted to 
1.3995 by the addition of more CsCl or water. The final solution was 
filtered through 0.45jiM filter units (Millipore) and stored at room 
temperature in foil covered bottles to protect it from the light.
4. Forthern and dot-blot analyses
_(a) 10 x MOPS pH7. 0 - 42g sodium morpholino propanesulphonic acid 
(Sigma), 6,8g sodium acetate and 3.7g EDTA were dissolved in water and_^. 
the pH was adjusted to 7.0 with glacial acetic acid. The volume was made 
up to 1 litre and the final solution was stored in the dark at 4°C. 
fb) 20 x SSC - 175.2g of sodium chloride and 88.2g of sodium citrate
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were dissolved in water and the pH adjused to 7.0. The volume was made 
up to 1 litre and the final solution was stored at room temperature.
(r.) 20 x SSPE - This buffer used in prehybridisation and hybridisation 
buffers was composed of 0.2M sodium phosphate buffer, pH7.7 containing 
3M MaCl and 0. 02M EDTA. 20 x SSPE was stored at room temperature.
(d) 100 x Denhardts solution - 2g Ficoll (Sigma) were dissolved in 75ml 
water and then 2g polyvinyl pyrollidine (Sigma) and 2g BSA (Sigma) were 
added. The volume was made up to 100ml and the solution was stored at 
4°C in the dark.
(e) Salmon sperm DNA (lmg/ml) - 0. lg salmon sperm DMA (Sigma) was added 
to 100ml of water. The DMA was dissolved by autoclaving and the final 
solution was stored at 4°C in the dark.
5. Synovial tissue explant cultures
(a) Transport medium - Sodium bicarbonate (70mg) was dissolved in 
water to which was added 20ml lOxHank’s solution (Gibco), 4ml fetal calf 
serum (heat inactivated for two hours at 56°C) (Gibco) and 10ml 
penicillin/streptomycin (5000units/ml; 5000pg/ml). The volume was made up 
to 200ml with water and the final solution was filtered through 0.2pM 
filter units (Swinnex) into 10ml aliquots which were stored at -20°C. 
fb) Dulbecco's Modified..£agl.e .Medium (DMEM) with 10%.fetal calf serum - 
20ml 10 x DMEM (Gibco), 8ml 7.5% sodium bicarbonate (Gibco), 20ml fetal 
calf serum (Gibco) (heat inactivated for 2 hours at 56°C), 2ml 0.2M 
glutamine (Gibco) and 2ml penicillin/streptomycin (5000units/ml; 
5000pg/ml) were mixed together and the volume made up to 200ml with 
water. The final medium was filtered through 0.2/iM filter units 
(Swinnex) and stored at 4°C for up to two weeks.
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6. Enzyme linked immunosorbent assays (EL IS As)
(a) Coating buffer - Sodium bicarbonate (Nas.-COat; 0.79g) and sodium 
hydrogen bicarbonate (NaHCCb; 1.46g) were dissolved in water and the pH 
was adjusted to 9,6 if necessary. The volume was made up to 500ral with
water and stored at 4°C for up to one week.
Cb) PBS/0.05% Tween (PBST) - 20 x PBS was prepared by dissolving 320g
sodium chloride, 48. 4g dipotassium hydrogen phosphate and 13.6g
potassium dihydrogen phosphate in water and the volume made up to 2 
litres. PBS/0.05% (v/v) Tween was prepared by adding 1ml Tween 20
(Sigma) to 100ml 20 x PBS and making the volume up to 2 litres with
water.
(c) Blocking buffer - Bovine serum albumin (0.5g; Sigma) was dissolved 
in 500ml 1 x PBS. Blocking buffer was stored at 4°C for up to one week.
(d) Peroxide substrate - 28ml 0.2H disodium hydrogen phosphate were 
added to 44ml 0.1M citric acid and the pH adjusted to 5.6 by the
addition of either of these solutions. The volume was made up to 100ml
with water and the solution was covered from the light. 34mg o- 
phenylenediamine (Sigma) were dissolved in the solution which was then 
kept in the dark. Immediately before its use as the substrate, 40pl
hydrogen peroxide was added to the solution.
7. Haemolytic assays of complement components
(a) Alsever's solution - D-glucose (41g), sodium citrate (16g), sodium 
chloride (8.4g) and citric acid (0.8g) were dissolved in a final volume
of 1 litre of water (the final pH was between 6.0 and 6.5). Alsever's
solution was stored at 4°C for two weeks.
(b) Veronal buffered saline. 5 x VBS - Sodium chloride (85g), sodium 
barbitone (3.75g; Sigma) and barbitone (5.75g; Sigma) were dissolved in
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water and the volume made up to 2 litres. 5 x VBS was stored at 4°C.
(c) Isotonic veronal-buffered saline containing gelatin and cations._
GVB2•*' - 5ml 10% gelatin was added to 100ml 5 x VBS, 2.5ml 0.03M calcium 
chloride and 5ml 0. 1M magnesium chloride and the volume made up to 500ml 
with water. GVB2"* was stored at 4°C for up to 3 days.
GVB2~ is GVB2- without MgCl2 and CaCl2 .
(d) Isotonic dextrose containing cations. D5V2- - D-glucose (25g) was 
added to 2.5ml 0.03M calcium chloride and 5ml 0. lM magnesium chloride 
and the volume made up to 500ml with water. D5V2- was stored at 4°C for 
up to 3 days.
D5V2- used in the preparation of Mg-EGTA is D5V2- without MgClz 
and CaCla.
(e) DGVB2- - equal volumes of GVB2- and D5V2- were mixed together.
DGVB2- was prepared fresh daily.
pH 7. sT
Xf) EDTA (lQmmol/1) GVB2~ - 58ml isotonic 86mM EDTA A was mixed with 442ml 
GVB2~ and stored at 4°C.
(g) D50S - Glucose (50g) and sodium chloride (5.95g) were dissolved in 
water and the volume made up to 100ml. D50S was stored at 4°C.
(h) Mannitol;GVB2- - Three parts 20% (w/v) mannitol were mixed with 1
part GVB2-* and the mixture was stored at 4°C.
SI) C2 oxidising reagent - Potassium iodide (8.25g) and iodine (300mg; 
Sigma) were dissolved in 100ml 0. 1M phosphate buffer (pH6.0). This 
solution was stored at 4°C in the dark for several weeks and was diluted
1/200 in 0.1M phosphate buffer (pH6. 0) immediately prior to use.
l.i) EDTA (40mmol/l) GVB2- - 232.5ml isotonic 86mM EDTA and 267.5ml GVB2~ 
were mixed and stored at 4°C. This reagent chelates calcium and 
magnesium ions, preventing the formation of the classical and
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alternative pathway C3 and C5 convertases and thus provides a source of
(k) Mg-EGTA - 10ml lOOmM EGTA, 7ml lOOmM magnesium chloride and 83ml 
DGVB2" <3 parts D5\F~:1 part GVB2") were mixed together and the pH was 
adjusted to 7.4-7.6. Mg-EGTA was prepared fresh daily. EGTA selectively 
chelates Ca2_* ions, to prevent Cl activation and thus classical pathway 
activation. The Mg2'*' ion content permits alternative pathway activation 
as it is required for the formation of C3bBb,
8. Incorporation of SI -methionine into complement proteins
(a) Solution A. pH7.5 - This buffer was made up to a volume of 100ml 
with water and contained 50mM NaCl, lOOmM KC1, 50mM Tris, 5mK EDTA, 0.5% 
(w/v) BSA (Sigma), 0.5% (w/v) sodium deoxycholate (Sigma), 1% (w/v) 
Triton X100, 5mM PMSFA (Sigma) in dimethylsulphoxide (Sigma), 0.02% (w/v) 
sodium azide (Sigma) and lOmM benzamidine (Sigma). Solution A was 
protected from the light and stored at room temperature,
(b) Solution B - This buffer was composed of 63.8mM Tris.HCl, pH6.8 
containing 3% (w/v) SDS, 5% (v/v) mercaptoethanol (Sigma) and 10% 
glycerol. This solution was protected from the light and stored at room 
temperature.
9. Isolation of synovial cells from synovial tissue
la) Collagenase/DNase 1 - lOOmg collagenase (Type 1, Sigma), lOmg deoxy­
ribonuclease 1 (DN-25, Sigma) and 35mg sodium bicarbonate were dissolved 
in 10ml 10 x Hank's balanced salt solution (Gibco) and 2ml penicillin/ 
streptomycin (5000units/ml; 5000pg/ml). The volume was made up to 100ml 
with water. The final solution was filtered through 0.2pM filter units 
(Swinnex) into 25ral aliquots and stored at -20°C.
- 54 -
(b) Trypsin/EDTA - lOOmg trypsin (Type 111, Sigma) and 40rag EDTA were 
dissolved in 20ml 10 x phosphate buffered saline (Gibco) and the volume 
was made up to 200ml with water. The final solution was filtered through 
0.2pM filter units (Swinnex) into 25ml aliqouts and stored at -20°C.
10. Immunahistochemical analysis of cultured synovial cells
(a) Veronal acetate buffer, YAB - Sodium acetate trihydrate (1.94g) and 
sodium barbitone (2.94g; Sigma) were dissolved in 100ml water. 5ml of 
this solution was added to 16ml water and the pH adjusted to 9.2 with
0. Ilf hydrochloric acid.
ib)..-Preparation of phosphate substrate - ffaphthol AS-MX phosphate (80mg; 
Sigma) (dissolved in a drop of dimethyl formamide), fast red violet LB 
salt <80mg; Sigma) and levamisole (8mg; Sigma) were added to 20ml VAB 
and filtered through Whatman filter paper (qualitative 1) in the dark 
immediately before use.
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MATERIALS AID- METHODS
1. Preparation of plasmid DMA
1.1 - Preparation of competent JM101 cells
(i) E. coli JM101 cells were streaked from frozen stock onto a ya plate
and incubated at 37°C overnight.
(ii) A single colony was picked and used to inoculate 5ml yb medium (yb
is ya without the agar). The culture was then incubated at 37°C
overnight.
(iii) 5ml of the overnight culture was subcultured into 100ml yb and 
grown for a further 2 hours until the optimal ODsso of 0.48, had been 
reached.
(iv) The culture was chilled on ice for 5 min and then centrifuged 
(^oooppm for 5 min at 4°C) in a Sorvall centrifuge.
(v) The cells were resuspended in 40ml of Tfbl, left on ice for 5 min 
and then centrifuged (3oc?orpm for 5 min at 4°C) in a Sorvall centrifuge
(vi) The cells were resuspended in 4ml of TfblI and left on ice for 15 
min.
(vii) The competent cells were dispensed into 200pl aliquots using a 
prechilled pipette and tubes. The cells were snap frozen in dry ice and 
stared at -70°C.
1x2 ~ Transformation of competent JM1Q1 cells with plasmid D M
(i) 50ng plasmid DUA was added to lOOpl competent JM101 cells, mixed 
well and left on ice for 45 min,
(ii) The sample was incubated at 42°C for 90 sec and returned to ice for 
2 min.
(iii) 400pl L-broth was added and incubated at 37°C on a shaker for 1
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hour.
(iv) lOOpl of the sample was plated onto each of 3 agar (Bactoagar) 
plates containing ampicillin (50 pg/ml) (or tetracycline (12.5 jig/ml) 
for the ^^-microglobulin plasmid only), which were then incubated at 
37°C overnight.
1.3 - Small-scale preparation (miniprep? of plasmid . D M
(i) 5ml L-broth containing ampicillin (50 jig/ml) (or tetracycline (12.5 
jig/ml) for j^-microglobulin) was inoculated with one colony picked from 
the above plates. This liquid culture was then incubated at 37°C in an 
orbital incubator overnight.
(ii) 2ml of the liquid culture was removed and centrifuged (lOOOOrpm for 
5 min at room temperature) in an Eppendorf microfuge, [The 2ml medium 
removed from the 5ml culture in this step was replaced with 2ml L-broth 
containing ampicillin (50 jig/ml) or tetracycline (12,5 jig/ml) and 
incubation of the culture was continued at 37°C.]
(iii) After centrifugation, the pellet was resuspended in 200jil lysosyme 
mix and incubated at room temperature for 5 min.
(iv) 400jil 0.2M sodium hydroxide containing 0.1% SDS was added and the 
tube was inverted gently until lysis had occurred.
(v) 300/il 3K sodium acetate pH4.8 were added to the sample which was 
then left on ice for 15 min before centrifugation at lOOOOrpm for 5 min 
at room temperature,
(vi) 800jil of the supernatant was transferred to a fresh tube and 480pl 
isopropanol were added. The sample was then incubated at -20°C for 1 
hour to precipitate the DNA.
(vii) The sample was centrifuged at lOOOOrpm for 10 min at room 
temperature and the pellet was washed in 1ml 100% ethanol, freeze-dried
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and resuspended in 30pl TE buffer.
Restriction enzyme digests were performed on the plasmid 
minipreps to ensure the correct restriction map of the plasmid was 
obtained thus indicating that the correct plasmid had been amplified. 
Once this had been confirmed, 500ml L-broth containing ampicillin 
(50 pg/ml) or tetracycline (12.5 pg/ml) was inoculated with the 5ml 
culture [from step (ii)3 and incubated at 37°C overnight.
1.4 - Large-scale preparation of plasmid DM.
(i) The 500ml culture was centrifuged (5000rpm for 5 min at 4°C) in a 
Sorvall centrifuge and the pellet was resuspended in 10ml 50mM Tris.HCl 
(pH8.0) containing 25% (w/v) sucrose
(ii) lOOmg lysosyme was added and the sample stored on ice for 20 min.
(iii) 5ml 0.2M EDTA pH8.0 were added, mixed well and the sample stored 
on ice for 20 min.
(iii) 600/jlL 10% (v/v) UP-40 detergent in 50mM Tris.HCl (pH8. 0) 
containing 25% (w/v) sucrose was added and the sample inverted until the 
mixture became viscous. The sample was then centrifuged (15000rpm for 30 
min at 4°C) in a Sorvall centrifuge.
(iv) The supernatant was collected and an equal volume of phenol 
(equilibrated with TE buffer) was added. The sample was mixed well for 
15 min and centrifuged (2500rpm for 20 min at room temperature) in an 
MSE 4L centrifuge,
(v) An equal volume of chloroform: isoamyl alcohol (24:1 mixture) was 
added to the aqueous layer and the sample was centrifuged (2500rpm for 5- 
min at room temperature) in an MSE 4L centrifuge.
(vi) The aqueous layer was collected and the following ribonucleases:
10/il RNase A (lOmg/ml) and 20/il T1 RUase (20mg/ral) were added. [Both
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RNase enzymes had previously been boiled for 10 min to remove any 
deoxyribonuclease activity.] The sample was then incubated at 37°C for 
30 min with constant mixing.
(vii) 1/2 volume phenol was added, mixed well for 2 min and the sample 
was centrifuged (2500rpm for 5 min at room temperature) in an MSE 4L 
centrifuge.
(viii) An equal volume chloroform: isoamyl alcohol was added to the 
aqueous layer and mixed well for 2 min. The sample was then centrifuged 
(2500rpm for 5 min at room temperature) in an MSE 4L centrifuge. The 
aqueous layer was collected and half of its volume of 3M sodium acetate 
pH6.8 and an equal volume of isopropanol were added to the aqueous 
layer. After mixing, the tube was incubated at room temperature for 90 
min to precipitate the DMA.
(ix) The sample was centrifuged (lOOOOrpm for 10 min at 4°C) in a 
Sorvall centrifuge, after which the pellet was washed in 100% ethanol 
and freeze-dried. The plasmid DMA was resuspended in 1ml TE buffer and 
the absorbances at 260nm (OD^so) and 280nm (OD^oo) were measured.
Extensive restriction enzyme digests were performed on the 
plasmid to ensure the correct plasmid had been prepared before it could 
be used to prepare radioactivelly-labelled cDNA probes for Uorthern and 
dot-blot analyses.
2. Characterisation of the plasmid DMA
2L1 - Restriction mapping of the plasmid DMA
Table 7 summarises the cDNA probes used in this study. E.coli 
JM101 cells were used as the host for amplifying all of these plasmids.
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cDNA PROBE 
(plasmid vector)
INSERT Region to which the 
cDNA probe corresponds
Reference
BamHl Hindlll A region containing
C2 1-------------1 the active site serine Bentley
(pAT153) 400bp residue and the second­ and
ary substrate binding Porter
of the serine protease. (1984)
EcoRl EcoRl The N-terminal region
C3 |-------------1 of C3 - containing the De Bruijn
(pAT153) 2400bp entire 0-chain and a and Fey
segment of the a-chain. (1985)
BamHl Hindlll A segment of the C4d Carrol1
C4 1------------ 1 region within the a- and Porter
(pAT153) 200bp chain. (1983)
BamHl Hindlll The C-terminal region Lundwall
C5 1- - - - - - - - 1 of the 0-chain. et al
(pBR322) 940bp (1985)
BamHl Hindlll Virtually the entire Morley and
Factor B I- - - - - - - - 1 Ba fragment. Campbell
(pAT153) 540bp (1984)
BamHl Hindlll The 3' end of the Cl- Lappin et
Cl-INH \- - - - - - - - 1 INH gene. al (1989)
(pAT153) 1250bp
Pstl Pstl Muscle actin amino Katcoff
Act in \- - - - - - - - \ acids of the region et al
(pBR322) 630bp AA 162 to the C-term. (1980)
Pstl Pstl 328bp(97%) of the
02- \- - - - - - - - \ coding region and Suggs
mi croglobul in 545bp 217bp of the 3' un­ et al
(pBR322) translated region (1981)
of the mRNA.
- A summary of the cDNA probes used in the Northern and dot-blot 
analyses of total RNA isolated from synovial membrane.
2.2 - Preparation of the cloned cDJFA inserts.
(i) The appropriate restriction enzyme digest was performed on the 
plasmid at 37°C for 3 hours to remove the cloned cDITA insert from 
plasmid vector DMA
(ii) Electrophoresis on a 1% low melting point agarose (Bethesda 
Research Laboratories) gel in the cold room at 50 V for 30 min in 1 x
TBE buffer, separated the excised cDMA insert from plasmid vector DMA.
(iii) The cDMA insert was then cut out of the gel, 500pl water were 
added and the agarose block melted completely at 65°C for 10 min.
(iv). 500pl phenol (equlibrated with TE buffer) were added and after 
mixing, the sample was stored on ice for 15 min and then centrifuged at 
lOOOOrpm for 5 min (all centrifugations in this procedure were performed 
at room temperature in an Eppendorf microcentrifuge).
(v) 500pl chloroform:isoarayl alcohol was added to the aqueous layer and 
mixed well. The sample was then stored on ice for 5 min and centrifuged 
at lOOOOrpm for 5 min.
(vi) 1/10 volume 3M sodium acetate pH6.8 and 2 volumes 100% ethanol were 
added to the aqueous layer and mixed well. The cDNA insert was then 
precipitated overnight at -20°C.
(vii) After centrifugation at lOOOOrpm for 10 min, the cDITA insert 
pellet was washed sequentially in 70% and absolute ethanol, freeze dried 
and resuspended in TE buffer to give a DMA concentration of 5ng/pl.
2-l-3. Recloning of the cDNA inserts into pGem 1 plasmid vector
Several of the cDMA inserts (Cl-IMH, factor B, C2, C4 and C5) 
were recloned into the pGem-1 (Promega Biotec) transcription vector. The 
2.9 kb pGem-1 vector was constructed using the bacteriophage SP6 
promoter-containing plasmid pSP64 (Melton et al. , 1984) and a
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bacteriophage T7 promoter. Each plasmid was digested with BamHl and 
Hindlll. The pGem-1 vector was also digested with BamHl and Hindlll and 
then treated with 1 unit of phosphatase enzyme for 1 hour at 37°C to 
prevent religation of the plasmid vector. The ligation reaction was 
performed in the following way:
(0 ^*3 } 5)
(i) lOpl c D M  insert was added to Ipl phasphatased-digested pGem-1
(ii) To this mixture the following were added: 2pl D M  ligase, 2pl 10 x 
ligation buffer and 4pl 3mM ATP. The volume was then made up to 20pl 
with water and incubated at room temperature for 48 hours.
(iii) The resultant plasmid was used to transform JM101 cells as 
described above,
3. Radioactive labelling of the cloned cDSA inserts
As described above, c D M  inserts were excised by restriction 
enzyme digestion and isolated by electrophoresis through a 1% low 
melting point agarose gel. In all cases radioactive labelling of the 
c D M  probes was performed using the Random Primed Labelling Kit 
(Boehringer Mannheim) and high specific activity (3000Ci/mmol) a-3:2P- 
dCTP (Amersham International). 25ng D M  (denatured by boiling for 10 min 
then cooling rapidly on ice) was added to a mixture of Ipl 0.5mM dATP, 
lpl 0.5mM dGTP, lpl 0.5mM dTTP and 2pl reaction mixture (hexanucleotide 
mixture in 10 x concentrated reaction buffer). 5pl (50pCi) oc-3:2P-dCTP 
were added to this mixture and the volume made up to 19pl with water.
Ipl D M  polymerase (Klenow enzyme; Boehringer Mannheim) (2 units/pl) was 
introduced into the sample which was then incubated at 37°C for 30 min.--' 
The unincorporated deoxyribonucleosides were removed by gel filtration 
on a BioGel (A1.5m) column. Before hybridisation, the radioactive c D M  
probe was denatured by boiling for 15 min and cooling rapidly on ice.
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4. Collection of synovial tissue specimens for RNA analysis
Specimens of synovial tissue were collected at the time of 
surgery from 20 patients with rheumatoid arthritis, 23 with osteo­
arthritis and 5 other patients, 1 with chondrocalcinosis, 2 with 
psoriatic arthritis and 2 with ankylosing spondylitis. In addition, 
normal synovium was obtained from a patient who underwent patellectomy 
for recurrent patellar dislocation. In all but 7 patients (four elbow 
and three shoulder) the knee or hip joints were the source of synovium. 
Immediately after collection the tissue specimens were snap-frozen in 
liquid nitrogen and stored at -70°C for analysis. Tissue fragments were 
removed from 12 of these synovium specimens immediately after surgery, 
for use in organ culture studies (see Materials and Methods, section 7).
5. Preparation of SNA
Total RUA was prepared much as described (Chirgwin et al, 1979; 
Birnie and Graham, 1984), with all solutions being pre-treated with 
diethylpyrocarbonate (DEPC). 300mg of synovial tissue was pulverised 
under liquid nitrogen and transferred to 20ml of 5M guanidinium 
thiocyanate (Bethesda Research Laboratories), pH7.0, containing 5% (v/v) 
mercaptoethanol and 50mM Tris/50mM EDTA. After sonication, 2ml of a 20% 
(w/v) solution of sodium-N-lauroyl sarcosine was added and the mixture 
was heated to 65°C for 2 min before cooling to room temperature. 
Following centrifugation (35000rpm for 40 hours at 15°C, using a 6x14ml 
rotor in a Centrikon T-2070 ultracentrifuge) over 2.5 ml of 5.7M CsCl 
containing 50mM EDTA (pH7.0, refractive index 1.3995). The RIA pellet 
was resuspended in 200pl of water and precipitated overnight at -20°C 
using 1/10 volume 0.3M sodium acetate (pH7.0) and 2.5 volumes of 100% 
ethanol. The pellet was then washed sequentially in 70% and 100% ethanol
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and resuspended in 500pl of TE buffer. The ODaso and OD^so were measured 
and when necessary, contaminating protein was removed by a 
phenol/chloroform extraction (Maniatis, Fritsch & Sambrook, 1982).
6. Northern and dot-blot analyses
6.1 - Northern blot analysis;
(  t2c<v.»<§cw ^
Mini-gels (50ml) were used for Northern blot analysis. The gels 
were prepared by melting 0.5g agarose (Bethesda Research Laboratories) 
in 43.5ml water. When the molten agarose had cooled to approximately 
50°C, 5ml 10 x MOPS and 2.6ml 37% (v/v) formaldehyde were added. The 
molten agarose was poured into the gel mould and allowed to set at room 
temperature. Total RNA (20pg) was resuspended in 8pl of freshly prepared 
sample buffer: 750pl farmamide (Fluka), 150pl 10 x MOPS, 240pl 
formaldehyde, lOOpl water, lOOpl glycerol and 80pl (10% w/v) bromophenol 
blue, and denatured at 65°C for 15 min, then rapidly cooled on ice. 
Before loading, ethidium bromide d p i  of a lmg/ml solution) was 
introduced into each sample. Electrophoresis was performed at 100 V for 
90 rain at room temperature in 1 x MOPS, pH 7.0. Immediately after 
electrophoresis, the gels were visualised on a UV transilluminator. The 
gels were then blotted onto Hybond-N nylon membrane (Amersham 
International) using 20 x SSC for at least 24 hours after which time the 
filter was fixed with UV light for 10 mins and the gels viewed for 
efficiency of transfer on a UV transilluminator.
6x2...- Prehybridisfltion and hybridisation
The prehybridisation and hybridisation buffer was composed of 
62.5ml 20 x SSPE, 12.5ml 100 x Denhardt's solution, 5ml of a lmg/ml 
solution of salmon sperm DMA, 12.5ml 10% (w/v) SDS and 125ml formamide,
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made up to 250ml with water. All prehybridisation and hybridisation 
reactions were performed overnight at 42°C. Hybridisation was performed 
with 1 x 10e counts/min of 32P-labelled probe per ml, and all filters 
were washed sequentially in 2 x SSC, 0.5 x SSC and finally in 0.1 x SSC, 
each containing 0.1% (w/v) SDS. Each wash was performed at 65°C and 
lasted for 30 min. Filters were stripped for rehybridisation by boiling 
in 0.1% (w/v) SDS for 20 min.
Autoradiography was performed at -70°C using Kodak X-Omat AR 
film far 1-15 days with an intensifying screen,
6.3 - Dot-blot analysis
Total RNA (10/ig) dissolved in 2.5pl water was applied as a 
single drop onto Hybond-N nylon membrane, dried in air and fixed with TJV 
light for 10 min. Duplicate dots of each specimen were tested. 
Prehybridisation, hybridisation and autoradiography were performed as 
described for Northern blot analysis. Autoradiographs were scanned using 
a densitometer (AutoScanner, Helena Laboratories). Results were 
standardised using a rat actin cDNA probe (approximately 80% homologous 
to human actin) to control for the amount of RNA loaded onto the dot 
blots. Yeast tRNA was used as a negative control on all dot blots.
7. Synovial tissue explant cultures
Synovial tissue specimens were collected at the time of surgery 
from a total of 12 patients (3 with rheumatoid arthritis, 8 with 
osteoarthritis and one undergoing patellectomy for recurrent patellar 
dislocation) and transported to the laboratory in transport medium. The 
tissue was then washed thoroughly in Dulbecco’s calcium and magnesium 
free phosphate buffered saline (1 x PBS) (Gibco). Each culture was set
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up with fragments of tissue from different areas of the specimen, with 
40-80mg tissue used per culture. The tissue was cultured in 1.5ml of 
Dulbecco's Modified Eagle Medium (Gibco) with 10% heat inactivated (2 
hours at 56°C) fetal calf serum (Gibco) (DMEM. FCS) at 37°C in a 
humidified atmosphere consisting of 5% CCb in air. The culture medium 
was changed daily for 6 days. The culture supernatants were divided into 
aliquots and stored at -70°C for analysis. Six cultures were set up for 
each patient, with two cultures being treated with 2,5pg/ml cyclo- 
heximide to inhibit protein synthesis. Complement synthesis was 
expressed as pg complement component produced per lOOmg tissue.
8. Enzyme linked immunosorbent assays (ELISAs)
Double antibody sandwich ELISAs were used to measure the 
synthesis of complement components by cultured fragments of human 
synovial membrane. The IgG fraction of the goat anti-human Cl-INH, 
factor B, C4, C3, C5 (Atlantic Antibodies) and C2 (SciPac) antibodies 
were used. One complement component was studied per ELISA plate and the 
procedure outlined below was followed:
(i) Each well of the ELISA plate [either Dynatech Immunolon A (Cl-INH, 
factor B, C3 and C5) or Nunc (C2 and C4)], was coated with lOOpl of the 
antibody diluted in coating buffer. The concentration of each antibody 
is listed below:
anti-Cl-INH lOpg/ml anti-C3 5pg/ml
anti-factor B 5pg/ml anti-C4 2,5pg/ml
anti-C2 lOpg/ml anti-C5 5pg/ml _~
The plates were then covered and incubated at 4°C overnight.
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(ii) Each well was washed five times with PBS containing 0.05% (v/v) 
Tween (PBST) using a Dynatech plate washer, which was used for washes at 
every step. Blocking buffer (250pl) was then added to each well and the 
plates were incubated in a moist atmosphere at room temperature for 1 
hour.
(iii) Each well was washed five times in PBST and then lOQpl of a 1:5 
dilution (in PBST) of each culture supernatant was added to duplicate 
wells. A pool of normal human serum which contained known concentrations 
of the complement components under investigation, was used as a 
standard. The pool was diluted serially in PBST and lOOpl of each 
dilution was added to a duplicate series of wells. The following range 
of complement component concentrations was used to plot the standard 
curves:
Cl-IJH (60ng/ml to 0,06ng/ml> C3 <299ng/ml to 0.3ng/ml)
factor B (412ng/ml to 0,4ng/ml) C4 (12ng/ml to O.Olng/ml)
negative controls used on each plate were lOOpl of PBST and 
100/j.I of DMEM.FCS, both of which were added in duplicate.
After addition of the samples the plates were incubated in a 
moist atmosphere at room temperature for 2 hours.
(iv) Each well was washed five times in PBST and then lOOpl of biotin 
conjugated antibody (Bonnard, Papermaster & Krachenbuhl, 1986) were 
added to each well. Each conjugate antibody^was diluted as follows;
C2 (800ng/ml to 0.8ng/ml) C5 (75ng/ml to 0,07ng/ml)
Cl-INH 1/1600 C3 1/1000
factor B 1/2000 C4 1/10000
C2 1/2000 C5 1/750
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The plates were then incubated in a moist atmosphere at room 
temperature for 1 hour.
(v) Each well was washed five times in PBST and then lOOpl of a 1/5000 
dilution (in PBST) of avidin-linked horseradish peroxidase (Vector 
Laboratories) were added to each well. The plates were then incubated in 
a moist atmosphere at room temperature for 1 hour.
(vi) Each well was washed five times in PBST and then lOOpl of peroxide 
substrate was added to each well. The plates were left in the dark until 
the colour reaction had developed sufficiently and the reaction was then 
stopped by the addition of 25pl 4N sulphuric acid. The intensity of 
colour in each well was then measured on a microplate reader (Dynatech, 
MR700 microplate reader).
A standard curve was constructed for each plate by plotting the 
optical density readings of each standard against the concentration of 
the complement component in the standard. The concentration of each 
complement component in the culture supernatants was determined by 
interpolation of the standard curve. A comparison of the levels of 
complement found in the cycloheximide-treated cultures with the 
untreated cultures made it possible to determine that the complement 
components detected in the medium had been synthesised by the tissue and 
not simply released into the medium as a result of contamination
with blood or inflammatory exudate.
In addition to the ELISAs for the complement components an ELISA 
to detect albumin was also performed (on Dynatech Immunolon A ELISA 
plates) as a control for protein being released into the medium as a 
result of contamination with blood or inflammatory exudate. The 
procedure used was the same as described above except for two steps;
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(1) the blocking buffer used was PBST
(2) the second antibody was conjugated directly to the 
horseradish peroxidase enzyme and hence the biotin-avidin 
binding step was omitted.
The concentrations of antibody, culture supernatants, standards 
and conjugate antibody used were as follows;
(1) anti-albumin antibody 5pg/ml (in coating buffer)
(2) culture supernatants diluted 1:20
(3) standard range 500ng/ml to 2ng/ml
(4) conjugate antibody diluted 1/2000 ^
All dilutions were performed in PBST.
9. Haemolytic assays of complement components
Haemolytic assays were performed on the synovial membrane 
culture supernatants for C2, C3, C4, C5 and factor B in order to 
determine that the complement components detected by ELISA were 
functionally active. The haemolytic assays were performed as described 
by Vhaley, (1985) using erythrocytes as the target. The cell suspensions 
were standardised by lysing lOOpl of suspension in 2,9ml of water and 
measuring the optical density of the released haemoglobin in lysates. 
Oxyhaemoglobin has three major light absorption peaks at 576, 541 and 
414 nm. For the standardisation of erythrocyte suspensions used in 
complement assays, the optical densities of cell lysates were determined 
at either 541 nm (for suspensions of 5 x 10s cells/ml or 1 x 1021 
cells/ml) or 414 nm (for suspensions of 1 x 10° cells/ml or 2 x 10e 
cells/ml) (see Table 8).
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ERYTHROCYTE COECEHTRATIOtf OPTICAL DEJTSITY
SHEEP 1 x 108/ml 0.385 (541 nm)
5 x 10®/ml 0.192 (541 nm)
2 x 108/ml 0.654 (414 nm)
1 x 108/ml 0.327 (414 nm)
RABBIT 1 x 108/ml 0.294 (414 nm)
Table 8 - Standardisation of erythrocyte suspensions. The optical
density is measured on lysate prepared by the addition of 
lOOjil suspension to 2.9ml water.
9.1 - Preparation of cells for haemolytic ..assays
(a) Sheep erythrocytes, E
Sheep blood was drawn aseptically into an equal volume of 
sterile Alsever's solution. cells
were stored in Alsever's solution at 4°C for up to two weeks.
(b) Antibody-sensitised sheep erythrocytes, EA
(i) Sheep erythrocytes, E were washed in lOmM EDTA.GVB2- and resuspended 
to 1 x 10®/ml in the same buffer.
(ii) Antibody to sheep E was diluted in lOmM EDTA.GVB2- and prewarmed to
37°C as were the cells.
(iii) The antiserum was then added to the erythrocyte suspension and the 
mixture incubated at 37°C for 30 min in a shaking water bath.
(iv) The antibody-sensitised cells were washed once in 10mM EDTA.GVB2-,
twice in GVB2'*' and resuspended to their original volume in GVB2 .^ The
cells were stored at 4°C for up to one week.
The dilution of antiserum used in the preparation of EA was the
minimum dilution which did not agglutinate an equal volume of sheep E at
a concentration of 1 x 10®/ml.
(c) EAC4 cells (Borsos & Rapp, 1967)
(i) 500ml EA cells were washed and resuspended to 5 x 10®/ml in 
DGVB2^ and prewarmed to 30°C.
( U . U ~ , J - c A  , 1 ™ )
(ii) Cl (400units/mlwas added slowly to the EA suspension which was 
shaken continuously. After 15 min at 30°C, the EAC1 cells were
centrifuged (2000rpra for 5 min at 2°C) and resuspended in 500ral ice-cold
DGVB2^ and cooled to 0°C.
(iii) 100ml fresh human serum was mixed with 400ml lOmM EDTA.GVB2" and
- 69 -
cooled to 0°C. When the serum and EAC1 had been cooled to 0°C, they were 
mixed and shaken continuously at 0°C for 15 min. The EAC4 were washed 
three times in lOmM EDTA. GVB:zr'~, then incubated at 37°C in 200ml lOmM 
EDTA.GVB*" to decay off any C2 which may have been incorporated into 
C4b2a. The EAC4 were washed once in GVTF*' and stored at 4°C. 
Alternatively the EAC4 could be stored frozen at -70°C.
(i) EAC4 cells (50% suspension in DGVB2”' 
were prewarmed to 37°C.
(ii) The glycerol buffer was added (dropwise) to the cells in three
aliquots and the cells were shaken at 37°C for 10 min after each 
addition. The sizes of the aliquots were 0.15, 0.45 and 1.2 times the 
initial volume of the 50% suspension. The cells were dispensed into 
0.8ml aliquots, snap-frozen and stored at -70°C.
(e> Reconstitution of EAC4 cells
(i) An aliquot of EAC4 cells was thawed at 37°C and D50S, mannitol: GVB12"*'
and DGVB2'*' were prewarmed to 37°C.
(ii) 230pl D50S was added to the EAC4 cells and incubated for 5 min at
37°C.
(iii) Mannitol:G V B ^  was added in three aliquots; 1, 2 and 8ml. Between 
the first and second and second and third aliquots, the cells were 
incubated at 37°C for 2 rain. Fallowing the addition of the third 
aliquot, the cells were incubated at 37°C for 5 min.
(iv) DGVB2"1" was added in four aliquots, the first being 5ml and the 
remaining three, 10ml. Fallowing the addition of the first three 
aliquots, the cells were incubated at 37°C for 2 min but after the
(d) Freezing EAC4 cells s'/K.W)
D  t->w>A l/C C \ r~, ,-.C7v\ fsle.W 1 f*c2i^  I
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fourth aliquot the incubation time at 37°C was 5 min.
(v) The cells were then centrifuged (2000rpm for 10 min at 2°C), washed 
three times in DGVBa ' and resuspended in DGVB2'1' to give a final 
concentration of 1x10s cells/ml.
(f) EAC14 cells
(i) EAC4 cells were washed three times in DGVB2'*' and resuspended to a 
concentration of 1x10s cells/ml in DGVB2 .^ The cells were then prewarmed 
to 37°C.
t/vcUcA
(ii) Complement component Cl, at a/yponcentration of 100 units/ml in 
DGVB2'1' was prewarmed to 37°C.
(iii) Equal volumes of EAC4 cells and Cl were mixed together and 
incubated for 15 min at 37°C.
(iv) The EAC14 cells were then centrifuged (2000rpm for 5 min at 2°C) 
and the supernatant was discarded. The cells were resuspended in DGVB2^ 
to a concentration of 1x10s cells/ml and were used immediately.
L av test - used to measure the functional activity of C4b on EAC14. A
batch of EAC4 is accepted if tn,ax is less than 6 min,
2ml EAC4 (lxl0s/ml in DGVB2'*') were converted to EAC14 and
resuspended in 2ml DGVB12^ . EAC14 and 2ml DGVB2"1' containing C2 (lunit/ml)
were prewarmed to 30°C in a shaking water bath. After 5 min, the C2 and
EAC14 were mixed and at 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7.5, 10 and 15
min, 200pl of cells were transferred to test tubes containing 300pl 
Qrc\r 5e /u ~ \ J J U W  V, 5- ^  14-O ^rt fe>rA . Gsi&- )
Qr«t— EDTA^and incubated at 37°C for 1 hour. Saline (2ml) was then added
to each tube (except 100% lysis to which was added 2ml water) after the
one hour incubation and the tubes were centrifuged at 2000rpm for 5 min
at 2°C. The haemoglobin released into the supernatants was measured
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spectraphotometrically (ODaia ).
Controls: DGVB*'+ EAC142 EAC14 C>-»t,_EDTA
Cell blank 300/j.l
Reagent blank 100/j.l
100% lysis 200/j.l
200 j*l
100/ud 300/il
300/il
300/ilComplement colour 200/il
(EAC142 at 5 x 107/ml and EAC14 at 1 x 10®/ml)
(g) EAC140~Y2 cells
C2 was oxidised by mixing equal volumes of C2 (50 units/ml) and 
oxidising reagent and incubating at room temperature for 5 min until the 
solution paled. (Polley & Muller-Eberhard, 1967)
Oxidised C2 was prepared fresh each time it was required. The 
oxidation of SH groups in the C2 molecule increases the haemolytic 
activity of the molecule and stabilises the C4b2a enzyme by preventing 
the decay of C2a from the complex.
(i) EAC14 (1 x 10e/ml in DGVB2"*') and an equal volume of DGVB2'*' 
containing oxidised human C2 (Co:s<:v2) at 50 units/ml were prewarmed to 
30°C.
(ii) The EAC14 cells were mixed with the oxidised C2 and incubated at 
30°C for 15 min. The EAC14o:Ky2 were resuspended to 1 x 10s/ml in DGVB2_H 
and used immediately.
(h> EAC43b cells
(i) EA cells were washed three times in GVB2'*' and resuspended to a
concentration of 2 x 10e cells/ml in GVB2 ,^
(ii) 1ml R3 (see below) and 19ml EA cells were prewarmed to 37°C, mixed —  
rapidly and incubated at 37°C for 75 seconds,
(iii) Antrypol was added to a concentration of lmg/ml and left for 2 min
at 37°C to stop the reaction.
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(iv) The cells were centrifuged at 2000rpm for 5 min at 2°C.
(v) The cells were then resuspended in 20ml lOmM EDTA:GVB2~ and 
incubated for 2 hours at 37°C in a shaking water bath.
(vi) The cells were washed twice in lOmM EDTA.'GVB2^, twice in DGVB2‘h and 
resuspended to a concentration of 1 x 10s cells/ml in DGVB2 .^ These 
EAC43b cells were stored at 4°C for up to 2 weeks.
Preparation of R3:
(i) Zymosan (lOmg/ml) was washed three times in lxPBS.
(ii) 1ml packed zymosan was added to 10ml normal human serum (to give a 
final zymosan concentration of lmg/ml) and then incubated at 37°C for 1 
hour with regular mixing.
(iii) After centrifugation to remove the zymosan pellet, the supernatant 
(R3) was kept and stored in aliquots at -70°C.
Several different concentrations of zymosan were tested:
0.5mg/ml, lmg/ml, 5mg/ml and lOmg/ml. The concentration of zymosan used 
in the preparation of R3 was the dilution immediately preceding that 
which produced 5-10% lysis.
Titration of R3: (see figure 7)
(i) The following dilutions of each R3 were made in GVB2'*';
1/10, 1/20, 1/40, 1/80 and 1/160.
(ii) lOOpl of each of the above dilutions were added to lOOpl EA (2xl0e 
cells/ml) and incubated for 1 hour at 37°C in a shaking water bath. 
Controls:
GVB2^ EA
Cell blank lOOpl lOOpl
100%. lysis lOOpl lOOpl
(iii) The reaction was stopped with 2ral saline (0.9% sodium chloride in
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Figure 7 -  Titration of S3 reagent. A 1/20 dilution of the lmg/ml 
zymosan preparation was used.
%  l y s i s
R 3  T i t r a t i o n100-
8 0 -
7 0 -
6 0 -
Z y i n o s a n  c o n c .
o — o  0 . 5 m g / m l  
• — •  l m g / m l  
■ — ■  5 m g / m l
□ — □  l O m g / m l
4 0 -
3 0 -
20-
160 80
1 / R 3  d i l u t i o n
distilled water), except 100% lysis to which was added 2ml water), the 
assays centrifuged (2000rpm for 5 min at 2°C) and the measured.
(i) Rabbit erythrocytes, Erat'blt-
Rabbit blood was obtained fron the marginal ear vein. The blood 
was collected in an equal volume of Alsever's solution and stored at 
4°C.
&,_2 -..Protocols for haemolytic assays
In all cases, the assays were stopped by the addition of 2ml 
saline to each tube (except 100% lysis to which was added 2ml water).
The tubes were then centrifuged (2000rpm for 5 min at 2°C) and then 
measured the QDa -ia to determine the haemoglobin release.
(a) C2 assay 
Raagsnts;
(i) EAC14 cells at 1x10* cells/ml in DGVB2""
(ii) C2 standard diluted in DGVB2'*' from 1/5000 to 1/80000.
(iii) Crat- (rat serum) diluted 1/15 in 40mM EDTA/GVB2"
Procedure;
(i) lOOpl culture supernatant diluted 1/4 in DGVB2'4' was added to assay 
tubes. lOOpl C2 standard dilutions were also added to a series of assay 
tubes.
(ii) The assay tubes, EAC14 cells and were prewarmed to 30°C.
(iii) lOOpl EAC14 cells were added to each assay tube (except complement 
colour, CC) and incubated for 2 min at 37°C.
(iv) 300pl Cv'a,‘t was added to each tube (except cell blank, CB) and 
incubated for 1 hour at 37°C, after which the assay was stopped.
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Controls: __
DGVB':?" EAC14 C'-f-
Reagent blank, RB lOOpl lOOpl 300pl
Cell blank, CB 400pl lOOpl
Complement colour, CC 200pl - 300/il
100% lysis lOOpl lOOpl 300pl
Bote: a medium blank (MB) was also set up for all assays using the 
same dilution of DMEM.FCS as the sample dilution.
(b) C4 assay
Reagents:
(i) EA cells at 1x10® cells/ml in DGVB2*
(ii) C4-deficient guinea pig serum diluted 1/50 in DGVE2*
(iii) Pooled human serum standards with doubling dilutions in DGVB2^ 
from 1/8000 to 1/1024000
Procedure;
(i) 100/jlI culture supernatant diluted 1/4 in DGVB2^ were added to the 
assay tubes, followed by lOOpl C4-deficient guinea pig serum and lOOpl 
EA cells.
(ii) The assay was then incubated for 1 hour at 37°C in a shaking water 
bath, after which the assay was stopped.
Controls:
DGVB2"- C4 deficient 
guinea pig serum
EA cells
Reagent blank lOOpl 1 0 0 /il 1 0 0 /il
Cell blank 2 0 0 pl - lOOpl -
Complement colour 200/jiI lOOpl -
1 0 0 % lysis lOOpl lOOpl lOOpl
- 75 -
(c) C3 assay 
Reagents;.
(i) EAC14-'' y2 cells at 1x10s cells/ml in DGVB2+.
(ii) DGVB2 * containing C5, C6  and C7 (Cordis reagents), each at a 
concentration of lOOunits/ml.
(iii) DGVB2 " containing C8  and C9 (Cordis reagents), each at a 
concentration of 50units/ml.
(iv) Serum standards in doubling dilutions from 1/25 to 1/8000 in 
DGVB2".
Procedure;.
(i) The culture supernatants were diluted 1/2 in DGVB2"^ and lOOpl were 
transferred to a series of assay tubes.
(ii) lOOpl DGVB2^ containing C5, C6  and C7 and lOO/il EAC140;,<y2 cells 
were added to each tube and incubated for 30 min at 37°C in a shaking
water bath to form EAC1-7.
(iii) lOOp.1 DGVB2'4' containing C8  and C9 were then added and incubation
was continued at 37°C for a further hour, before the assay was stopped.
Controls:
DGVB2^ C5,C6,C7 EAC14— y2 C8,C9
Reagent blank lOOpl 100pl lOOpl lOOpl
Cell blank 300pl - lOOpl
100% lysis lOOpl lOOpl lOOpl lOOpl
(d) C5 assay
Titration of C5 followed the same procedure as for C3 but 
different Cordis reagents were used in the initial mixture ie. DGVB2^ 
containing C3, C6  and C7 (instead of C5,C6,C7) each at a concentration 
of lOOunits/ml.
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(e) Titration of D activity for use in the factor B assay
The D used initially for these studies was contaminated with 
factor B which meant it could not be used in factor B assays. As a 
result more D was purified from human serum (see below). When the D was 
removed from the serum by Biorex 70 cation-exchange chromatography, the 
exclusion peak represented serum that contained no D and hence was 
termed the RD reagent. In order to titrate the purified D, 
reconstitution of the RD reagent was used in the following assay.
Reagents:
(i) Ep*bblt cells at 1x10® cells/ml in Mg-EGTA.
(ii) The RD reagent diluted 1/5 in Mg-EGTA.
Procedure;
(i) The purified D was serially diluted from 1/5 to 1/5120 in Mg-EGTA 
and 50/il of each dilution was added to a series of assay tubes that 
contained 50pl of RD reagent.
(ii) lOO/il cells were added and the assay incubated at 37°C for 
30 rain in a shaking water bath, after which the assay was stopped. 
Controls:
Mg-EGTA
Reagent blank lOOpl lOOpl
100% lysis lOOjutl lOOpl
(f> Factor B assay
Reagents;
(i) EAC43b cells at 1x10® cells/ml in DGVB2'*
(ii) D (19.3 units/ml) diluted 1/40 in DGVB2"*
(iii) C ’’*'1 diluted 1/15 in 40mM EDTA. GVB:;:“
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Procedure
(i) 50/il culture supernatant diluted 1/2 in DGVB2^ were added to a 
series of assay tubes containing 50/il D (0.5 units/ml).
(ii) 100/il EAC43b cells were added to each tube which were then 
incubated for 30 min at 37°C in a shaking water bath.
(iii) 300/il Crmt- EDTA were added and incubation was continued at 37°C
for a further hour, after which the assay was stopped.
Controls:
D G V B ^ D EAC43b CT'“,t EDTA
Reagent blank 1 0 0 /il - 1 0 0 /il 300/il
Cell blank 400/il - 1 0 0 /il -
D alone 50/il 50/il 1 0 0 /ml 300/il
Complement colour 2 0 0 /il - - 300/il
1 0 0 % lysis 1 0 0 /il - 1 0 0 /il 300/il
9.3 - Calculation of haenolytic assay results
In each of the above assays, the amount of lysis was measured by 
reading the optical density of the sample at 414 nm. To convert the 
optical density measurement into per cent lysis the following 
calculations were performed:
y = QD..sample - QD reagent blank
OD 100 % lysis - OD reagent blank
Per cent lysis = 100 x y
Vhen y is plotted against serum dilution (following the 
haemolytic titration of complement components e.g. D above), the curve 
is concave to the x-axis. The shape of the curve led Mayer and his 
colleagues (Borsos et al., 1961) to postulate that complement-mediated
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lysis was due to a single effective hit by a complement molecule (one-
hit theory). Thus, if the number of effective molecules offered per cell
= Z then the proportion of unlysed cells (cells with nil hits) will be 
e^.
Therefore,
-Z = In (1-y)
or Z = -In (1-y)
In all the above component assays, 100/il of sample dilution and 
1 0 0 /il of cell suspension (containing 1 x 1 0 scells/ml ie, 1 0 7  cells/tube) 
were used.
(a) Calculation of the haemolytic activity of complement components in 
the synoyial membrane culture supernatants
The number of effective molecules per lOOmg tissue was 
calculated by:
Z value x ________100______  x total volume of culture
weight of tissue sample volume used in assay
The resultant haemolytic activity was expressed as: 
effective molecules (e.m. ) x 1 0 7 /1 0 0 mg tissue
Haemolytic tiAration of...complament...gtunpfliifiiits e,g. P
Vhen haemolytic titration of a component is performed (e.g. D, 
see below), Z is plotted against the concentration of that particular 
component. A straight line, passing through the origin'is obtained. Vhen 
Z = 1, then -In (1-y) = 1, and y = 0.632. In other words, 63.2% of the - —  
cells have been lysed. To calculate the number of effective molecules 
of a component in a given volume, a vertical line is drawn from the 
point on the graph which passes through Z = 1 to the x-axis. The number
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of units of component were calculated by the:
distance along x-axis to initial dilution x initial dilution
distance along x-axis to Z = 1
Therefore, the concentration of effective molecules = units x
1 0 7 /ml, which is usually expressed as units/ml.
10. Partial purification of D  from human serum
D was purified from human serum as described by Tenner, Lesavre 
& Cooper, (1981).
I.p.n..excha.iige_gIur-QfflatQgraphy
Biorex-70 cation exchange chromatography was performed at 4°C. 
Using a 2.6cm x 80cm column which had been equilibrated with starting 
buffer (50m3t phosphate buffer, pH 7.3 containing 82mM HaCl, 2mM EDTA). 
Human serum (180ml) was loaded onto the column at a flow rate of 
10ml/hour and 10ml fractions were collected. Fallowing the application 
of the sample, the column was washed with starting buffer at a flow rate 
of 50ml/hour until the protein content (ODzeo) of the eluate was zero. 
The fractions of the exclusion peak were pooled and retained for use as 
an RD reagent for the D haemolytic assay (see above).
The column was then eluted using a gradient consisting of 300ml 
starting buffer and 300ml starting buffer containing 300mM HaCl at a 
flow rate of 30ml/hour. Fractions were screened for ODseo and D 
haemolytic activity by their ability to reconstitute the haemolytic 
activity of the RD reagent. Fractions containing D activity were pooled 
and concentrated using an Amicon YM-10 filter.
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11. Incorporation of 3 3 S-methionine into complement proteins
11.1 - Synovial tissue explant cultures
Synovial tissue explant cultures were set up as described above 
but DMEM containing 10% (v/v) fetal calf serum and methionine at a 
concentration of 6 pg/ral was used. After the addition of 500 pCi ®GS- 
methionine (Amersham International) the cultures were incubated at 37°C 
in a humidified atmosphere of 5% COs in air for 24 hours. The medium was 
removed, treated with protease inhibitors (5mM PMSF, lOmM benzamidine 
and lOmM EDTA) and stored at -70°C prior to analysis.
11.2 - Measuring acid-precipitable counts
GF/A filters (Whatman) were soaked in 2mM unlabelled methionine 
for 10 min and then air dried. Culture supernatant (5pl) was dotted on 
the filter, which was then subjected to the following washing procedure;
(i) 10% trichloroacetic acid (TCA) for 1 min
(ii) 5% TCA for 1 min
(iii) 1 0 0 % acetone for 1 min
(iv) 50% acetone for 1 min
(v) 50% ethanol for 1 min
(vi) 1 0 0 % ethanol for 1 min
The filters were then air dried and the radioactivity measured 
on a scintillation counter using 2,5ml scintillation fluid (Ecoscint). 
The percentage incorporation of 3S[ S]-methionine into acid-precipitable 
protein was calculated.
11.3 - Immunoprecipitati-Qii-of 3SSr.aethiQiuiie .labelled complement.... 
components
(i) Formalin fixed Staph, aureus protein A was washed three times in PBS
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containing Triton X100 (1% w/v). Fallowing the final wash, 100/il of 
packed Staph, aureus protein A was added to each culture supernatant 
(lml) as a preabsorption step to remove excess immunoglobulin and immune 
complexes. The samples were incubated at room temperature for 1 hour on 
a rotating mixer and then centrifuged at 6000rpm for 2 min. The pellets 'vnk.-c 
discarded and the supernatants transferred to fresh tubes.
(ii) The supernatants were diluted 1/10 in solution A and split into ten 
1 ml aliquots.
(iii) lOpl IgG fraction of the following antibodies at lmg/ml (in PBS) 
were added to the appropriate culture supernatant aliquot:
anti-Cl-IBH anti-C4
anti-factor B anti-C5
anti-C2 anti-human serum albumin
anti-C3
The samples were then incubated overnight at 4°C,
(iv) 20pl packed Staph, aureus protein A was added to each sample which 
were then incubated at room temperature for 1 hour on a rotating mixer.
(v) The samples were centrifuged (6000rpm for 2 min at room temperature)
and the supernatants were removed and stared at -70°C.
(vi) The pellets were washed five times in PBS containing 0.1% (w/v) SDS 
and 1% (v/v) Triton and then the complexes were eluted with solution B 
(50pl) for 15 min at 37°C.
(vii) The radioactivity of the samples was determined using a 
scintillation counter to ensure that the same number of counts/min were 
loaded onto each track for SDS-polyacrylamide gel electrophoresis.
11.4 - SDS-polyacrvlamide gel electrophoresis (SPS-PAGE)
The percentage of gel used in SDS-PAGE was determined by the
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size of the proteins being studied - larger proteins require lower 
percentage gels. All the proteins being investigated had molecular 
weights of approximately 50-100 kDa and 10% reducing gels were used.
Reagents:
(i) 10% SDS (iv) 0.75M Tris.HCl pH8 . 8
(ii) 0.75 M Tris (v) 30% acrylamide Us
(iii) 0.75M Tris.HCl pH6 . 8
Procedure:
(i) The glass plates and spacers were cleaned and greased with 
isobutanol and the following 10% separating gel was poured: 10ml 30% 
acrylamide, 4.7ml water, 15ml 0.75M Tris.HCl pH8 .8 , 300pl 10% SDS, 30mg 
ammonium persulphate (Sigma) and 15pl TEMED (Sigma).
(ii) Once the separating gel had polymerised the following stacking gel 
was poured: 1.8ml 30% acrylamide, 13ml water, 3ml 0.75M Tris.HCl pH6 .8 , 
180/jlI 10% SDS, 18mg ammonium persulphate and 9pl TEMED.
(iii) 5pil bromophenol blue was added to each sample which were boiled 2 
min before loading. The sizes of the proteins were determined by 
including a series of radioactively-labelled (1 4 C) proteins of known 
molecular weights (Sigma); 14 kDa, 30 kDa, 46 kDa, 69 kDa, 92.5 kDa and
200 kDa. The gels were run at 50 V for 3 hours.
(iv) The gels were stained (0.1% (w/v) Coomassie blue (Sigma), 50%
methanol, 10% acetic acid) for one hour and destained (10% methanol, 5%
acetic acid) overnight.
(v) The gels were impregnated with 1M salicylic acid (Sigma) for 1 hour 
and dried for 3 hours. Fluorography was performed at -70°C with Kodak X- 
Omat AR film and intensifying screens for 1-4 weeks
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12. Isolation of synovial cells from synovial tissue
Synovial cells were isolated from synovial tissue much as 
(^CxVV sA/Ar>"v. wtr* W-iU^  
described by Dayer et al. , (1976)a Synovial tissue specimens were
collected at the time of surgery from 10 patients (5 with rheumatoid
arthritis and 5 with osteoarthritis) and transported to the laboratory
in transport medium. The tissue was then washed thoroughly in Dulbecco's
calcium and magnesium free 1 x PBS, chopped into small l-2mm3  fragments
and washed a further three times in 1 x PBS. The tissue was then
digested with 25ml Hanks balanced salt solution containing collagenase
(lmg/ml) (Type 1, Sigma) and DBase 1 (0. lmg/ml) (Sigma) for 3-4 hours at
37°C in a shaking water bath. Cells and debris were removed by
centrifugation at 1500rpm for 10 min in a MSE swing-out centrifuge. The
supernatant was discarded and the cells and tissue were resuspended in
50ml lxPBS containing trypsin (0.5mg/ml) (Type 111, Sigma) and EDTA
(0.2mg/ml) and incubated for a further hour at 37°C in a shaking water
bath. The cells were separated from the undigested tissue by standing at
room temperature for 5 min. The supernatant containing the cell
ioC fJJ c«/f
suspension was removed and the cells washed three times in^ (|)MEM. FCS.) A ^  ~"’v 
cell count was taken and after appropriate dilution in DMEM.FCS, the 
cells were plated onto 35x10mm petri dishes (Nunc) at a cell density of 
lxlQe cells/dish in a volume of lml/dish. The cultures were then 
incubated at 37°C in a humidified atmosphere of 5% CO2 in air.
After 24 hours, the medium was removed and centrifuged for 5 min 
at 1500rpm to precipitate the non-adherent cells. The non-adherent cells 
from each culture were resuspended in lml DMEM.FCS and plated onto fresh 
35x10mm petri dishes. The adherent cells on the original dishes were 
supplemented with lml DMEM containing 10% fetal calf serum. All cultures
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were incubated at 37°C in a humidified atmosphere of 5% CO2  in air. Each 
day the culture medium was removed from the adherent cell cultures which 
were then supplemented with lml DMEM.FCS. The culture medium was also 
removed daily from the non-adherent cultures and the supernatants 
were separated from the non-adherent cells by centrifugation (1500rpm 
for 5 min at room temperature). The supernatants were collected and the 
cells were resuspended in lml DMEM.FCS before being replated onto the 
same dishes from which they had been removed. In each case, two cultures 
were treated with 2.5pg/ml cycloheximide which inhibits protein 
synthesis and therefore can be used as negative control cultures when 
synthesis of complement components is being investigated. The medium 
removed from the cultures was stored in aliquots at -20°C prior to 
analysis.
13. Immunohistochemical analysis of cultured synovial cells
13.1 - Cell fixation
The culture medium was removed from the cells which were then 
washed three times in 1 x PBS. The cells were fixed in 10% neutral 
buffered formalin (100ml formaldehyde and 900ml water containing 4g 
BaHzPCU.HzO and 6.5g NasHPCU - the pH was adjusted to 7.0 if necessary) 
for 1 hour at room temperature. The cells were then washed four times in 
1 x PBS and if not used immediately were stored in 1 x PBS at 4°C 
overnight.
13.2 - Immunohistochemistry
(i) The cells, which had been grown on plastic coverslips (Therraanox), 
were flooded for 10 min with a 1/5 dilution of normal swine serum as a 
blocking agent,
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(ii) The cells were washed thoroughly in 1 x PBS and a predetermined 
dilution of rabbit antiserura (i-W ckst ; diluted in a 1/25 dilution of 
normal swine serum), was added. After incubation for 1 hour at room 
temperature, the monolayers were washed extensively in 1 x PBS. Hormal 
rabbit serum was used as a negative control for all cells.
(iii) A 1/20 dilution of swine anti-rabbit IgG alkaline phosphatase 
(Dako-Patts; in 1/25 normal swine serum) was then applied to the cells 
which were then incubated at room temperature for a further 90 min.
a fibroblast marker and was diluted 1/40 in 5% bovine serum albumin. 
Babbit anti-mouse IgG conjugated to alkaline phosphatase (Dako-Patts) at 
a dilution of 1/20 in 5% BSA was used on the anti-vimentin treated 
cells.
(iv) After the cells were washed extensively in 1 x PBS they were 
incubated with the phosphate substrate for 1 0  min at room temperature.
(v) The cells were sequentially washed in 1 x PBS and tap water and then 
fixed in 1% neutral buffered formalin (contains 1 / 1 0  of the formaldehyde 
concentration in 1 0 % neutral buffered formalin) for 1 0  min at room 
temperature.
(vi) The cells were washed in tap water, counterstained in haematoxylin 
and alkaline tap water substitute, mounted on slides with Aquamount 
(BDH) and stored at 4°C until examined by light microscopy.
A mouse monoclonal anti-human vimentin
C A  cxwvA}
•odyl was also used as
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1. CHARACTER I SAT I Q1P QF PLASMID M A
After preparation of the cDNA probes used in these studies (see 
Table 7), it was necessary to characterise each plasmid using the 
appropriate restriction enzymes. Figures 8 - 1 2  show' the restriction 
enzyme digests performed on the plasmids.
Figure 8 shows the restriction digests of the pAT153.Pvull 8.C3 
plasmid. The C3 insert (2400bp) was excised from the plasmid vector 
using the restriction enzyme EcoRl.
Figure 9 shows the restriction digests of the pAT153.Pvull 8.C2, 
pAT153.Pvull 8 .factor B and pGem. Cl-INH plasmids. The C2 insert (400 
bp), factor B insert (540 bp) and Cl-INH insert (1250 bp) were each 
excised from their plasmid vectors with the restriction enzymes BamHl 
and Hind 111.
Figure 10 shows the restriction digests of the pAT153.Pvull 8.C4 
and pGem.C5 plasmids. The C4 insert (300 bp) and C5 insert (940 bp) were 
excised from their plasmid vectors using the restriction enzymes BamHl 
and Hind 111.
Figure 11 shows the restriction digests of the pAT153.Pvull 8 . 
C4BP and pBR322. ^ 2 -microglobulin plasmids. The C4BP insert (1400bp) was 
excised from the plasmid vector using the restriction enzymes BamHl and 
Hind 111 while the Ps-microglobulin insert (525 bp) was excised from the 
pBR322 vector using the restriction enzyme Pstl.
Figure 12 shows the restriction digests of the pAT153.Pvull 8 . 
Clq B-chain plasmid. The Clq B-chain insert (1000 bp) was excised from 
the plasmid vector using the restriction enzymes BamHl and Hind 111.
Several of the cDNA inserts (Cl-INH, factor B, C2, C4 and C5)
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pC3.11a + Clal 
pC3.11a + Sa11 
pC3.11a + Clal + Sail 
pC3,11a + EcoRl 
pC3.lib + Clal 
pC3.lib + Sail 
pC3.lib + Clal + Sail 
pC3.11b + EcoRl 
Lambda DNA markers
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^5148
-4973 1-3 pC3.11a + EcoRl
'4277
s3530 4 Lambda DNA markers
-2027
"1904
"1584
'1330
- 9 8 3
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— 564
Figure 8 - Restriction enzyme digests of pAT153.C3. The top gel shows 
the various restriction enzyme digests performed on the pAT153.C3 
plasmid. The lower gel represents the EcoRl digest of pAT153.C3 which 
excised the 2400bp cDNA insert which could then be extracted from this 
low melting point agarose gel. In all cases, the gels were calibrated 
with X markers (X phage DMA digested with EcoRl and Hindlll; Boehringer 
Mannheim).
pAT153.C2 and pAT153.factor B
1 L
2 3 4 5 6 7 8 9101112
LANE RESTRICTION DIGEST
2 Undigested pAT153.C2
3 pAT153.C2 + BamHl
4 pAT153.C2 + Hindlll
5 pAT153.C2 + BamHl + Hindlll
6 pAT153.C2 + Hindlll
7 pAT153.C2 + BamHl
8 Undigested pAT153.C2
9 Lambda DNA markers
10 pAT153.FB + BamHl
11 pAT153.FB + Hindlll
12 pAT153.FB + BamHl + Hindlll
pGem.Cl-INH
 — -
f
to 
to *
LAIE. RESTRICTION DIGEST
2 pGem.Cl-INH + BamHl + Hindlll 
4 Lambda DNA markers
Figure 9 - Restriction enzyme digests of pAT153.C2, pAT153.factor B and 
pGem.Cl-IITH.
*l#*» !«-s*
1  2 3 4 5 6 8 9 1 0  1 1 1 2
l a n e RESTRICTION DIGEST
i p A T 153.C4 + BamHl
2 Undigested pAT153.C4
3 pAT153.C4 + BamHl. + Hindlll
5 pAT153.C4 + Hindlll
6 pAT153.C4 + BamHl + Hindlll
8 Lambda DNA markers
9 pGem.C5 + BamHl
10 pGem.C5 + Hindlll
11 pGem.C5 + BamHl + Hindlll
12 Undigested pGem. C5
Figure 10 - Restriction enzyme digests of pAT153.C4 and pGem. C5.
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1 Undigested pAT153.C4BP
2 pAT153.C4BP + BamHl
3 pA1153.C4BP + BamHl + Hindll.
4 pAT153.C4BP + BamHl + Clal
5 pAT153. C4BP + BamHl + EcoRl
6 Lambda DNA markers
LMI. RESTRICTION DTC.BST
pBR322. + Pstl
pBR322.6. H + Pstl 
Lambda DNA markers
Figure 11 - Restriction enzyme digests of pAT153.C4BP and pBR322.J3 
microglobulin.
pAT153.Clq B-chain
EESIBICTIfm nrrrF.c:" 
pAi153.ClqB + BamHl 
pAT153.ClqB + BamHl + Hindlll 
pAT153.ClqB + BamHl + Clal 
Lambda DNA markers
RESTRICT T O W  prrrT?,gT 
pAT153.ClqB + BamHl + Hindlll 
Lambda DHA markers
1 3
Figure 12 - Restriction enzyme digests of pAT153.Clq B-chain.
were recloned into the pGem-1 (Promega Biotec) transcription vector. The 
2.9 kb pGem-1 vector was constructed using the bacteriophage SP6 
promoter-containing plasmid pSP64 (Melton et al. , 1984) and a 
bacteriophage T7 promoter. The resulting plasmid has SP6 and T7 
promoters separated by a short length of DMA containing multiple cloning 
sites (Figure 13). The single stranded RNA probes produced by this 
system were reported to yield greater sensitivity in Northern and dot- 
blot analyses because RNA/RNA duplexes are more stable than the 
corresponding DNA/RNA hybrids obtained with DNA probes. Hybridisation 
with RNA probes allows background an blots to be further reduced by 
RNase A treatment which is not possible with DNA probes.
In each case, the Cl-INH (pAT153.Pvull 8), factor B (pAT153, 
Pvull 8), C2 (pAT153. Pvull 8), C4 (pAT153.Pvull 8) and C5 (pBR322) 
plasmids were digested with BamHl and Hindlll to excise the cDNA insert 
which was then ligated into the BamHl/Hindlll digested pGem-1 vector.
However these RNA probes gave rather disappointing results. 
During optimisation of the Northern blot analysis procedure, most 
workers in this laboratory started to use random primed labelled cDNA 
probes which gave much clearer results than the conventional nick 
translated cDNA probes. These random primed cDNA probes, like the RNA 
probes described above, involved labelling the specific insert sequence 
only and not the plasmid vector DNA, which decreases the risk of non­
specific background hybridisation.
In an attempt to improve the Northern blot analysis of the 
synovial tissue mRNA, random primed cDNA probes were used and were found 
to give much better results than the RNA probes. However, when the 
Northern blots were analysed with the fSz microglobulin random primed
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Rrul 
Pvu
X m n l
Multiple Clonjpg Site
Hind 111 
Pst 1 
Sal 1 
Acc 1 
Hinc 11 
Xba 1 
Bam HI 
Ava 1 
Sma 1 
Sac 1 
Eco R1
M C S Mp G e m - 1  
( 2 . 9  K b )
pGem-1 plasmid promoter and multiple cloning site sequence:
SP6 Promoter SPG transcription start 
ATTTA GGTGA CACTA TAGAA TACAA GCTTG GGCTG CAGGT CGACT CTAGA
 I
Hind 111 Pst r H  \
Sal 1 
Acc 1 
Hinc 11
Xba 1
T7 transcription st^rt T7 promoter
GGATC CCCGG GCGAG CTCGA ATTCC GGTCT CCCTA TAGTG AGTCG TATTA
h  "------ *Sma 1 Sac 1
Bam HI Ava 1 Eco R1
The sequence shown is the coding strand for T7 REA polymerase and the 
non-coding strand for SP6 REA polymerase.
Figure 13 - Restriction map and DNA sequence of the promoters and
multiple cloning site of the pGem-1 transcription vector.
c D M  probe (jS^  microglobulin mREA is a relatively intact mREA in vivo), 
the j^-microglobulin mREA on the Eorthern blots analysed with the REA 
probes was shown to be substantially more degraded than the j3s-micro- 
globulin mREA on the Eorthern blots analysed with random primed cDEA 
probes. Therefore, the better results achieved with the random primed 
cDEA probes are more likely due to the better quality of mREA on the 
Eorthern blots rather than any inherent property of the cDEA probes 
being superior to the REA probes. However, because satisfactory results 
were being obtained with the random primed cDEA probes it was decided to 
continue using them instead of reverting to the REA probes.
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Optimising the procedure for the isolation of undegraded REA 
from synovial tissue required many detailed modifications of the 
conventional techniques of REA isolation to be tested, which resulted in 
this aspect of the study becoming rather time-consuming.
As stated in the Materials and Methods section, the guanidinium 
thiocyanate procedure for REA isolation was used. This was the standard 
procedure used in this laboratory and had previously been shown to 
isolate undegraded REA from ribonuclease-rich tissues such as pancreas. 
Many other studies had also shown this to be the best method available 
for the extraction of intact REA from both tissues and cells (Birnie & 
Graham, 1984).
Isolation of REA from rat liver was initially used in order to 
gain experience in the technique. Liver contains a large number of 
endogenous ribonuclease-inhibitors which should ensure that the 
isolation of REA from liver is relatively straightforward. Therefore, 
rat liver was a good model system to ensure that, in my hands, the 
method being used was working satisfactorily. Using the rat actin cDEA 
probe the actin mREA was shown to be undegraded which shows that 
guanidinium thiocyanate can be used to isolate intact REA from rat 
liver.
However, when the same technique was used to isolate REA from
human synovial tissue, several technical problems were encountered.
The first problem that had to be overcome was the sheer
toughness of the synovial tissue which made it extremely difficult to
pulverise. On a number of occasions the mortar and pestle broke before 
the tissue, so a solid steel mortar and pestle was used. This allowed me
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to pulverise the frozen synovial tissue under liquid nitrogen using a 
large hammer. This procedure resulted in the formation of a coarse 
synovial tissue powder. However, the tissue tended to thaw very quickly 
in this steel mortar and hence the time taken to pulverise the tissue 
had to be minimised. After the initial pulverisation, the tissue was 
ground into a fine powder in a conventional mortar and pestle under 
liquid nitrogen before being transferred to guanidinium thiocyanate.
The next (and most important problem) was the inconsistent 
quality of REA being isolated from the synovial tissue. Some specimens 
consistently yielded undegraded REA free of contaminating protein while 
other specimens always yielded degraded REA. Because undegraded REA was 
isolated from a number of specimens, the guanidinium thiocyanate method 
appeared to be suitable for this type of tissue and some other factor is 
required to explain why the REA was degraded in some cases. Over a 
period of time, it became obvious that the most important factor was to 
minimise the delay between the removal of the synovium from the patient 
and the tissue being snap-frozen in liquid nitrogen. Although there was 
no strict rule, the isolation of undegraded REA usually became 
impossible if the tissue was left at room temperature for longer than 10 
minutes. Thus in order to minimise REA degradation, synovial tissue was 
snap frozen in liquid nitrogen within 10 minutes of being removed from 
the patient.
Another method for REA isolation, REAzol, was recently reported 
to be much faster and more reliable than the guanidinium thiocyanate 
method (Chomczynski & Sacchi, 1987). To investigate this claim further,
I pulverised some synovial tissue and added half of the powder to 
guanidinium thiocyanate and half to the REAzol solution and proceeded to
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prepare REA by these two separate methods. The experiment was repeated 
with rat liver. Staining the gel with ethidium bromide followed by 
Eorthern blot analysis showed that liver mREA was undegraded when 
prepared by either method, while synovial tissue REA was only undegraded 
when it had been prepared by the guanidinium thiocyanate method. The 
REAzol method always produced totally degraded synovial tissue mREA.
Thus it appears that REAzol is suitable for REA extraction from tissues 
such as liver and is also now being used routinely in this laboratory 
for the isolation of REA from cultured cells such as monocytes. However, 
it was clear that REAzol was not suitable for the extraction of REA from 
human synovial tissue and the original guanidinium thiocyanate method 
was retained as the most suitable for this purpose.
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3. NORTHERN BLQT ANALYSIS OF. SYNOVIAL TISSUE RNA
In addition to the modifications to the RNA isolation 
procedures, the Northern blot analysis procedure was also optimised. The 
major modification in these analyses was the use of nylon membranes 
(Hybond-N) in both Northern blots and dot-blots instead of the more 
widely used nitrocellulose. It was shown that the nylon membranes had 
two major advantages over the nitrocellulose:
(a) in almost every case, non-specific background hybridisation was not 
present when Northern and dot-blot analyses was performed on nylon 
membranes. This however, was a major problem when nitrocellulose was 
used. Both types of filters were washed to the same stringency (0.1 x 
SSC containing 0.1% SDS).
(b) the nylon membranes were stripped and reprobed up to six times 
without significantly affecting either the intensity of the radioactive 
signal after reprobing or the physical structure of the membrane itself. 
However, nitrocellulose becomes brittle even after being stripped once.
In order to optimise the hybridisation conditions, several 
buffers and incubation conditions were tested. Both prehybridisation and 
hybridisation were found to be most efficient when performed at 42°C for 
at least 16 hours, although prehybridising at 65°C for only two hours 
seemed to have no effect on the quality of the end result. The buffer 
used for both prehybridisation and hybridisation is described in detail 
in the Materials and Methods section 6.2. --
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RNA ladder markers
(Kb)
Figure 14 - RNA sized ladder markers (Bethesda Research Laboratories) 
used to calibrate Northern blot analysis.
SYNOVIAL 
PATIENT JOINT
TYPE OF ANALYSIS
RNA
STUDIES
Northern Dot 
blot blot
SYNOVIAL MEMBRANE 
CULTURES
ELISA Haemolytic SDS-PAGE 
assay
SYNOVIAL CELL 
CULTURES
ELISA Iimnuno
histochem
RA1 Knee + + _ _ _ _ _
RA2 Knee + + - - - -
RA3 Hip + + + - - -
RA4 Shoulder + + + - - -
RA5 Knee + + - - - -
RA6 Knee + + - - - -
RA7 Knee + .+ - - - -
RA8 Knee + + + - - -
RA9 Hip + + + - - -
RA10 Shoulder + + - - - -
RA11 Hip + + - - -
RA12 Hip + + - - - -
RA13 Knee - - . - - + -
RA14 Knee - - - - -; + +
RA15 Knee - — - — - + +
0A1 Knee + + — — — — —
0A2 Knee + + - - - -
0A3 Hip + + - - - -
0A4 Knee + + - - - -
0A5 Knee + + + - - -
0A6 Hip + - - - - -
0A7 Hip + + + - - -
0A8 Hip + - + - - -
0A9 Knee + + + - - -
OAIO Hip + + - - - -
0A11 Knee + + - - - -
0A12 Hip + + - - - -
0A13 Hip + + - - - ■ -
0A14 Hip + + - - - -
0A15 Knee - - + + - -
0A16 Knee - - - - + -
0A17 Knee - - - - + -
0A18 Hip - - - - + -
0A19 Knee - - - - - + +
OA20 Knee - - - - - + +
AS1 Knee + + — — — —  -
CC1 Knee + + - - - -
N1 Knee - + + + - -
TABLE 9 - List of patients used in these studies (RA - rheumatoid
arthritis, OA - osteoarthritis, AS - ankylosing spondylitis, 
CC - chondrocalcinosis, N - normal synovium).
RNA was prepared from the synovial membrane of 49 patients, 20 
with rheumatoid arthritis, 23 with osteoarthritis, 1 with 
chondrocalcinosis, 2 with psoriatic arthritis and 2 with ankylosing 
spondylitis. In addition, RNA was isolated from one specimen of normal 
synovium from a patient who underwent patellectomy for recurrent 
patellar dislocation.
However, due to some patients' RNA being consistently degraded 
or insufficient RNA being prepared for analyses, only 28 patients were 
included in the Northern blot analysis (20pg RNA/track). Of the 26 
patients examined in this study, there were 12 with rheumatoid 
arthritis, 12 with osteoarthritis, 1 with chondrocalcinosis and 1 with 
ankylosing spondylitis (see Table 9). However, even within this group, 
RNA isolated from a small number of patients was consistently shown to 
be degraded.
These 26 patient samples were divided into three groups: two 
groups containing nine patients and another group of eight patients. 
Each group was analysed in sets of four identical Northern blots; A - D 
(group 1), E - H (group 2) and I - L (group 3).
Figure 14 shows the RNA sized ladder markers (Bethesda Research 
Laboratories) used to calibrate the Northern gels while figures 15 - 20 
show the results from Northern blot analysis of RNA isolated from the 
synovial membrane of the 26 patients.
Northern blots A - D (figures 15 and 16) contain RNA isolated 
from the synovial membrane of 5 rheumatoid arthritis patients (RA1 - 
RA5) and four osteoarthritis patients (0A1 - 0A4).
Figure 15 (a) shows the results of Northern blot A which was 
initially analysed with the factor B cDNA probe. Factor B mRNA (2.6 kb)
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Factor B
2.6-
i !
B j-microglobulin
1.4-
Cl-INH
2.1-
C2
2.9-
1 2 3 4 5 6 7  8 9
Northern blot A
Bi-microglobulin
/
1 2 3T 47 5 6 7 8 9 
Northern blot B
Figure 15 - Northern blot analysis of RNA isolated from the synovial 
membrane of 9 patients (group 1). Both Northern blot A and B contain RNA 
from the same patients loaded in the following order: left to right, 
lanes 1-9; RA1, RA2, RA3, RA4, RA5, 0A1, 0A2, 0A3 and 0A4. Northern blot 
A was probed for factor B mRNA, stripped and then reprobed for jl^-micro-x- 
globulin mRNA. Northern blot B was probed, stripped and reprobed with 
different cDNA inserts in the following order; Cl-INH, C2 and J32-raicro- 
globulin.
C3
5.2-
C5
B -microglobulin
p?' • 13
1.4- *
1 2 3 4 5 6 7 8 9  
Northern blot C
C4
1 # :
Clq B chain
ri \
B 2-microglobulin
TTf
0
* f
1 2 3 4 5 6 7 8 9  
Northern blot D
Figure 16 - Northern blot analysis of RNA isolated from the synovial 
membrane of 9 patients (group 1). Both Northern blot C and D contain RNA 
from the same patients as Northern blots A and B and were loaded in the 
following order: left to right, lanes 1-9; RA1, RA2, RA3, RA4, RA5, 0A1, 
0A2, 0A3 and 0A4. Northern blot C was probed, stripped and reprobed with 
different cDNA inserts in the following order; C3, C5 and |32-micro-
globulin. Northern blot D was probed, stripped and reprobed with
different cDNA inserts in the following order; C4, Clq B-chain f^-micro-
globulin.
was detected in all samples except RA1, 0A1 and QA3. However when this 
filter was stripped and reprobed for jS^-microglobulin mRNA (1.4 kb) (a 
relatively stable mRNA in vivo), intact mRNA was detected for samples 
RA2, RA3, RA4, RA5, 0A2 and 0A4. However the mRNA from samples RA1, 0A1 
and 0A3 was totally degraded. This observation, which was repeated on 
Northern blots B, C and D, explains the negative results obtained for 
these three patients with all cDNA probes.
Figure 15 (b) shows the results of Northern blot B which was 
initially analysed with the Cl-INH cDNA probe. Cl-INH mRNA (2.1 kb) was 
detected in all samples (except RA1, 0A1 and 0A3). This filter was 
stripped and reprobed with the C2 cDNA probe which revealed C2 mRNA (2.9 
kb) in all samples although only very weak signals were detected for RA2 
and 0A2. However, when the filter was reprobed with the ^2 -microglobulin 
cDNA probe substantial amounts of mRNA were detected in these two lanes.
Figure 16 (a) shows the results of Northern blot C which was 
initially analysed with the C3 cDNA probe. A weak band corresponding to 
intact C3 mRNA was detected in only one sample (RA4). Only low molecular 
weight material (degraded C3 mRNA) was detected in the other samples,
RA2, RA3, RA5, 0A2 and 0A4. C5 mRNA was not detected in any sample but 
when the filter was reprobed for fls-microglobulin mRNA, not only was 
mRNA present in all six lanes but it did not show any sign of 
degradation.
Figure 16 (b) shows the results of Northern blot D which was 
initially analysed with the C4 cDNA probe. Similar results were obtained 
as for C3 mRNA although a faint band corresponding to intact C4 mRNA 
(5.5 kb) was detected in three samples RA2, RA5 and 0A2. Law molecular 
weight material was detected in all other samples. The filter was
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B :-microglobulin
■nr ’ •
1 2 3 4 5 6 7 8 9
Northern blot E
C2
B z-micr oglobulin
1.4- *  •
2 3 4 5 6 7 8 9  
Northern blot F
Figure 17 - northern blot analysis of RNA isolated from the synovial 
membrane of 9 patients (group 2). Northern blot E and F contain RNA from 
the same patients (except lane 1 is omitted in Northern blot F) loaded 
in the following order: left to right, lanes 1-9; RA6, RA7, RA8, RA9,
0A5, RA10, RA11, 0A6, AS1. Northern blot E was probed for factor B mRNA.^, 
and then stripped and reprobed for J^-microglobulin mRNA. Northern blot 
F was probed, stripped and reprobed with different cDNA inserts in the 
following order; Cl-INH, C2 and jSz-microglobulin.
C3 C4
C5
B t-microglobulin
1.4-
1 2 3 4 5 6 7 8
Bz-microglobulin
1.4-
1 2 3 4 5 6 7 8
Northern blot H
Northern blot G
Figure 18 - Northern, blot analysis of RNA isolated from the synovial 
membrane of 8 patients (group 2 - AS1 is omitted). Both Northern blot G
and H contain RNA from the same patients loaded in the following order:
left to right, lanes 1-8; RA6, RA7, RA8, RA9, 0A5, RA10, RA11, 0A6.
Northern blot G was probed, stripped and reprobed with different cDNA - —
inserts in the following order; C3, C5 and J^-microglobulin. Northern 
blot H was probed for C4 mRNA and then stripped and reprobed for 02- 
microglobulin mRNA.
reprobed with the Clq B-chain cDNA probe and intact Clq B-chain mRNA 
(1.4 kb) was detected in samples RA3, RA4, RA5, 0A2 and 0A4. Only lower 
molecular weight material was detected in sample RA2. Reprobing the 
filter with the 02-microglobulin cDNA probe showed undegraded mRNA in 
all six lanes.
Northern blots E-H (figures 17 and 18) contain RNA isolated from 
the synovial membrane of 6 rheumatoid arthritis patients (RA6 - RAH), 2 
osteoarthritis patients (0A5 and 0A6) and 1 patient suffering from 
ankylosing spondylitis (AS1).
Figure 17 (a) shows the results of Northern blot E which was 
initially analysed with the factor B cDNA probe. Factor B mRNA (2.6 kb) 
was detected in all samples although only very weak signals were 
detected in RA10 and 0A6. Reprobing this filter with the 02-micro­
globulin cDNA probe showed there was a much smaller amount of mRNA in 
the 0A6 track and the RA10 mRNA was more degraded than the other 
samples.
Figure 17 (b) shows the results of Northern blot F on which 
sample RA6 was omitted. This filter was initially analysed with the Cl- 
INH cDNA probe. Cl-INH mRNA (2,1 kb) was detected in all samples 
although only a very weak signal was obtained for 0A6. When the filter 
was reprobed for C2 mRNA, a band at 2.9 kb was detected in all samples 
with a more intense signal for 0A6 than that obtained with the Cl-INH 
probe. Reprobing the filter for 02-microglobulin mRNA showed intact mRNA 
in all lanes except 0A6.
Figure 18 (a) shows the results of Northern blot G on which 
sample AS1 was omitted. This filter was initially analysed with the C3 
cDNA probe and similar results to Northern blot C were obtained.
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Degraded C3 mRNA was present in all samples and when the filter was 
reprobed with the C5 cDNA probe, C5 mRNA was not detected in any sample. 
However, analysis with the 02-microglobulin cDNA probe showed undegraded 
mRNA in each track except 0A6,
Figure 18 (b) shows the results of Northern blot H on which 
sample AS1 was omitted. This filter was initially analysed with the C4 
cDNA probe and similar results to Northern blot D were obtained. A faint 
band corresponding to intact C4 mRNA (5.5 kb) was detected in samples 
RA6, RA7, RA8 and 0A6 and low molecular weight material (degraded C4 
mRNA) was detected in all other samples. Reprobing with the 02- 
microglobulin cDNA probe showed intact mRNA in each track except 0A6.
Northern blots I-L (figures 19 and 20) contain RNA isolated from 
the synovial membrane of 1 rheumatoid arthritis patient (RA12), 6 
osteoarthritis patients (0A7 - 0A12) and 1 chondrocalcinosis patient 
(CC1).
Figure 19 (a) shows the results of Northern blot I which was 
initially analysed with the factor B cDNA probe. Factor B mRNA (2.6 kb) 
was detected in all samples except 0A8 but when the filter was reprobed 
for 02-microglobulin mRNA, the mRNA in this track was shown to be more 
degraded than the other samples.
Figure 19 (b) shows the results of Northern blot J which was 
initially analysed with the Cl-INH cDNA probe. Cl-INH mRNA (2. 1 kb) was 
detected in all samples although 0A8 RNA was degraded and only low 
molecular weight material was detected. Reprobing this filter with the 
C2 cDNA probe showed intact C2 mRNA (2.9 kb) in samples RA12, 0A7, 0A9 
and OA10. RNA samples 0A8, 0A11, 0A12 and CC1 only showed low molecular 
weight material corresponding to degraded C2 mRNA. When the filter was
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C2 
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Northern blot J
figure 19 - Northern blot analysis of RNA isolated from the synovial 
membrane of 8 patients (group 3). Both Northern blots I and J contain 
RNA from the same patients loaded in the following order: left to right 
lanes 1-8; RA12, 0A7, 0A8, 0A9, OAIO, 0A11, 0A12, CC1. Northern blot I 
was probed for factor B mRNA and then stripped and reprobed for J32- 
microglobulin mRNA. Northern blot J was probed, stripped and reprobed 
with different cDNA inserts in the following order; Cl-INH, C2 and J32- 
microglobulin.
C3 C4
Bz-microglobulin
L4- f f  f  f  •
i
1 2 3 4 5 6 7 8
, _ .. Northern blot L
B ^ microglobulm
i. . •
1 2 3 4 5v6 7 8
Northern blot K
C5
Figure 20 - Northern blot analysis of RNA isolated from the synovial 
membrane of 8 patients (group 3). Both Northern blots K and L contain 
RNA from the same patients as Northern blots I and J, loaded in the 
following order: left to right, lanes 1-8; RA12, 0A7, 0A8, 0A9, OAIO, 
0A11, 0A12, CC1. Northern blot K was probed, stripped and reprobed with 
different cDNA inserts in the following order; C3, C5 and j32-micro- 
globulin. Northern blot L was probed for C4 mRNA and then stripped and 
reprobed for Px-microglobulin mRNA.
reprobed with j3a— raicroglobulin cDNA, intact mRNA was detected in all 
samples except 0A8 and 0A11 in which the m R M  was more degraded than 
other samples.
Figure 20 (a) shows the results of Northern blot K which was 
initially analysed with the C3 cDNA probe. Extremely weak signals were 
obtained from this analysis but on reprobing the filter for £ 2 - 
microglobulin mRNA, weak signals were also obtained. It would appear 
likely that a substantial amount of the RNA had either not been properly 
fixed on the filter or had been removed during the stripping procedure. 
Once again, C5 mRNA was not detected in any sample.
Figure 20 (b) shows the results of Northern blot L which was 
initially analysed with the C4 cDNA probe. A band corresponding to C4 
mRNA (5.5 kb) was detected in sample OA10. Low molecular weight material 
was detected in samples 0A7, 0A9, 0A11 and CC1 while only an extremely 
weak signal was demonstrated for samples RA12, 0A8 and 0A12. Reprobing 
for ^z-microglobulin mRNA showed undegraded mRNA in all tracks, although 
0A8 mRNA was slightly more degraded than the other samples.
In summary, mRNAs corresponding to factor B (2.6 kb), Cl-INH 
(2.1 kb), C2 (2.9 kb), C3 (5.2 kb) and C4 (5.5 kb) were detected in all 
intact RNA samples using the appropriate cDNA probe, but C5 mRNA was not 
detected in any sample, Clq B-chain mRNA (1.4 kb) was also detected in 
all intact RNA samples (except RA2) analysed with the Clq B-chain cDNA 
probe. Low molecular weight material was present in most samples 
suggesting that degradation of the mRNA had occurred. The proportion of 
degraded RNA varied: Cl-INH, factor B and C2 mRNAs showed less degrad­
ation while mRNAs coding for C3 and C4 were usually largely degraded,
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although a faint band of undegraded mRNA could be detected in some 
samples. However, it is notable that when these same filters were 
stripped and reprobed with JU^-microglobulin cDNA, the fls-microglobulin 
mRNA showed no signs of degradation.
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4. DOT-BLOT ANALYSIS OF SYNOVIAL TISSUE SNA
Dot-blots were used to compare the relative abundances of Cl- 
INH, factor B, C2, C3 and C4 mRNAs between RNA isolated from different 
synovial tissue specimens. Although the presence of C5 mRNA was also 
sought, it was not detected in any sample.
RNA (lOpg/dot) isolated from the synovial membrane of 26 
patients (12 with rheumatoid arthritis, 12 with osteoarthritis, 1 with 
ankylosing spondylitis and 1 with chondrocalcinosis) were investigated. 
The specimens studied in these dot-blots were the same as for the 
Northern blot analysis except for samples 0A6 and 0A8 which were 
replaced by samples 0A13 and 0A14. Three identical dot blots are shown 
in figure 21, each containing RNA from the same 26 patients. Row A 
contains RNA from 8 rheumatoid arthritis patients (left to right: RA10, 
RA6, RA11, RA1, RA12, RA7, RA9 and RA2). Row B contains RNA from 9 
osteoarthritis patients and 1 patient suffering from ankylosing 
spondylitis (left to right: 0A13, OAIO, 0A14, 0A4, 0A3, 0A11, 0A1, 0A12, 
0A2 and AS1). Row C contains RNA from 4 patients suffering from 
rheumatoid arthritis, 3 osteoarthritis patients and 1 chondrocalcinosis
patient (left to right: 0A7, 0A5, CC1, RA3, RA8, 0A9, RA5, blank and
RA4), Each RNA sample was analysed in duplicate. The three dot blots 
were stripped and reprobed with different cDNA inserts in the following 
order: factor B, C3 and actin (dot blot I); Cl-INH, C2 and actin (dot
blot II) and C4, C5 and actin (dot blot III).
Each dot blot was analysed with a complement component cDNA 
probe in the order described above. The radioactive signal detected from 
each sample was measured by densitometric examination of the auto­
radiographs. Using one row of patients as a reference, the arbitrary
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Figure 21 - Dot-blot analysis of synovial membrane REA (lOpg/dot). Three 
identical dot-blots (I, II and III) are shown, each containing RITA from 
the same 26 patients. Row A contains REA from 8 rheumatoid arthritis 
(RA) patients loaded in the following order (left to right): RA10, RA6, 
RA11, RA1, RA12, RA7, RA9 and RA2. Row B contains REA from 9 
osteoarthritis (OA) patients and 1 patient suffering from ankylosing 
spondylitis (AS) loaded in the following order (left to right): 0A13, 
OA10, 0A14, 0A4, 0A3, OA11, 0A1, 0A12, OA2 and AS1. Row C contains REA 
from 4 RA patients, 3 OA patients and 1 chondrocalcinosis (CC) patient 
loaded in the following order (left to right): 0A7, 0A5, CC1, RA3, RA8, 
0A9, RA5, blank, and RA4. The three dot blots were stripped and reprobed 
with different cDEA inserts in the fallowing order: factor B, C3 and 
actin (dot-blot I); Cl-IEH, C2 and actin (dot blot II); C4, C5 and actin 
(dot-blot III). C5 mRNA was not detected in any sample and hence the C5 
autoradiograph is not shown. (All samples were analysed in duplicate).
units obtained from this analysis were used to measure the relative 
intensity of the signal detected from each sample.
In order to standardise the dot-blots, the filters were stripped 
after analysis with a complement component cDNA probe and reprobed with 
a rat actin cDNA. Actin is a constitutively expressed protein and hence 
was used to control for the amount of RNA loaded onto each dot. Measure­
ments from densitometric examination of a dot-blot analysed with a 
complement component cDNA probe were divided by the measurements 
obtained from the same filter that had been stripped and reprobed with 
the actin cDNA.
Table 10 summarises the results obtained from densitometric 
examination of the dot-blots. As with the Northern blot analysis, all 
patients were positive for each mRNA but to varying degrees. The mean 
densitometric measurement of each complement component mRNA from the 
rheumatoid arthritis patients was compared with the mean value for the 
osteoarthritis patients. Although there appears to be a trend towards 
higher levels of factor B, C3 and Cl-INH mRNA in rheumatoid arthritis 
synovium than osteoarthritis synovium the differences were not 
statistically significant, when analysed by the student's t-test.
However, the level of C2 mRNA in rheumatoid synovium was shown to be 
significantly higher (0.05 > P > 0.02) than the level found in 
osteoarthritis synovium while C4 mRNA was found in significantly greater 
abundance (0.05 > P > 0,02) in osteoathritis synovium. Comparison of the 
levels of different mRNAs cannot be made due to the varying specific 
activities of each cDNA probe.
However, it was possible to determine whether the ratio of a 
patient's steady state level of one particular complement mRNA to the
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mRNA DIAGNOSIS MEAN±SD t-test Probability, P
RA 1.60±1.36
Factor B 1.630 0,2 > P > 0. 1
OA 0.85±0.72
RA 1.46±1.19
C3 0.667 0.6 > P > 0.5
OA 1. 18±0.72
RA 2.18±1.13
Cl-INH 0.775 0.5 > P > 0.4
OA 1.87±0.70
RA 0. 80±0,57
C2 2.105 0.05 > P > 0.02
OA 0.40±0.28
RA 0.42±0.39
C4 2. Ill 0.05 > P > 0,02
OA 0.99±0.81
TABLE 10 - Comparison of the levels of each complement mRNA between 12 
rheumatoid arthritis (RA) and 12 osteoarthritis (OA) patients. 
Levels are expressed as arbitrary units obtained from 
densitometry measurements.
PATIEIT C2 Factor B C4 C3 Cl-INH
RA1 51% - 14% 63% 158%
RA2 13% 17% 104% 20% '58%
RA3 78% 48% - 9% 35%
RA4 76% 24% 36% 81% 40%
RA5 205% 117% 190% 101% 99%
RA6 91% 295% 283% 238% 208%
RA7 120% 188% 171% 158% 139%
RA8 120% 90% 118% 105% 80%
RA9 260% 19% 131% 75% 97%
RA10 60% 55% 44% 263% 106%
RA11 19% 295% 283% 38% 51%
RA12 104% 129% 95% 50% 108%
TABT/K 11 - Differential regulation of the expression of C2, factor B, 
C4, C3 and Cl-1 EH in rheumatoid synovium. The percentages 
refer to the C2, factor B, C4, C3 or Cl-1 IB mRNA densito- 
metric measurement for each patient compared to the mean 
value for the same component in all 12 rheumatoid arthritis 
patients, as obtained by dot-blot analysis (figure 21).
PATIENT C2 Factor B C4 C3 Cl-INH
0A1 70% - 24% 76% 111%
0A2 35% 24% 45% 25% 39%
0A3 140% 153% 84% 64% 134%
0A4 198% 41% 261% 85% 104%
0A5 73% 71% 82% 162% 156%
0A7 68% 261% 128% 197% 96%
0A9 253% 198% 242% 180% 116%
OAIO 145% 121% 179% 160% 98%
0A11 88% 102% 51% 64% 113%
0A12 103% - 56% 104% 127%
0A13 20% 162% 29% 72% 81%
0A14 15% 63% 20% 10% 25%
TABT/R 12 -  Differential regulation of the expression of C2, factor B,
C4, C3 and Cl-IHH in osteoarthritis synovium. The percentages 
refer to the C2, factor B, C4, C3 or Cl-INH mRNA densito­
metric measurement for each patient compared to the mean 
value for the same component in all 12 osteoarthritis 
patients, as obtained by dot-blot analysis (figure 21).
mean level for that component is the same for all the complement 
components studied. In other wards, if the s te a d y  state level of C2 mRNA 
in one patient is twice the mean C2 value for patients in the same 
disease group are the steady state levels of C4 mRNA, C3 mRNA, factor B 
mRNA and Cl-INH mRNA also twice their own mean values, ie, if steady 
state level of y mRNA is 2 times mean for y, are all complement mRNAs 
steady state levels 2 x their mean value?
The patients were divided into two groups - those with 
rheumatoid arthritis and those with osteoarthritis. To answer the above 
question, the ratio of the densitometric measurement of one complement 
component mRNA for each patient to the mean value for that component 
within the same disease group was calculated e.g. the ratio of the 
densitometric measurement of Cl-INH mRNA in RA1 to the mean RA value for 
Cl-INH mRNA calculated from all 12 rheumatoid arthritis patients. Tables 
11 and 12 show the results of these calculations. In almost every 
patient, the ratios calculated for each complement component mRNA show a 
marked difference from one another. These calculations show that in each 
patient the steady state levels of all the complement component mRNAs do 
not increase or decrease to the same extent when compared to the mean 
values for all patients suffering from the same disease. The data also 
suggests that there may be different regulatory mechanisms for the 
expression of each of the five complement components studied, C4, C2,
C3, factor B and Cl-INH.
In addition, normal synovium was obtained from a 19 year old 
patient who underwent patellectomy for recurrent patellar dislocation. 
RNA isolated from this normal synovium was also examined by dot-blot 
analysis (figure 22) using the Cl-INH cDNA probe. RNA from 10 patients
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Figure 22 - Dot-blot analysis of synovial membrane RNA (lOpg/dot). Dot- 
blot IV contains RNA from 10 patients loaded in duplicate in the 
following order: column ( - RA12, RA2, Nl, RA11 and RA7; column 2. - 
OA10, RA8, CC1, OA4 and RA4. The filter was analysed with the Cl-INH 
cDNA probe. Nl produces an extremely weak signal but less than 2pg of 
RNA from this sample was available for use in this dot-blot analysis.
"\o N  \ &s)l\ v5 »r\ 3>C ? uJcxS Ll(J~ UadZ'
was loaded in duplicate onto this dot blot in the following order: 
column 1; RA12, RA2, Nl, RA11 and RA7 and column 2; OAIO, RA8, CC1, 0A4 
and RA4, column 3; RA12, RA2, blank, RA11 and RA7 and column 4: OAIO,
RA8, CC1, 0A4 and RA4. mRNA coding for Cl-INH was detected in all 
samples including Nl. However, the low amount of RNA (less than 2pg) 
isolated from the small piece of tissue received from this patient, 
resulted in a weak signal being detected on dot-blot analysis, thus not 
enabling this patient’s results to be analysed alongside those described 
in Table 10.
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5. DETECTION OF COMPLEMENT PROTEINS IN 
SYNOVIAL MEMBRANE CULTURE SUPERNATANTS
Figures 23 - 28 show the results of ELISA analysis of synovial 
membrane culture supernatants from 6 patient samples (2 with rheumatoid 
arthritis (RA8 and RA9), 3 with osteoarthritis (0A5, 0A8 and 0A15) and 1 
normal synovium specimen (Nl) from a patient who underwent patellectomy 
for recurrent patellar dislocation). Synthesis of each complement 
protein was measured as /ig complement component/ml culture supernatant 
per lOOmg tissue.
(a) C4 synthesis
The concentration of C4 in the culture supernatants from each 
patient sample increased with time although the rate of increase 
diminished towards the end of the culture period. After six days in 
culture, the total concentration of C4 in the culture supernatants of 
the six synovial tissue specimens studied was: RA8 (3.07pg C4), RA9 
(7.91pg C4), 0A5 (11.21pg C4), 0A8 (2,52pg C4>, 0A15 (8.08pg C4> and Nl 
(5.93pg C4). When cycloheximide (2.5 pg/ml) was present in cultures RA8, 
RA9, 0A5 and 0A8, the concentration of C4 was only reduced after the 
third day in culture. However, the concentration of C4 in culture 
supernatants 0A15 and Nl was reduced after the second day in culture. In 
all cases, the accumulation of C4 in the culture supernatants not 
treated with cycloheximide, continued to increase throughout the period 
of culture (although accumulation of C4 was less in the OA8 culture). 
However, after 2-3 days C4 accumulation did not increase in the cyclo- —  
heximide-treated cultures.
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Figure 23 - ELISA analysis of supernatants from cultured fragments of 
synovial membrane from rheumatoid arthritis patient, RA8. The culture 
medium was changed completely every 24 hours and the amount of each 
complement component secreted into the culture medium each day was 
measured. After six days in culture, the results were plotted as 
cumulative curves and complement component levels are expressed as fig 
complement component produced by lOOmg tissue (mean±SD). Synovium 
fragment cultures were treated with 2.5/j.g/ml cycloheximide <A— A) or 
were left untreated and cultured in medium alone (■--■).
C3C2
•43 60“•3 12-
o  45-o  9- 
o
1  30-
15-
DayDay Day
Cl-INHFactor B
3 20- •43 20-
bo
!  15“ol5-
25-10-
bo
DayDayDay
Figure 24 - ELISA analysis of supernatants from cultured fragments of 
synovial membrane from rheumatoid arthritis patient, RA9, The culture 
medium was changed completely every 24 hours and the amount of each 
complement component secreted into the culture medium each day was 
measured. After six days in culture, the results were plotted as 
cumulative curves and complement component levels are expressed as 
jig complement component produced by lOOmg tissue (mean±SD). Synovium 
fragment cultures were treated with 2.5pg/ml cycloheximide (A— ▲) or 
were left untreated and cultured in medium alone <■---■).
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Figure 25 - ELISA analysis of supernatants from cultured fragments of 
synovial membrane from osteoarthritis patient, 0A5. The culture medium 
was changed completely every 24 hours and the amount of each complement 
component secreted into the culture medium each day was measured. After 
six days in culture, the results were platted as cumulative curves and 
complement component levels are expressed as pg complement component 
produced by lOOmg tissue (mean±SD). Synovium fragment cultures were 
treated with 2.5pg/ml cycloheximide (▲— A) or were left untreated and 
cultured in medium alone (■--■).
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Figure 26 - ELISA analysis of supernatants from cultured fragments of 
synovial membrane from osteoarthritis patient, 0A8. The culture medium 
was changed completely every 24 hours and the amount of each complement 
component secreted into the culture medium each day was measured. After 
six days in culture, the results were plotted as cumulative curves and 
complement component levels are expressed as pg complement component 
produced by lOOmg tissue (mean±SD). Synovium fragment cultures were 
treated with 2.5pg/ml cycloheximide (A— A) or were left untreated and 
cultured in medium alone (■-- ■).
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Figure 27 - ELISA analysis of supernatants from cultured fragments of 
synovial membrane from osteoarthritis patient, 0A15. The culture medium 
was changed completely every 24 hours and the amount of each complement 
component secreted into the culture medium each day was measured. After 
six days in culture, the results were plotted as cumulative curves and 
complement component levels are expressed as pg complement component 
produced by lOOmg tissue (mean±SD). Synovium fragment cultures were 
treated with 2.5pg/ml cycloheximide ( A — A) or were left untreated and 
cultured in medium alone (■--■).
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Figure 28 - ELISA analysis of supernatants from cultured fragments of 
normal synovial membrane from a patient who underwent patellectomy, 51, 
The culture medium was changed completely every 24 hours and the amount 
of each complement component secreted into the culture medium each day 
was measured. After six days in culture, the results were plotted as 
cumulative curves and complement component levels are expressed as 
pg complement component produced by lOOmg tissue (mean±SD). Synovium 
fragment cultures were treated with 2.5pg/ml cycloheximide (A— A )  or 
were left untreated and cultured in medium alone (■-- ■).
(b) C2 synthesis
Over the six day period of culture, the total amount of C2 
released into the culture medium in the six patient samples was: RA8 
(25.78pg C2), RA9 <11.33pg C2), 0A5 (1.44pg C2), 0A15 <5.38pg C2) and Nl 
(8.39pg C2). Only trace amounts of C2 were detected in the 0A8 culture 
supernatants, even although C2 mRNA had been detected for this sample in 
Northern and dot-blot analyses. The concentration of C2 was not signif­
icantly reduced by the presence of cycloheximide in cultures 0A5 and 
0A8, whereas the introduction of cycloheximide into the culture medium 
caused a significant reduction in C2 accumulation in RA8, RA9, 0A15 and 
Nl. Patient samples RA8, RA9, 0A15 and Nl all showed a delay in the 
initiation of C2 synthesis. In patients RA8 and RA9 this delay lasted 3 
days while a delay of 4 days was observed for 0A15 and Nl. Thereafter, 
the rate of C2 synthesis increased markedly for the remaining period of 
culture.
(c> C3. synthesis.
The pattern of C3 accumulation in the culture supernatants was 
similar to that seen for C4, ie. the concentration of C3 increases 
throughout the period of culture but the rate of increase diminishes 
with time. No delay in C3 synthesis was observed. In the presence of 
cycloheximide, the concentration of C3 was sigificantly reduced in all 
cases. After six days in culture, the concentration of C3 in the culture 
supernatants of the six patient samples was: RA8 (39.36pg C3), RA9 
<64.35pg C3), 0A5 (20. 42pg C3), 0A8 (53.53pg C3), 0A15 (9. 03pg C3> and 
Nl (12.42pg C3). All six samples showed similar patterns of C3 release 
into the culture medium, although the reduction in C3 concentration by 
cycloheximide was less marked in 0A5 and 0A8.
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(d2. C5 synthesis
Although C5 was detected in all culture supernatants, its 
concentration did not increase after the second or third day in culture, 
although in the presence of cycloheximide a reduction in C5 concen­
tration was observed. At the end of the culture period, the total amount 
of C5 released into the culture medium for the six samples was: RA8 
(7,33pg C5>, RA9 (19.29pg C5), 0A5 <16.3pg C5), 0A8 (4,67pg C5), 0A15 
(11.62/ig C5) and Nl (8,12pg C5). It is possible that the C5 detected was 
due to contamination of the synovial tissue with plasma or inflammatory 
exudate or from in vitro release of C5 from synovial cells following 
pinocytic uptake in vivo,
(e) Factoi:...ELsynthesis
After six days in culture, the total concentration of factor B 
in the culture supernatants of the six synovium specimens was: RA8 
(5.02pg factor B), RA9 (19,69pg factor B), 0A5 (3.98pg factor B), 0A8 
(25.07pg factor B), 0A15 (11.55pg factor B) and Nl (14.18pg factor B). 
The pattern of factor B synthesis by the synovial membrane cultures 
shows more similarity to C2 accumulation than C3 or C4 synthesis. In 
samples RA8 and RA9 there was a 2 day delay in factor B accumulation 
followed by a steady daily increase in factor B synthesis. This delay 
was not so marked in cultures 0A8, 0A15 and Nl, although like RA8 and 
RA9 the rate of accumulation of factor B in the culture supernatants did 
not appear to significantly increase or diminish during the period of 
culture. Unlike the cultures RA8, RA9, 0A8, 0A15 and Nl, factor B 
synthesis by sample 0A5 was not significantly reduced by the presence 
of cycloheximide although factor B mRNA had been detected in this sample 
by Northern and dot-blot analyses.
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(f) Cl-INH synthesis
The pattern of Cl-INH accumulation in the culture supernatants 
was similar to that seen for factor B and C2. A slight delay in Cl-INH 
synthesis was observed for samples RA8 and 0A15. All six samples showed 
a steady increase of Cl-INH concentration in the culture supernatants 
although the rate of accumulation did show a slight decline towards the 
end of the period of culture. In all cultures the concentration of Cl- 
INH was significantly reduced by the presence of cycloheximide. The 
concentration of Cl-INH in the culture supernatants at the end of the 
period of culture was: RA8 (19.97pg Cl-INH), RA9 (50.31pg Cl-INH), 0A5 
(31.73pg Cl-INH), 0A8 (78.16pg Cl-INH), 0A15 (56.61pg Cl-INH) and Nl 
(38.05pg Cl-INH). Of the six complement components investigated, Cl-INH 
and C3 were detected in the greatest abundance in the culture super­
natants.
(g) Albumin release from cultured fragments.of synovial membrane
As stated above, the accumulation of C5 in the culture super­
natants did not increase after the second or third day in culture. As a 
result it was thought that the C5 being detected by ELISA was due to 
contamination of the synovial tissue with plasma or inflammatory exudate 
or from in vitro release of C5 from synovial cells fallowing pinacytic 
uptake in vivo. Levels of albumin in the culture supernatants were 
measured as a control for either of these events. Figure 29 shows the 
results of this analysis on the RA8 culture supernatants but the other 
samples all showed similar results. Release of albumin into the culture^ 
supernatants followed a similar pattern to C5 release with the concen­
tration of albumin not increasing significantly more than the cyclo- 
heximide-treated cultures after the second day in culture. However, like
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Figure 29 - ELISA analysis for albumin release by synovial membrane 
cultures of rheumatoid arthritis patient, RA8. The culture medium was 
changed completely every 24 hours and the amount of albumin secreted 
into the culture medium each day was measured. After six days in 
culture, the results were plotted as cumulative curves and albumin 
levels are expressed as pg albumin produced by lOOmg tissue (mean±SD). 
Synovium fragment cultures were treated with 2.5pg/ml cycloheximide 
<A-A> or were left untreated and cultured in medium alone (■— ■),

C5 accumulation, in the presence of cycloheximide a reduction in albumin 
concentration was observed in the early period of culture.
In summary, C4, C2, C3, factor B and Cl-INH were detected in the 
culture supernatants and their levels increased throughout the period of 
culture. When cycloheximide was present the concentrations of these 
components were reduced markedly. In contrast, although C5 was detected 
by ELISA, its concentration did not increase after the second or third 
day of culture.
Levels of albumin were measured as a control for contamination 
of the synovial tissue with plasma or inflammatory exudate, or for 
release of protein from synovial cells fallowing pinocytic uptake in 
vivo. The pattern of albumin accumulation in the culture supernatants 
was similar to that seen for C5.
All samples (except 0A5 and 0A8) showed a delay in C2 synthesis. 
This delay in accumulation (although less marked) was also observed for 
factor B and Cl-INH synthesis in samples RA8, RA9 and 0A15. After the 
initial delay, the rate of accumulation of C2, factor B and Cl-INH 
continued steadily throughout the remaining period of culture.
There was no delay in the onset of C3 and C4 synthesis which 
began to accumulate on the first day of culture. The rate of 
accumulation of these two proteins decreased towards the end of the 
culture period.
The concentrations of Cl-INH and C3 in the culture supernatants 
were generally higher than the other complement components studied.
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6. DETECTION OF FUNCTIONALLY ACTIVE COMPLEMENT COMPONENTS 
II SYNOVIAL MEMBRANE CULTURE SUPERNATANTS
(a) Purification of D from human serum for use in the factor B 
haemolytic assay
In order to perform the factor B haemolytic assay, it was 
necessary to purify D from human serum. Biorex 70 cation-exchange 
chromatography was performed using 180ml of human serum and the 
resulting chromatograph is shown in figure 30, The exclusion peak 
(fractions 25-40) contained no D activity as shown by its failure to 
lyse rabbit erythrocytes. It was therefore used as an RD reagent (D 
depleted serum reagent) to screen the remainder of the column for D 
activity.
Fractions 184-195 were found to contain D activity and so they 
were pooled. A 1/10 dilution of this pool gave an OD^q o reading of 0.424 
which gave an approximate protein concentration of 4.24mg/ml in a total 
volume of 135ml. This pool was concentrated to 20.7mg/ml in a final 
volume of 20ml.
Before use in the factor B assay, it was necessary to titrate 
the purified D using a D assay and reconstitution of the RD reagent 
(figure 31). The concentration of D was calculated to be 19.3 units/ml. 
Vhen D was titrated in the factor B assay, some lysis occurred in the 
samples containing D in the absence of factor B. This finding indicated 
trace contamination of D with factor B.
However, at a 1/40 dilution, the D alone sample produced no 
lysis. Thus a 1/40 dilution of D was used in all the factor B haemolytic 
assays.
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-Figure 30 - Biorex-70 cation exchange chromatograph of D purification 
from human serum. The OD^eo (•——•) and conductivity at 4°C (£s— A) were 
measured. Fractions 25-40 were pooled as the RD reagent while fractions 
184-195 were found to contain the D activity,
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Figure 31 - Titration of D purified from human serum, using 
reconstitution of the RD reagent.
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(b) Tr.^x test
Before using a batch of EAC4 cells, a tmax test was performed. 
The reason for this test is explained below;
The natural decay of C2a from the C4b2a enzyme makes the 
titration of C2 somewhat more complicated than the titration of other 
components. When one studies the kinetics of formation of C142, it is 
noted that formation starts immediately, reaches its peak and then the 
enzyme decays. The time taken for the peak to be reached is called tm«*x 
and is dependent upon the concentration of C4b on EAC14, but is 
independent of the C2 concentration. The shorter the tmax the more 
functionally active C4b on EAC14 (Borsos et al, , 1961).
The per cent lysis in each tube and the number of haemolytic 
sites (Z) were calculated, Z was then plotted against time and tmax 
determined by inspection (figure 32). The tmax of this batch of EAC4 
cells was 3.5 min and in practice cells are accepted if they have a tmax 
of less than 6 min.
(b) Results of the haemolytic assays for C4. C2. C3, C5 and factor &
Figures 33 and 34 show the results of haemolytic assays 
performed on the synovial membrane culture supernatants from two patient 
samples (1 with osteoarthritis (0A15) and 1 patient (HI) who underwent 
patellectomy for recurrent patellar dislocation).
C4 assay
C4 haemolytic activity was detected in both samples on day 1: 
0A15 (12 x 107 e.m./lOOmg tissue) and HI (9 x 107 e.m./lOOmg tissue). 
Thereafter no significant level of C4 haemolytic activity was detected 
in culture supernatants from either sample. In both samples, the C4
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. Figure 32 - Plot of tmax assay.
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haemolytic activity was not significantly higher than the C4 haemolytic 
activity detected in the supernatants of the cultures treated with 
cycloheximide.
C2 assay
Substantial C2 haemolytic activity was detected in both samples. 
At the end of the six day culture period, the accumulated C2 functional 
activity in the two patient samples was: 0A15 (450 x 107 e.m./lOOmg 
tissue) and 51 (250 x 107 e.m./lOOmg tissue). 51 exhibited a steady 
increase in the rate of C2 activity increase throughout the period of 
culture while the rate increased from day 2 to 4 in 0A15. In both 
samples, the rate of increase of C2 haemolytic activity had started to 
diminish slightly towards the end of the period of culture,
C3 assay
C3 haemolytic activity was detected in the culture supernatants 
of the two patient samples. After six days in culture, the cumulative 
total of C3 haemolytic activity had reached 12 x 107 e.m./lOOmg tissue 
and 15 x 107 e.m./lOOmg tissue for 0A15 and 51 respectively. In both 
samples there was a slight increase in the rate of increase of C3 
haemolytic activity towards the end of the period of culture, although 
on day 6, the rate in OA15 had started to decrease again.
C5 assay
C5 haemolytic activity (approximately 10 x 107 e.m./lOOmg 
tissue for both samples) was detected on day 1. However, there was no _ —  
detectable C5 haemolytic activity during the remaining period of culture 
compared to the cycloheximide-treated cultures.
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Figure 33 - Haemolytic assays of supernatants from cultured fragments of 
synovial membrane from osteoarthritis patient, 0A15. Supernatants from 
the same cultures were analysed by both ELISA and haemolytic assay. 
Cumulative curves are plotted and haemolytic activity is expressed as 
effective molecules (e.m.) x 10-7' produced by lOOmg tissue (mean±SD). 
Synovium fragment cultures were treated with 2,5pg/ml cycloheximide 
( A — ▲) or were left untreated and cultured in medium alone (■-- ■).
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Figure 34 - Haemolytic assays of supernatants from cultured fragments of 
normal synovial membrane from a patient undergoing patellectomy, Nl. 
Supernatants from the same cultures were analysed by both ELISA and 
haemolytic assay. Cumulative curves are plotted and haemolytic activity 
is expressed as effective molecules (e.m.) x lO--7 produced by lOOmg 
tissue (mean±SD). Synovium fragment cultures were treated with 2.5pg/ml_^_ 
cycloheximide (A— A) or were left untreated and cultured in medium 
alone (■--■),
Factor B assay
Factor B haemolytic activity was detected at high levels in both 
samples. At the end of the six day culture period, the cumulative total 
of factor B haemolytic activity for the two patient samples was: 0A15 
(1000 x 107 e.m./lOOmg tissue) and FI (300 x 107 e.m./lOOmg tissue). 
Culture supernatants from both OA15 and Nl s.V>0w«J ar, increasing rate of 
increase of factor B haemolytic activity during the first three days of 
culture after which time the rate gradually decreased.
In summary, haemolytic assays revealed that C2, C3 and factor B 
in synovial membrane culture supernatants were functionally active, 
while C4 and C5 haemolytic activity was not detected. Cl-INH was not 
tested for functional activity as foetal calf serum contains high levels 
of Cl-inhibitory activity (Muller et al., 1978).
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7, I MCQRPQRAT I OH OF 3SS-nethionine INTO COMPLEMENT PROTEINS
Incorporation of 3SS-methionine into the complement proteins 
synthesised by fragments of synovial membrane cultured in vitro was 
investigated. Synovial membrane from four patients (1 with rheumatoid 
arthritis (RA13) and 3 with osteoarthritis (0A16 - 0A18)) was studied.
Table 13 shows the level of incorporation of 3sS-methionine into 
protein in each culture by measurement of the acid precipitable counts. 
On average, approximately 3% incorporation of 3SS-methionine was 
observed in each culture. Clearly, incubation of the synovial membrane 
cultures for 4 days (RAIS*) had no detectable effect on the level of 
incorporation.
Immunoprecipitation of complement proteins in the synovial 
membrane culture supernatants was performed. These immunoprecipitates 
were washed thoroughly to remove any non-specific binding to the 
complexes. However, electrophoresis of the immunoprecipitates on SDS- 
PAGE and subsequent fluorography produced the same high background 
pattern which included an intense 60 kDa band in all samples. Attempts 
to remove this background using a variety of incubations with:
(i) Staph, aureus protein A
(ii) Sepharose protein A and protein G 
or (iii) IgG-Sepharose,
resulted in only reducing or completely removing the entire signal 
previously detected by fluorography, including any bands considered to 
be specific.
Figures 35 and 36 show the SDS-PAGE results from the sample RA13 
but the other 3 samples produced similar results:
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PATIENT PERCENTAGE INCORPORATION OF 3SS-methionine
RA131 2. 02%
RA132 5.97%
RA131* 2.22%
RA132* 3. 08%
0A161 2.82%
0A162 2.75%
0A171 0.94%
0A172 0.66%
0A181 7.07%
0A182 5.39%
Table 13 - Incorporation of 3SS-nethionine into acid precipitable
protein. All samples were cultured in duplicate for 24 hours 
except for samples RA131* and RA132* which were cultured for
r
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Figure 35 - SDS-polyacrylamide gel electrophoresis of 35S-methionine 
labelled immunoprecipitates from the synovial membrane culture super­
natants of rheumatoid arthritis patient, RA13. The synovium fragments 
were cultured for 24 hours. Immunoprecipitation was performed with the 
IgG fraction of the following goat anti-human antibodies: factor B, C2 
and C5. Anti-human serum albumin was used as a negative control. Fluoro­
graphy of the gel was performed at -70°C for 4 weeks.
Cl-INH C3 C4 H S A
Figure 36 - SDS-polyacrylamide gel electrophoresis of 3eS-methionine 
labelled immunoprecipitates from the synovial membrane culture super­
natants of rheumatoid arthritis patient, RA13. The synovium fragments 
were cultured for 24 hours. Immunoprecipitation was performed with the 
IgG fraction of the following goat anti-human antibodies: Cl-IRH, C3 and 
C4. Anti-human serum albumin was used as a negative control. Fluoro- 
graphy of the gel was performed at -70°C for 4 weeks.
(a) Cl-IflH - a smeared pattern at approximately 90 kDa was always
detected for Cl-IM. However this is significantly less 
than the correct size of Cl-IHH <110 kDa) and may represent 
degraded or unglycosylated Cl-IHH.
(b) C3 - a band at 75 kDa was detected for each sample. This
band could represent the intact J3-chain of the C3 molecule. 
However a band corresponding to the a-chain of C3 was not 
detected and most likely has been degraded.
(c) Factor B - this component produced the best results with a definite
band at 92 kDa. This band corresponds exactly to the 
known molecular weight of the factor B protein.
Bands corresponding to the known molecular weights of the 
polypeptide chains of C4, C2 and C5 (or their cleavage products) were 
not detected in any patient sample.
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iL—  lit-gitra CQMPLEKBHT BIOSYNTHESIS BY CELLS ISOLATED FROM BUKAS
SYlfQVIAL KEJCBRAffE
The ability of the cells isolated from human synovial membrane 
to synthesise complement components in vitro was measured by ELISA.
The synovial membrane from 4 patients was used in these studies 
(2 with rheumatoid arthritis, RA14 and RA15, and 2 with osteoarthritis, 
0A19 and OA20). The cells isolated from these tissue samples were plated 
at a cell density of 1 x 10ecells/culture dish and then cultured for six 
days with the culture medium being changed daily. After 24 hours, those 
cells that had not adhered to the culture dish (usually 30-40% of the 
total number of cells) were separated from the adherent cells. The non­
adherent cells were then cultured in a separate culture dish for the 
same length of time as the adherent cells. The stage at which the 
adherent and non-adherent cells were separated (ie. after the initial 24 
hour culture period) was regarded as day zero in the biosynthesis 
experiments.
The concentrations of complement components in the culture 
supernatants from both the adherent and non-adherent cells were measured 
by ELISA in order to compare the rates of complement synthesis by these 
two cell populations. Figures 37-40 show the results of these ELISA 
analyses. In each case, complement biosynthesis was significantly 
reduced when cycloheximide (2.5pg/ml) was introduced into the medium.
C4 synthesis
After six days in culture, the non-adherent cells from samples 
RA14 and 0A19 synthesised significantly more C4 (RA14, 0,2jig C4; 0A19, 
4.2/jg C4) than the adherent cells (RA14, 0,05pg C4; OA19, 0.3pg C4). 
Indeed, the small amount of C4 synthesised by RA14 adherent cells was
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not significantly more than that produced by the cycloheximide-treated 
cultures. However, samples RA15 and OA20 did not show such a marked 
difference between the different cell populations. After six days, the 
adherent and non-adherent cells of RA15 released 0.21pg C4 and 0,2pg C4 
respectively into the culture supernatants while the adherent cells of 
OA20 released l.lpg C4 as opposed to 0,6pg C4 by the non-adherent cells. 
Samples RA14 and RA15 showed similar patterns of C4 accumulation ie. the 
rate of increase in the concentration of C4 decreased towards the end of 
the period of culture. OA20 cells synthesised C4 at a steady rate 
throughout the six days while the rate of C4 accumulation by 0A19 non­
adherent cells increased daily.
C3 synthesis
The adherent cells of RA15 and OA20 synthesised significantly 
more C3 (2.9pg C3 and 1.2pg C3 respectively) than the non-adherent cells 
(0.9pg C3 and 0.62pg C3 respectively). Both cell populations of RA14 
synthesised similar amounts of C3 (adherent, 1.45pg C3; non-adherent, 
l.lpg C3), while 0A19 non-adherent cells synthesised a lot more C3 
(8,5pg C3) than the adherent cells (2pg C3). A steady rate of C3 
synthesis throughout the culture period was shown for RA14 and RA15 
while an increasing rate of C3 accumulation was observed for 0A19 and 
also OA20.
Factor B synthesis.
At the end of the culture period, the non-adherent cells of RA14 
and 0A19 had synthesised more factor B (1.4pg factor B and 3.2pg factor 
B respectively) than the adherent cells (RA14, l.lpg factor B; 0A19, Ipg 
factor B) . The two cell populations of sample QA20 synthesised similar
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Figure 37 - Concentrations of complement components (measured by ELISA) 
in the culture supernatants from the adherent (#— 0)  and non-adherent 
(■— ■) synovial cells of rheumatoid arthritis patient, RA14. The culture 
medium was changed completely every 24 hours and the amount of each 
complement component secreted into the culture medium each day was 
measured. After six days in culture, the results were plotted as 
cumulative curves and complement component levels are expressed as fig 
complement component per 1ml of culture medium (mean±SD). One adherent 
and one non-adherent cell culture were treated with 2,5/ig/ml cyclo- 
heximide (A— A ) .
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Figure 38 - Concentrations of complement components (measured by ELISA) 
in the culture supernatants from the adherent (.%— 0) and non-adherent 
(■— ■) synovial cells of rheumatoid arthritis patient, RA15, The culture 
medium was changed completely every 24 hours and the amount of each 
complement component secreted into the culture medium each day was 
measured. After six days in culture, the results were plotted as 
cumulative curves and complement component levels are expressed as fig 
complement component per 1ml of culture medium (mean±SD), One adherent 
and one non-adherent cell culture were treated with 2.5jig/ml cyclo- 
heximide (A— ▲).
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Figure 39 - Concentrations of complement components (measured by ELISA) 
in the culture supernatants from the adherent (0 0 )  and non-adherent
(■— ■) synovial cells of osteoarthritis patient, OA19. The culture 
medium was changed completely every 24 hours and the amount of each 
complement component secreted into the culture medium each day was 
measured. After six days in culture, the results were plotted as 
cumulative curves and complement component levels are expressed as pg 
complement component per 1ml of culture medium (mean±SD). One adherent 
and one non-adherent cell culture were treated with 2.5pg/ml cyclo- 
heximide (A— ▲).
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Figure 40 - Concentrations of complement components (measured by ELISA) 
in the culture supernatants from the adherent ( # — -#) and non-adherent
(■-- ■) synovial cells of osteoarthritis patient, OA20. The culture
medium was changed completely every 24 hours and the amount of each 
complement component secreted into the culture medium each day was 
measured. After six days in culture, the results were plotted as 
cumulative curves and complement component levels are expressed as pg 
complement component per 1ml of culture medium (mean±SD). One adherent 
and one non-adherent cell culture were treated with 2.5pg/ml cyclo- 
heximide (A— A),
amounts of factor B (adherent, 4.2pg factor B; non-adherent, 3.7pg 
factor B). However, the RA15 adherent cells synthesised substantially 
more factor B (3.5pg) than the non-adherent cells (1.3pg). RA14 and RA15 
showed a steady decline in the rate of factor B synthesis while OA20 
maintained a steady rate of factor B accumulation throughout the period 
of culture. 0A19 showed a steady increase in the rate of factor B 
synthesis.
Cl-INH synthesis
The amount of Cl-INH synthesis by the adherent and non-adherent
cells from each of RA14, RA15 and OA20 showed no significant difference
(RA14 - adherent, lOpg; non-adherent, lO.lpg; RA15 - adherent, 15.5pg; 
non-adherent, 12pg; OA20 - adherent, 8jug; non-adherent, 6.5pg). The rate 
of Cl-INH synthesis by cells isolated from these three synovium 
specimens, continued at a steady rate throughout the period of culture, 
although there was a slight decline in RA14 after one day. The non­
adherent cells of 0A19 synthesised substantially more Cl-INH (20pg) than 
the adherent cells (2,5pg). Like the other complement components 
studied, a steady increase in the rate of Cl-INH synthesis was observed
throughout the culture period for 0A19.
In summary, both adherent and non-adherent cells isolated from 
human synovial tissue synthesise C4, C3, factor B and Cl-INH (although 
the adherent cells of one sample (0A19) synthesised only trace amounts 
of these four components). In most cases (except 0A19), the adherent 
cells synthesised complement components at the same or higher levels 
than the non-adherent cells. As with studies on synovial tissue explant 
cultures, C5 synthesis was not detected.
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9. IJOKJffQHISTQCHEMICAL CHARACTERISATION OF CULTURED HUMAN SYNOVIAL CELLS
Immunohistochemistry was used to characterise the various cell 
types in both the adherent and non-adherent synovial cell cultures. This 
analysis was performed to characterise the cells responsible for the 
synthesis of complement components by the two cell populations.
After six days in culture, the cells were fixed in 10% neutral 
buffered formalin and characterised using the mouse monoclonal 
antibodies against vimentin (fibroblast marker) and LeuM5 (macrophage 
marker). Figure 41 shows that the vast majority 095%) of the cells were 
fibroblasts while figure 42 shows that a small proportion of the cells 
were macrophages. These figures represent the results of immunohisto- 
chemistry performed on the adherent cells isolated from synovial tissue 
specimen RA15 but the non-adherent cells from this sample and the cells 
from all other samples showed similar results.
In all these studies normal mouse serum was used as a negative 
control and no positive staining was observed for any sample (figure 
43).
Vhen the non-adherent cells from RA15 were replated onto a 
separate culture dish each day, it was found that *70% of the cells 
adhered to the culture dish every 24 hours so that by the fourth 
replating, virtually all the cells had adhered to the surface of the 
coverslip. After replating, all the cells were cultured until day 6 and 
then fixed in 10% neutral buffered formalin at the same time. Like the 
experiment described above, fibroblasts were shown to be the cell-type 
present in the greatest abundance in every culture of replated non­
adherent cells, although a small number of cells were identified as 
macrophages (figures 44-49).
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Figure 41 - Anti- v i m e n t i n  (1/40) st ain i n g  of RA15 adherent synovial
cells (x250).
Figure 42 - Anti-LeuM5 (1/40) staining of RA15 adherent synovial cells 
(x250).
Figure 43 - Normal mouse serum (1/40) staining of RA15 adherent synovial 
cells (x250).
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Figure 44 ~ Anti-vimentin (1/40) staining of RA15 non-adherent synovial
cells replated on d ay 1 (x250).
Figure 45 - Anti-LeuM5 (1/40) staining of RA15 non-adherent synovial
cells replated on day 1 (x250).

Eigure 40 - A n ti-vimentin (1/40) staining of RA15 non-adherent synovial
cells replated on da y  2 (x250).
Anti LeuM5 (1/40) staining of RA15 non-adherent synovial
cells replated on da y  2 <x250).
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Elgore 4& - A n ti-vimentin (1/40) staining of RA15 non-adherent synovial
cells replated on day 3 (x250).
Elgore 49 Anti LeuM5 (1/40) stain i n g  of RA15 non— adherent synovial
cells replated on day 3 (x250).
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The concentrations of complement components in the culture 
supernatants were measured by ELISA to investigate the rates of 
complement synthesis by cells adhering at different stages of the 
culture period. Figure 50 shows the results of the ELISA analysis of the 
culture supernatants from sample RA15 but all other specimens showed 
similar results. The measurements first recorded on day 2 are for cells 
replated on day 1 (referred to as the second replating) while measure­
ments first recorded on day 3 are for cells replated on day 2 (third 
replating), and so on.
Cells from the first replating showed a similar pattern of 
accumulation of C4, C3, factor B and Cl-IITH as the initial non-adherent 
cell cultures. Even after the second and third replating, the rate of C4 
and Cl-IITH synthesis fallowed that of the initial non-adherent cultures, 
although the same levels were not reached presumably because of the 
fewer number of cells. However by the second replating the accumulation 
of C3 and factor B was not significantly higher than the cycloheximide­
treated cultures.
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Figure 50 - Concentrations of complement components (measured by ELISA) 
in the culture supernatants from the adherent (•— •) and non-adherent 
(■— ■) synovial cells of rheumatoid arthritis patient, RA15. Conditions 
were as described for fig. 38. In addition, for the first three days of 
culture the non-adherent cells were replated onto a separate culture 
dish each day. The amount of C4, C3, factor B and Cl-IRH synthesised by 
these cell papulations was also measured, represented as follows: cells 
replated on day 1 (□— □, 1), cells replated on day 2 (A-A, 2) and cells 
replated on day 3 (O— O, 3).
10. IWtUITQHISTQCHEKlCAL LOCALISATION QF CQKPLEKEIT COKPOSEITS 
IJ CULTURED HUKAJS SYROV IAL CELLS
Immunohistochemical analysis was used to localise C4, C3, C5, 
factor B and Cl-INH within the adherent and non-adherent cells of 
cultured human synovial cells. Whole rabbit antisera were used for 
this analysis and normal rabbit serum was used as the negative control.
Figures 51-61 show the results of immunohistochemical local­
isation of C4, C3, C5, factor B and Cl-IIH in human synovial cells 
isolated from a patient suffering from osteoarthritis (0A21). The cells 
were fixed in 10% neutral buffered formalin after six days in culture. 
All other patient samples examined by immunohistochemical analysis 
(RA14, RA15, 0A19 and OA20) showed similar results.
Cl-IHH and factor B were found in most cells in both the 
adherent and non-adherent cell cultures (figures 51-54). The positive 
pink staining was especially strong for factor B which was present in 
all cell types, C1-IRH was also present in all cell types but the 
intensity of staining was not as strong as for factor B. However, the 
staining intensity may be due to different binding affinities of the 
antisera and not concentration of the complement component within cells.
C3 and C4 were also present in most cells of both adherent and 
non-adherent cell cultures (figures 55-58). However, the intensity of 
signal was not as strong (particularly C4) as factor B and Cl-INH.
As expected from the studies on synovial tissue described above, 
C5 was not detected in either the adherent or non-adherent cell cultures 
from any sample (figures 59 and 60).
Figure 61 shows the negative staining obtained with normal 
rabbit antiserum which acted as the negative control for these analyses.
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Elgure 5 1 ~ Ant i - f a c t o r  B  (1/100) s t a i n i n g  of 0A21 adherent synovial
cells (x250>.
EiglLCSL_52. - Anti-factor B  (1/100) stain i n g  of 0A21 non-adherent synovial
cells (x250).
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Flgurs 53 Anti Cl-INH (1/100) s t a ining of 0A21 adherent synovial cells
(x250),
Anti Cl-IIfH (1/100) staining of 0A21 nan-adherent synovial
cells (x250).

Elgure Anti-C3 (1/100) s t a i n i n g  of 0A21 adherent synovial cells
(x250).
Figure - Anti-C3 (1/100) staining of 0A21 nan-adherent synovial cells
(x250).
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Figure 57 - Anti-C4 (1/100) staining of 0A21 adherent synovial cells
(x250).
Figure 58 - Anti-C4 (1/100) staining of 0A21 non-adherent synovial cells
(x250).
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Elgure 59 - Anti C5 (1/100) s t a i n i n g  of 0A21 adherent synovial cells
(x250>,
Figure 6Q Anti C5 (1/100) stain i n g  of 0A21 non-adherent synovial cells
<x250>.

Figure 61 - Jformal rabbit serum (1/100) staining of 0A21 adherent 
synovial cells (x250).
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Li_-_GEKERAL APPROACH TO THE STUDY OF COMPLEMEHT 
BIQSYITHESIS IH HUKAff SYJTOVIAL TISSUE
The principle aim of this study was to detect extrahepatic 
synthesis of complement components in vivo using inflamed synovium from 
patients with rheumatoid arthritis or osteoarthritis as a model system. 
In addition to being one of the first comprehensive studies of in vivo 
extrahepatic complement biosynthesis, it was hoped that, given the 
inflammatory effects of complement and the previous evidence for 
complement activation within the rheumatoid joint, the findings from 
this study would contribute to the understanding of the pathogenesis of 
rheumatoid arthritis.
Although plasma levels of most complement components are 
maintained by hepatic synthesis, the cell responsible being the 
hepatocyte (Colten, 1976), it is now well established that other cells 
including monocytes, macrophages, fibroblasts and the epithelial cells 
of the gastrointestinal and genitourinary tracts synthesise complement 
components when cultured in vitro (Colten, 1976). Such cells are 
potential sources of extrahepatic synthesis of complement components in 
vivo. Synovial fluid macrophages and adherent synovial membrane cells 
have been shown to synthesise complement components when cultured in 
vitro (De Ceulaer et al., 1980), as have cultured fragments of synovial 
membrane from patients with either rheumatoid arthritis or osteo­
arthritis (Ruddy & Colten, 1974). However, the only evidence for extra-- 
hepatic synthesis of complement occurring in vivo comes from metabolic 
studies with radiolabelled (12S[ I)) C3, which indicated that up to 50% 
of C3 present in the rheumatoid joint was synthesised locally (Ruddy &
Colten, 1974).
The present studies, which have revealed the detection of the 
mRNAs coding for several complement components in human synovial tissue, 
as well as demonstrating complement component biosynthesis by cultured 
fragments of synovial tissue, have provided conclusive evidence that 
synthesis of a number of complement components including C4, C2, C3, 
factor B and Cl-inhibitor, occurs locally within normal and inflamed 
synovium in vivo. The local synthesis of complement within normal 
synovial joints may be of importance in their defence against infection, 
whereas in inflamed joints it may contribute to the inflammatory 
response.
These conclusions are based upon the fallowing observations:
(a) the detection of the mRNAs coding for C4, C2, C3, Clq B-chain, 
factor B and Cl-INH by Northern blot and dot-blot analyses of total RNA 
isolated from the synovial membrane of rheumatoid arthritis and 
osteoarthritis patients and the detection of Cl-INH mRNA in normal 
synovium. The expression of C5 mRNA was also investigated but was not 
detected by either Northern blot or dot-blot analyses.
(b) the demonstration of the accumulation of C4, C2, C3, factor B and 
Cl-INH in the supernatants of cultured fragments of normal and inflamed 
synovial membrane. The observation that the presence of cycloheximide in 
the culture medium resulted in a reduction in the concentrations of 
these components in the supernatants shows that they were being 
synthesised in vitro rather than being released into the culture medium 
as a result of contamination of the synovial membrane by blood or 
inflammatory exudate.
(c) the C3, C2 and factor B produced by the cultured fragments of 
normal and inflamed synovial membrane were shown to be haemolytically 
active. C4 and C5 haemolytic activity, significantly higher than the 
cycloheximide-treated cultures were not detected.
(d) the incorporation of 3SS-methionine into a polypeptide corresponding 
to the correct molecular weight for factor B (92 kDa), released by 
cultured fragments of synovial membrane. A band corresponding to the 
molecular weight for the J3 chain of C3 (75 kDa) was visible but the a- 
chain was not detected. A smeared band below the correct molecular 
weight of Cl-INH was detected while bands corresponding to C4, C2 and C5 
were not detected.
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2, JUL APPEAISAL...QF- THE. TBCHJIgU.ES FOR ISQLATIQE 
QE EJA-ERQH SYNQYIAL TISSUE
The isolation of total REA from human synovial tissue produced 
the greatest technical problem of this study. As stated in the Results 
chapter, the isolation of undegraded synovial tissue REA was virtually 
impossible if there was a significant delay ie. more than 10 minutes, 
between removal of the tissue from the patient and the tissue being 
snap-frozen in liquid nitrogen.
The guanidinium thiocyanate method of REA isolation was used to 
prepare REA from synovial tissue. However, the major drawback of this 
method was the time involved to prepare REA, which including the 
centrifugation steps, lasted 3 days. REAzol, which has only recently 
become commercially available, was reported to be at least as effective 
as the guanidinium thiocyanate method but had the advantage that REA 
could be prepared from either tissue or cells in less than one day. 
Testing the REAzol solution showed that it could be used to isolate 
intact REA from liver tissue as well as a wide range of cultured cells. 
However, when used on synovial tissue, the REA was completely degraded 
while REA prepared from the same tissue by the guanidinium thiocyanate 
method was intact. The degree of REA degradation was tested by ethidium 
bromide staining of the Eorthern gel and analysis of the Eorthern blot 
for a relatively stable mREA in vivo e.g. flz-microglobulin.
Therefore, even although the guanidinium thiocyanate procedure 
is time-consuming, it would appear to be the better of the two methods 
for isolating REA from human synovial tissue.
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3,_5QRTHERE BLQT ANALYSIS QF SYEQVIAL TISSUE REA
Northern blot analysis demonstrated the presence of mREAs coding 
for C4, C2, C3, Clq B-chain, factor B and Cl-IEH in the synovial tissue 
from patients with rheumatoid arthritis, osteoarthritis, ankylosing 
spondylitis and chondrocalcinosis.
Human cDEA probes were used throughout the Eorthern blot 
analysis and as such the filters could be washed in 2 x SSC, 0.5 x SSC 
and finally 0.1 x SSC each containing 0.1% SDS. Each wash was performed 
at 65°C for 30 min. Washing down to a stringency of 0.1 x SSC containing 
0.1% SDS, ensured that all non-specific hybridisation was removed and 
therefore only specific DEA-REA hybrids remained on the filter.
The Eorthern blot analysis demonstrated that mREAs coding for 
C2, factor B, Cl-IEH and especially C3 and C4 in synovial tissue, show 
evidence of degradation. In order to exclude the possibility that these 
mREAs had been degraded during the REA isolation procedure the same 
Eorthern blots were reprobed with £2-microglobulin cDEA, as the mREA 
coding for this protein is known to be stable in vivo. As this mREA was 
shown to be undegraded in the Eorthern blots, it was concluded that the 
mREAs which code for the complement components being studied are 
unstable in synovial tissue in vivo.
The varying degrees of degradation of the different complement 
component mREAs observed on Eorthern blot analysis probably occur 
because each mREA species has a different rate of turnover in synovial 
tissue in vivo. The results would suggest that C3 and C4 mREAs are more 
labile than Cl-IEH, C2, factor B and Clq B-chain mREAs in vivo, while 
all are less stable than mREA coding for p:s-microglobulin.
The reason for complement component mREAs being relatively
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unstable in human synovial tissue in vivo remains unclear as does the 
apparent differences in the in vivo stability of C2, factor B, Cl-IEH 
and Clq B-chain mREAs compared with the mREAs coding for C3 and C4.
The mREAs coding for C3 and C4 are 5.2 kb and 5.5 kb long 
respectively, and are thus approximately twice as long as the mREAs 
coding for C2 (2.9 kb), factor B (2.6 kb), Cl-IEH (2.1 kb) and Clq B- 
chain (1.4 kb). It is possible that because the mREAs coding for C3 and 
C4 are longer, they are more susceptible to degradation. One possible 
cause may be that more of these REA molecules could be exposed to ribo- 
nucleases resulting in a greater degree of degradation of C3 and C4 
mREA.
However, it is passible that mREA instability constitutes a 
mechanism by which the expression of complement components is regulated. 
If this is the case, then the differences in mREA stability may be 
related to the importance of individual proteins during complement 
activation.
As discussed previously, complement plays a major role in 
immunologically mediated inflammation. Thus, because of the inflammatory 
effects of the complement system, it is possible that complement 
component mREAs, particularly C3 and C4 which play a central role in the 
activation of the complement system, have a short half-life in vivo, 
especially at extrahepatic sites such as synovial joints. This could be 
a possible mechanism for regulating the expression of the complement 
components, designed to prevent the complement proteins accumulating at 
high concentrations which may prove harmful to the local tissue 
environment.
la) Possible mechanism for regulation of local C4 synthesis in 
synovial tissue
A mechanism for the regulation of C4 synthesis in guinea pig 
macrophages has been postulated, which if present in human synovial 
membrane could help explain the observations seen in Northern blot 
analysis of human synovial tissue REA.
In guinea pigs, the proportion of macrophages producing C4 
varied from one tissue site to another and at different stages of 
maturation of the mononuclear phagocyte series of cells. Auerbach et al 
(1983) showed that the binding of extracellular C4 protein to guinea pig 
peritoneal macrophages results in a specific inhibition of C4 
biosynthesis and this correlates with a decrease in the steady state 
level of C4 mREA. This feedback inhibition was reversible and was not 
accompanied by a change in C2 mREA or factor B mREA levels or total REA 
content. These data suggest that feedback inhibiton of C4 biosynthesis 
is regulated at the level of transcription or post-transcriptional 
processing. In other words, C4 feedback inhibition may operate by 
preventing transcription of the C4 gene or by interrupting the post- 
transciptional processing of C4 mREA, Alternatively, the feedback 
inhibition may decrease the stability of the C4 mREA which would result 
in a reduction in the steady state level of C4 mREA in addition to 
inhibiting translation into C4 protein
Coupled with the fact that human synovial membrane C4 mREA 
appears to be labile in vivo, as suggested by Eorthern blot analysis, 
the above hypothesis of direct regulation of C4 would have important 
consequences in the evolution of an inflammatory response ie. would 
provide a mechanism for controlling constitutive secretion of C4 by
complement producing cells within the synovial tissue as well as a basis 
for replenishing C4 levels following complement consumption or diffusion
s
from a site of inflammation.
Therefore local C4 synthesis within the synovial joint would not 
only be controlled by the inherent instability of C4 mREA in vivo, but 
also by the feedback inhibition mechanism described above. The direct 
control of C4 synthesis would thus not depend on or necessarily 
correlate with the plasma concentrations of C4, but would reflect the 
local concentration of extracellular C4 in the synovial tissue 
environment.
(b) Possible mechanism for the regulation of local C3 synthesis in 
synovial tissue
Activation of C3 is the key step in the activation sequence of 
the complement system and as such it is possible that the regulation of 
C3 gene expression may be under even more stringent control than the 
other complement components.
It has been suggested that the local production of ^-interferon 
by activated T lymphocytes at sites of chronic inflammation, for 
example, the rheumatoid joint, plays a major role in the modulation of 
local complement synthesis (Lappin & Whaley, 1989). This suggestion was 
initially based on the observation that recombinant ^-interferon (rlFN- 
¥) increases C2, factor B and Cl-IEH synthesis but reduces synthesis of 
C3 and properdin by cultured human monocytes (Hamilton et al., 1987; 
Lappin & Whaley, 1987). Synovial membrane T lymphocytes, which release 
)f-interferon, have been shown to have the same effect on complement 
biosynthesis by human monocytes as rlFH--# (Lappin & Whaley, 1989). The 
effects of both the T lymphocytes and rIFE-){ were abrogated in the
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presence of a monoclonal antibody to y-interferon. Thus it appears that 
K-interferon may be the lymphocyte product which is responsible for the 
modulation of monocyte complement synthesis in vivo.
Monocytes and macrophages are present in large quantities in 
inflamed synovial tissue and from in vitro studies are suspected of 
playing a major role in the local synthesis of complement in the 
synovial joint in vivo. At sites of chronic inflammation e.g. in 
rheumatoid joints, y-interferon is also present in abundance and as 
stated above, y-interj-sLroo, reduces monocyte C3 synthesis. The Eorthern 
blot analysis of human synovial tissue REA showed that C3 mREA was 
particularly labile in vivo, which may not only act as an inherent 
regulator of C3 synthesis but may also facilitate y-interferon to exert 
its inhibitory effect on C3 synthesis.
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4. DOT BLOT ANALYSIS OF SYNOVIAL TISSUE REA
Both Eorthern and dot-blot analyses of synovial tissue REA 
detected a wide range of steady state levels of each mREA even within a 
group of patients suffering from the same joint disorder. Densitometry 
was performed on the dot-blot autoradiographs and quantitative analysis 
of the data by the students’ t-test revealed no statistically 
significant difference between the steady state levels of C3, factor B 
or Cl-IEH mREA between the two groups of patients, although there was a 
trend towards higher levels of C3, factor B and Cl-IEH mREA in 
rheumatoid synovium compared with osteoarthritis synovial tissue. 
Although, the levels of C2 mREA were significantly higher in rheumatoid 
synovium, and C4 mREA levels were higher in osteoarthritis synovium, the 
P value was only marginally significant in both cases (<0.05>.
This may appear rather surprising because rheumatoid arthritis 
is regarded as a classical example of chronic inflammation where one 
might expect local synthesis of complement components while osteo­
arthritis is more of a 'wear and tear' disease as opposed to an 
inflammatory reaction.
Dot-blot analysis of REA isolated from normal synovial membrane 
identified the expression of Cl-IEH mREA by the normal tissue, although 
the small amount of REA isolated from the small piece of synovium 
isolated from the normal patient, made it impossible to quantitatively 
compare the steady state level of Cl-IEH mREA with that found in 
synovium from rheumatoid and osteoarthritis patients.
The suggestion that normal synovium may synthesise complement 
was first made by Katz and Strunk (1988b) who demonstrated that 
fibroblast-like cells isolated from normal synovium synthesised seven
complement components in vitro. However, apart from the fact that this 
evidence is based entirely on in vitro cell cultures, biosynthesis of 
complement components was only studied after these cells had been 
passaged several times.
Therefore, the demonstration of Cl-IEH mREA in normal synovium 
provides the best evidence to date that local synthesis of complement in 
synovial tissue is constitutive. Such extrahepatic synthesis of 
complement may play a major role in host defence as well as contributing 
to the inflammation present in arthritic joints.
From the data presented here, it is difficult to interpret 
directly any of the results in relation to specific mechanisms for the 
regulation of gene expression. However, when considered alongside 
investigations performed by other workers, the dot-blot analysis of 
synovial tissue REA and the subsequent statistical analysis of the data, 
supports the evidence for differential regulation of the closely linked 
C2, factor B and C4 genes.
The genes encoding complement components C2, factor B and C4 are 
closely linked in the class III region of the major histocompatibility 
complex on human chromosome 6 (Carroll et al., 1984). However several 
studies have previously shown that despite this close linkage, 
regulation of the expression of each of the three components is under 
independent control. Statistical analysis of the dot-blot data presented 
here, show that the steady state levels of factor B mREA were not 
significantly different between rheumatoid arthritis and osteoarthritis 
patients. However, higher mean levels of C2 mREA were detected in the 
rheumatoid synovium while the osteoarthritis synovium contained more C4 
mREA.
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However, dividing the rheumatoid arthritis and osteoarthritis 
patients into two separate groups and studying the results of each 
patient individually, allowed a much closer examination of the densito­
metry data from the dot-blot analyses shown in Figure 21 and provides 
stronger evidence for differential regulation of C2, factor B and C4 
expression in the synovial tissue of both rheumatoid arthritis and 
osteoarthritis patients. If one assumes the null hypothesis that 
expression of all three components is not independently regulated then 
following densitometry, the ratio of each patient's measurement to the 
mean value for the same component should equal the ratio obtained by the 
same calculation for the other two components ie. C2/mean C2 = FB/mean 
FB = C4/mean C4. However, Tables 11 and 12 show the results of such 
analysis on the densitometry data from the rheumatoid arthritis and 
osteoarthritis patients. For example, patient RA2 contains only 13% C2 
mREA of the mean value for C2 obtained from all 12 rheumatoid arthritis 
patients. This same patient contains 17% C4 mREA compared to the mean C4 
value and thus is quite similar to the C2 ratio. However, RA2 contains 
104% factor B mREA compared to the mean value obtained for factor B, 
which is almost seven times greater than the ratios calculated for C2 
and C4 mREAs,
Examination of the data reveals that virtually all patients show 
differences in such ratios between C2, factor B and C4 which supports 
the theory proposed from the results of several studies, that these 
closely linked genes are regulated independently.
For example, Strunk, Whitehead & Cole (1985) showed that the 
lipid A component of endotoxin increased the steady state level of 
factor B mREA in cultured human monocytes which corresponded to a 2-3
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fold increase in factor B protein. The steady state level of C2 mREA was 
also increased but not to the same extent as factor B. However there was 
no net increase in the C2 protein production thus suggesting that 
perhaps a second signal is required to initiate a change in the 
translation rate of C2 mREA,
Studies on a human hepatoma cell line (Ramadori et al., 1985) 
showed that interleukin-1 (IL-1) caused an increase in the steady state 
levels of factor B and C3 mREAs but C2 gene expression was unaffected.
A cosmid bearing the factor B and C2 genes on a 30 kb segment of 
human DEA was introduced into mouse L-cells and both components were 
constitutively expressed (Perlmutter et al., 1985). These transfected 
cells synthesised and secreted functionally active C2 and factor B 
indistinguishable from the products released in primary human cell 
cultures. When the cells were incubated with IL-1, synthesis of human 
factor B and endogenous murine C3 expression were increased but as in 
the hepatoma cell line studies, human C2 synthesis was unaffected.
In the mouse, the C2, factor B and C4 genes are also closely 
linked in the MHC region. Similar studies to investigate the 
differential regulation of these three closely linked genes have been 
performed on resident peritoneal macrophages (Sewell, Shreffler & 
Atkinson, 1982). In short term primary cultures of these cells, the rate 
of C4 secretion declined rapidly within the first few hours, although 
total protein synthesis remained constant while there was an apparent 
increase in factor B synthesis. During these experiments, there was an 
increase in steady state levels of factor B mREA with a decrease in C4 
mREA levels. Hence the observed decrease cannot be simply due to a 
limitation of in vitro culture conditions. Instead it is most likely due
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to a change in the rates of transcription of C4 and factor B or a change 
in post-transcriptional processing or a difference in the stability of 
the specific C4 and factor B mREAs.
Factors regulating C2 and factor B synthesis have also been 
shown to depend on the stage of maturation of human mononuclear 
phagocytes (Cole et al., 1982, 1983). The secretion of active C2 exceeds 
factor B by 3.5 and 7 fold in milk and lung macrophages respectively 
whereas the ratio of C2 to factor B secreted by the peripheral blood 
monocytes is constant ie. the ratio is 1, for several weeks in culture.
Thus, currently available evidence points towards there being 
differential regulation of the closely linked C2, factor B and C4 genes 
in both murine and human cells.
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5*. DETECTION OF COMPLEMENT PROTEINS IE 
SYNOVIAL MEMBRANE CULTURE SUPERNATANTS
(a) Kinetics of synthesis of complement components
ELISA analysis of synovial membrane culture supernatants showed 
the patterns of accumulation of complement components could be divided 
into two groups:
(i) C3 and C4 - showed a steady increase in C3 and C4 concentration over 
the first two days of culture but this rate of accumulation decreased 
towards the end of the period of culture in all samples.
(ii) C2. factor B and Cl-INH - either showed a steady increase in 
accumulation of these components throughout the period of culture or, in 
the case of RA8, RA9, 0A15 and Nl, a delay in the initiation of C2, 
factor B and Cl-INH synthesis followed by an increasing rate of 
accumulation of these three components in the culture medium.
Therefore, ELISA analysis of most samples revealed a delay in 
the initiation of synthesis of C2, factor B and Cl-INH while synthesis 
of C3 and C4 showed no such delay. Moreover, Northern blot analysis 
showed that the mRNAs coding for C2, factor B and Cl-INH were 
substantially more stable in vivo than those coding for C3 or C4,
These observations could be explained if the mRNAs coding for 
C2, factor B and Cl-INH were masked by proteins in stable ribonucleo- 
protein particles which protect them against degradation but also 
prevent translation. If this is the case then the in vitro culture 
conditions must allow the unmasking of the mRNAs. This 'masked message' 
hypothesis has previously been proposed to explain events during the 
fertilisation of sea urchin eggs (Grainger & Winkler, 1987) and the lack
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of keratin synthesis by mouse squamous cell carcinomas that contain 
keratin mRNA (Vinter & Schweizer, 1983).
As a corollary, the observation that the mRNAs coding for C3 and 
C4 are unstable in synovial tissue in vivo could be interpreted as 
evidence that they are not masked by ribonucleoprotein particles. This 
would permit translation of C3 and C4 mRNAs to proceed almost 
immediately in the synovial membrane fragment cultures.
As with all in vitro culture systems, these fragments of 
synovial membrane have been removed from their natural environment. 
Hence, it is unlikely that the stimulus or stimuli (which remain 
unknown) responsible for initiating complement synthesis and activation 
in synovial tissue, is being replenished and thus will probably be 
exhausted after a relatively short time, leading to an inhibition of 
complement synthesis. Alternatively, as the concentration of C3 and C4 
increases in the culture supernatants, a feedback inhibition mechanism 
may operate switching off further synthesis of C3 and C4, as has been 
suggested for C4 synthesis by guinea pig peritoneal macrophages 
(Auerbach et al., 1983). It is possible that these inhibitory mechanisms 
may act at the level of transcription which would explain why synthesis 
of C3 and C4 decline towards the end of the culture period. The mRNAs 
coding for C3 and C4 have been shown to have a short half-life in 
synovial tissue. Hence, if after 2-3 days in culture, transcription of 
the C3 and C4 genes is terminated, then because of their short half-life 
the mRNAs coding for C3 and C4 will be rapidly degraded, and the rate of 
C3 and C4 protein synthesis will decrease markedly.
Such a mechanism, coupled with the 'masked message* theory, 
would also hold for the observed patterns of C2, factor B and Cl-INH
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accumulation. Even if transcription of these three genes was inhibited, 
translation of the RNA would continue as more of the ribonucleoprotein 
particles, which are protecting the RNA from degradation, were removed 
from the RNA molecule. If this hypothesis is correct, then once the 
ribonucleoprotein particles have been removed from the mRNAs coding for 
C2, factor B and Cl-INH, degradation of these mRNAs would occur 
resulting in decreasing rates of C2, factor B and Cl-INH synthesis. 
Indeed in some cases, the rate of synthesis of these three complement 
proteins did start to decrease even after six days in culture. 
Presumably, the patterns of C2, factor B and Cl-INH accumulation would 
have reached a plateau (like C3 and C4 synthesis) if the cultures had 
been continued for a longer time.
One simple experiment which would help to answer whether control 
was being exerted at the transcriptional level, would be to introduce a 
transcription inhibitor, such as actinomycin D into the synovial 
membrane cultures and compare the results with the untreated cultures. 
Actinomycin D inhibits transcription by binding tightly to double­
stranded DNA but not to single-stranded DNA or RNA, double-stranded RNA 
or RNA-DNA hybrids. At low concentrations, actinomycin D inhibits 
transcription without appreciably affecting DNA replication. Also, 
protein synthesis is not directly inhibited by actinomycin D. If the 
kinetics of complement component synthesis in the actinomycin D- 
treated cultures were similar to the untreated cultures, this would 
suggest that regulation of complement synthesis was possibly being 
exerted at the level of transcription.
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(b> .Different rates of GQflgleBrent synthesis by synovial membrane 
fragments frow the same patient
In most cases, ELISA analysis showed that the four synovial 
membrane cultures from one patient synthesised similar amounts of 
complement as one another. However, there were examples when some 
cultures synthesised significantly higher or lower levels of complement 
components than other cultures from the same patient.
However, each culture contained fragments of tissue removed from 
different areas of the specimen. It is unlikely that the potential for 
complement biosynthesis was uniform throughout the entire specimen 
because some areas will contain higher concentrations of complement 
producing cells and hence will synthesise more complement proteins than 
others. Indeed, when studying the histology of synovial membrane the 
uneven distribution of various cell types is clearly visible (Athanasou 
et al., 1988). This uneven distribution of cell types would be the most 
likely explanation for the different amounts of complement synthesised 
by fragments of synovial membrane from the same patient.
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tLt„JffiIBCTIQI OF FCTCTIQBALLT ACTIVE CQKPLEMEET GQHPQBEBTS 
II. SYNOVIAL .MEHBRAIB -CULTURE .SUPEREATAETS
Haemolytic assays were performed on the synovial membrane 
culture supernatants from one osteoarthritis patient (0A15) and one 
specimen of normal synovium from a pateint (Nl) suffering from recurrent 
patellar dislocation. C2, C3 and factor B were shown to be functionally 
active in the culture supernatants from both patient samples, while C4 
and C5 haemolytic activity, significantly higher than the cycloheximide- 
treated cultures, were not detected.
Discrepancy between the ELISA data and the haemolytic assay data 
concerning C2 ..synthesis
C2 synthesis data showed a discrepancy between the ELISA 
results, where a delay in the initiation of synthesis was detected, and 
the haemolytic assay where this delay was not apparent.
It has been shown that monocyte C2 behaves differently from 
serum C2 by having a higher specific functional activity <units/ng 
protein) and forming a C3 convertase (C4b2a) which is more stable (Tte = 
9.2 min at 30°C) than the C3 convertase formed with C2 purified from 
serum (Tte = 3 . 5  min at 30°C) (Lappin & Whaley, 1989). Thus monocyte C2 
behaves like oxidised serum C2 (Polley & Muller-Eberhard, 1967). It is 
likely that C2 which has been synthesised by monocytes has been oxidised 
by the secretory oxygen products of these cells. This conclusion was 
supported by the observation that purified C2 which had been incubated 
with monocyte cultures formed a more stable C3 convertase (Tfc = 7 . 2  min' 
at 30°C) than that formed with the untreated C2. Furthermore, since the 
C3 convertase formed with monocyte C2 which had been oxidised with Iz.-/KI 
only showed a slight prolongation in its half-life, it is likely that
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monocyte C2 has already been oxidised.
Y-interferon has been shown to stimulate the secretion of 
macrophage oxygen products (Nathan et al.f 1983). In the above 
experiments, the specific functional activity of C2 and the stability of 
C4b2a of monocytes were increased by the presence of rIFN-Y, which is 
thought to be due to further oxidation. When a monoclonal antibody to 
rIFN-Y was introduced into monocyte cultures, which had been treated 
with peripheral blood lymphocytes or lymphocytes from rheumatoid 
synovial membrane, any increase in C2 synthesis was inhibited but 
neither the specific functional activity of C2 or the stability of C4b2a 
returned to the values seen in control monocyte cultures. This suggests 
that another lymphocyte product is responsible for much of their effects 
on C2 activity.
Therefore the discrepancy in the ELISA data and the results 
obtained from haemolytic assays for C2 synthesis by cultured fragments 
of synovial tissue may be explained if in the early stages of synovial 
membrane cultures, C2 is more oxidised and hence more functionally 
active than it is during the later period, resulting in C2 activity 
being detected when little C2 protein was present. The presence of 
'oxidised' C2 at sites of inflammation will increase the efficiency of 
C3 activation by the classical pathway and may influence the outcome of 
the inflammatory response.
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ZI1GQRPQR AT ION OF 35S-methionine INTO COMPLEMENT PROTEINS
This aspect of the study did not yield as clear results as was 
hoped. Indeed, the identification of a band corresponding to the correct 
molecular weight of factor B was the only positive result obtained from 
these experiments. A band corresponding to the molecular weight of the 
j3 -c h a in  of C3 was also detected but a band corresponding to the a-chain 
was not visible. A smeared pattern was observed for Cl-INH but it 
appeared below the correct molecular weight for Cl-INH and hence its 
specificity must be questioned. Bands corresponding to the correct 
molecular weights of C2, C4 and C5 were not detected in any of the 4 
patient samples studied (RA13, 0A16, 0A17 and 0A18).
(a) Possible explanations for the lack of detection of C4. C2. and C3
The most likely explanation for the poor results in the 
incorporation of 3SS-methianine studies is that there was a high degree 
of degradation of C4, C2 and C3 within the synovial membrane cultures. 
However, within the same culture system, C2 and C3 haemolytic activity 
had been demonstrated which argues against excessive degradation of 
these two proteins.
One final possibility could be that insufficient cells were 
synthesising complement components for synthesis to be detected by this
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type of analysis.
(b). Attempts to identify the 60 kDa band visible on all fluorographs
Although there was a lack of detection of C4, C2 and C3 in each 
patient sample, every track showed the presence of a very intense band 
at 60 kDa. Initially it was thought that this band may correspond to the 
heavy chain of IgG molecules which had been synthesised by the synovial 
membrane cultures and were iminunoprecipitated along with the complement 
component immune complexes even although the culture supernatants had 
been preabsorbed with Staph, aureus protein A to remove any non-specific 
immune complexes. However, IgG heavy chains have a molecular weight of 
only 50 kDa which is smaller than the band detected. Indeed when 
incubations designed to remove immunoglobulin were performed e.g. Staph, 
aureus protein A, Sepharose protein G and protein A or IgG-Sepharose, 
they only succeeded in removing all the bands from the subsequent 
fluorograph, with no specific removal of the 60 kDa band. These 
experiments provided further evidence that this band did not correspond 
to the IgG heavy chain.
Another possibility considered was that this unidentified 60 kDa 
molecule was the recently characterised glycoprotein, gp60 (Ahmed & 
Vhaley, 1988). This glycoprotein, which is found in normal sera, 
inhibits complement-mediated prevention of immune precipitation and the 
complement-dependent solubilisation of immune complexes. The sera of 
patients with rheumatoid arthritis contain increased concentrations of 
this protein. However, ELISA analysis of synovial membrane culture -- 
supernatants revealed no detectable synthesis of gp60 by cultured 
fragments of synovial tissue. Thus, it is unlikely that the 60kDa band 
represents gp60 and at present remains unidentified.
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8. G5; SYEIHESIS QR RELEASE?
In contrast to a previous report (Ruddy & Colten, 1974), these 
studies have been unable to demonstrate synthesis of C5 by synovial 
membrane fragments cultured in vitro. C5 mRNA was undetectable in any 
sample by either Northern blot or dot-blot analyses, and the release of 
C5 into the culture supernatants was not significantly different from 
cycloheximide-treated cultures, after the first day of culture. The C5 
detected by ELISA could represent C5 present in contaminating plasma or 
inflammatory exudate in the synovial tissue, or C5 pinocytosed in vivo 
and later secreted in vitro. These possibilities are supported by the 
observation that the release of albumin followed a similar pattern to 
that seen for C5 release, which suggests that the C5 detected by 
ELISA was not due to synthesis of the protein. Failure to detect C5 mRNA 
in any of these samples by Northern and dot-blot analyses supports this 
theory.
However, the serum concentration of albumin is approximately a 
thousand fold greater than C5, but albumin was found at a concentration 
only ten times higher than the C5 concentration in synovial membrane 
culture supernatants. This raises the possibility that the C5 detected 
in the culture supernatants may not be due to simple plasma 
contamination.
Another interesting finding from this study was that in every 
case, including C5 and albumin, the presence of cycloheximide reduced 
the amount of protein being released into the culture fluid. In light of 
the above studies, it is possible that in addition to its inhibitory 
effects on protein synthesis, cycloheximide may also inhibit the 
secretion of proteins.
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I have been unable to explain the differences between my result 
and those of Ruddy and Colten (1974), but in view of the importance of 
the C5b-9 membrane attack complex, both as a cytolytic agent (Podack, 
1986) and as an activator of inflammatory cells (Morgan et al, 1988), 
and of C5a as an anaphylatoxin and chemotactic agent (Chenoweth, 1987), 
it is important to resolve this issue.
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ft. IDEHTIFYIIG...THE ..CELLS RESPONSIBLE FOR COMPLEMENT
BIOSYNTHESIS IN HUMAN SYNOVIAL TISSUE
In vitro cultures of cells isolated from human synovial tissue 
were studied as an initial step in determining the identification of the 
cells within synovial tissue that are responsible for complement 
biosynthesis in vivo.
Using ELISA analysis, primary cultures of cells isolated from 
synovial tissue were shown to synthesise C4, C3, factor B and Cl-INH.
The vast majority 095%) of these cells are fibroblasts (as determined 
by performing immunohistochemistry on the cells with a mouse monoclonal 
antibody against human vimentin, which is a fibroblast marker), which is 
probably due to the rapid proliferation of these cells in culture 
compared with other cell types.
In the first case studied (0A19), the non-adherent cells 
synthesised more complement than those cells that readily adhered to the 
coverslip in the culture dish. It was thought likely that these non­
adherent cells belonged to a different subset of cell types which were 
capable of synthesising higher levels of complement e.g. mononuclear 
phagocytes. However, investigation of these cells using an antibody 
against the fibroblast marker vimentin, identified them as predominantly 
095%) fibroblasts. This finding suggests that the rates of synthesis of 
complement components are reduced when fibroblasts are adherent to the 
surface of the culture dish. However subsequent studies of synovial 
membrane cells isolated from other patient samples showed that the 
adherent cells synthesised the same or higher levels of complement 
components as the non-adherent cells. In both cell papulations, 
fibroblast-like cells comprised at least 95% of the total cell
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population, and hence any differences in the rates of complement 
biosynthesis were unlikely to be due to the presence of different cell- 
types. Unlike sample 0A19, (discussed above) the adhering of cells to 
the culture dish surface appeared to have little or no effect on the 
ability of the cells to synthesise complement components.
Although, these studies show that fibroblasts appear to be the 
cell most likely to synthesise complement components in synovial 
membrane, they are inconclusive, as the cells could have acquired the 
ability to synthesise the complement proteins during the isolation 
procedure or during the subsequent culture period. Similar immuno- 
histochemical analyses will have to be performed on synovial tissue 
sections to identify the sites of complement accumulation in the 
synovial tissue, as well as determining the morphology of the various 
cell types present in the synovial membrane. However, this type of 
analysis would still detect proteins that have been pinocytosed by 
cells. Thus, to identify the cells that actually synthesise the 
complement components, in situ hybridisation experiments will have to be 
performed on frozen sections of synovial tissue. In situ hybridisation 
will identify the cells in which the genes coding for the complement 
components are being expressed, by detecting the mRNAs encoding the 
complement proteins.
A number of cell-types that are present in synovial membrane 
have been shown to be capable of synthesising complement components in 
vitro. These include mononuclear phagocytes (Einstein et al, 1976;
Vhaley, 1980), and possibly the B-cells of the synovial membrane lining, 
fibroblasts (Katz et al, 1988) and endothelial cells (Ripoche et al, 
1988b). In the human, none of these cells have been shown to synthesise
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C4 or C5 so the synovial membrane cell which synthesises these 
components remains to be identified.
As discussed above, the finding of the synthesis of complement 
components in synovial tissue from patients with other forms of chronic 
inflammatory synovitis or with osteoarthritis, as well as in normal 
synovium, shows that this function of synovial tissue is not unique to 
rheumatoid arthritis.
The characteristic histopathological finding in osteoarthritis 
synovium is hyperplasia of the synovial lining cells, with only 
occasional foci of chronic inflammatory cells (Athanasou et al, 1988).
In this disease, it is unlikely that these chronic inflammatory cells 
are the principle site of complement component synthesis, and raises the 
possibility that the synovial membrane lining cells or some other cell 
type may be involved. Indeed, in addition to the data presented here, 
Katz and Strunk (1988b) have shown that, after several passages, 
fibroblasts isolated from normal synovial membrane, synthesise a number 
of complement components during in vitro culture.
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10, AREAS FOR FURTHER STUDY
I consider the fallowing four areas to be sufficiently important
to require further study:
(1) The definition of the range of complement components synthesised by 
the synovial membrane. As c D M  probes for nearly all the complement 
components are now available and can therefore be used in both 
northern and dot-blot analyses of R M  isolated from human synovial 
membrane.
(2) The identification of and the distribution of cells which synthesise 
complement components within the intact synovial membrane should be 
undertaken. This study will involve the use of in situ 
hybridisation, histochemistry and immunohistochemistry on frozen 
sections of human synovial tissue,
(3) Studies of the regulation of the expression of each of the 
complement genes in each cell type.
(4) The interactions between the different cell types involved in
complement synthesis and with other synovial membrane cells in the
regulation of complement component synthesis.
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Synovial membrane from patients with rheumatoid arthritis and 
with osteoarthritis have been shown to synthesise a number of complement 
components including C4, C2, C3, factor B and Cl-IKH. However, quanti­
tative analysis of the dot-blots containing RITA isolated from the 
synovial membrane of these patients, showed no statistically significant 
difference in the steady state level of the mRNAs coding for these 
complement components (with the possible exception of C2 and C4) between 
the two disease groups. Furthermore, although the rheumatoid synovium 
did synthesise markedly greater quantities of C2 protein than the osteo­
arthritis synovial membrane fragments, no significant differences in the 
amount of the other complement proteins synthesised by cultured frag­
ments of synovial membrane were observed between the rheumatoid arth­
ritis and osteoarthritis patients.
Therefore, the significance of the contribution made by local 
complement biosynthesis to the inflammation seen in rheumatoid joints 
may not appear quite so apparent as was initially suspected. This 
statement arises because such severe inflammation of the synovium is not 
typical of osteoarthritis, but from these studies the ability of 
synovial tissue from osteoarthritis patients to synthesise complement 
does not appear to be significantly different from rheumatoid synovium. 
Moreover, normal synovium removed from a patient suffering from 
recurrent patellar dislocation was shown to synthesise C4, C2, C3, 
factor B and Cl-IMH in vitro while Cl-IMH mRNA was detected in a sample 
of this normal synovium that had been snap-frozen in liquid nitrogen 
immediately after removal from the patient. The demonstration of Cl-INH 
mRNA in normal synovium provides the best evidence to date that
synthesis of complement components by synovial membrane is constitutive. 
Such extrahepatic synthesis of complement may play a major role in host 
defence.
It would have been advantageous to have examined more specimens 
of normal synovium. However, as with many studies of biological systems, 
the securing of physiologically normal tissue proved to be virtually 
impossible. The only synovium available was from patients undergoing a 
joint operation of some description and even in the above case of the 
recurrent patellar dislocation, it is likely that some degree of 
inflammatory response had occurred within the joint. Hence, this caveat 
has to be borne in mind whenever a comparative study such as this is 
undertaken.
However, even although complement biosynthesis has been detected 
in normal synovium, its role in the pathogenesis of chronic inflammatory 
synovitis in diseases such as rheumatoid arthritis cannot be discounted 
due to the biological effects of the complement system which are likely 
to contribute to the inflammatory response.
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